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1Introduction
Although the incidence of colorectal cancer decreases in the United States and seems 
to stabilize in The Netherlands, it remains the third most common malignancy among 
women and men in most Western countries.1,2 Rectal cancer accounts for approximately 
one third of the total number of colorectal cancer patients and differs substantially from 
colon cancer. Generally, rectal malignancies are located under the peritoneal reflection, 
are closely related to the surrounding vital structures and are fixed within the pelvis. 
Colon malignancies are located intraperitoneally and are less often related to structures 
nearby. This factor makes rectal cancer different than colon cancer with different surgical 
and therapeutic options.
The treatment of rectal cancer has improved drastically in the last 3 decades, leading 
to improved outcomes. Historically, the outcome of rectal cancer has been poorer than 
the outcome of colon cancer. However, due to advancements in the treatment of rectal 
cancer the long-term outcome is now similar to colon cancer.3,4 The main advancement 
is the introduction of a surgical technique, called total mesorectal excision (TME). Sir 
Bill Heald first described the TME-technique in 19795 and first long-term outcome of a 
large cohort of rectal cancer patients treated by this procedure was published in 1986.6 
This technique comprises a complete removal of the lymph node bearing mesorectum 
along with its intact enveloping fascia. This procedure has two advantages attributing 
to an improved long-term outcome. Firstly, the TME technique leads to a higher number 
of complete resections by leaving the visceral fascia intact. Secondly, TME leads to a 
complete removal of all possible regional lymph node metastases, which could potentially 
evolve into local recurrences.7 Before the introduction of TME, local recurrence rates were 
reported up to 45%.8-10 Currently, the local recurrence rate rarely exceeds 10% after 
rectal cancer surgery. Although no randomized controlled trials are available, it is highly 
likely that TME is the main cause of the decreased local recurrence rate and a prolonged 
overall survival after rectal cancer surgery.11
Simultaneously with the introduction of the TME technique, radiotherapy made its 
entry in rectal cancer management. The first high quality meta-analysis was published 
in 1989 demonstrating an improvement in local control without a beneficial effect on the 
overall survival.12 Since then, many randomized trials have been executed on the effect 
of radiotherapy. The ‘Dutch TME trial’ and the German trial CAO/ARO/AIO-94 were one 
of the most important studies. The Dutch TME trial showed that even with TME surgery 
a short-course radiotherapy (5x5 Gy) leads to an improved local control.11 The CAO/
ARO/AIO-94 trial demonstrated that pre-operative radiotherapy resulted in a lower local 
recurrence rate compared to post-operative radiotherapy.13 This has led to the current 
practice only to administer radiotherapy in a neo-adjuvant manner. The last important 
advancement concerning radiotherapy was combining it with concurrent chemotherapy. It 
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was shown that radiotherapy with concurrent chemotherapy as a radiosensitizer improves 
local control without an effect on survival benefit.14,15
The third major advancement in the treatment of rectal cancer is the quality of rectal 
cancer imaging. Two decades ago a digital rectal examination was standard of care to 
determine the extensiveness of the rectal malignancy. The introduction of Magnetic 
Resonance (MR) imaging has greatly improved rectal cancer staging. First single center 
series exploring the use of MR imaging in rectal cancer staging were published in the 
80s,16,17 but MR-imaging became standard of care in the first decade of the 21th century. 
The accuracies of tumor staging, nodal staging and circumferential resection margin 
involvement are superior compared to computed Tomographic scans (CT) or endoscopic 
ultrasound sonography (EUS).18-20 Moreover, the Mercury trial has showed that MR 
imaging could accurately assess the completeness of the surgical resection margins 
and that MR imaging was accurately reproducible in multiple centers.21 These factors 
have led to the recommendation to use MR imaging for pre-operative local staging in all 
guidelines.
TME surgery, neoadjuvant radiotherapy and improved imaging modalities have brought 
a great quality improvement in rectal cancer management, resulting in improved local 
control and improved overall survival after rectal cancer surgery. Currently, the treatment 
has shifted towards a more personalized approach, depending on the local tumor stage. 
Early stages of rectal cancer require a different treatment strategy than the more 
advanced stages of rectal cancer. For example, early stage rectal cancer (T1-2N0) can 
be treated safely by performing surgery alone without neo-adjuvant radiotherapy.22 
Moreover, these patients may be offered organ-sparing procedures resulting in a 
lower morbidity rate.23 Presently, there is even evidence that surgery can be omitted 
in highly selected patients in case of a complete clinical response after neo-adjuvant 
chemoradiotherapy. Several single center series have suggested that this so called ‘watch 
and wait’ approach is safe.24,25
The more advanced stages (e.g. locally advanced rectal cancer), on which the current 
thesis focuses, require a different approach. Locally advanced rectal cancer (LARC) is 
associated with higher local recurrence rates and poorer overall survival rates compared 
to the less advanced stages.26 Therefore, LARC requires a multimodality approach 
with optimal staging, neo-adjuvant therapy and ‘tailor-made’ surgery to improve 
outcome. The circumferential resection margin (CRM) is often at risk and standard 
TME-surgery would lead to incomplete resections. Incomplete resections are detrimental 
for oncological outcome.27 Neo-adjuvant (chemo-)radiotherapy is an essential part 
of the treatment of LARC, because it leads to lower local recurrence rates and tumor 
shrinkage (e.g. downstaging). Downstaging may render initially unresectable rectal 
malignancies into resectable tumors and thereby facilitating a complete resection.14,15,22 
Despite the downstaging effect of neo-adjuvant (chemo-)radiotherapy, a more radical 
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1surgical approach, such as extralevatory abdominoperineal resections and partial or total exenterations, are often necessary to achieve complete resection magins.28 These 
‘beyond TME’ procedures are technically demanding with high complication and morbidity 
rates and may benefit from an experienced surgical team.29
Despite the advancements in primary rectal cancer treatment, 6-10% of the patients 
still develop a local recurrence.11,14 Locally recurrent rectal cancer (LRRC) is usually 
accompanied by severe progressive pain, a poor quality of life and a poor overall survival. 
The treatment of LRRC is challenging. It is a heterogeneous disease varying from small 
central anastomotic recurrences to large pre-sacral or lateral recurrences with bony 
involvement of the sacrum or pelvis. A complete surgical resection is the only chance 
on durable local control and overall survival.30 Several institutes across the world have 
explored the possibilities of the surgical treatment of LRRC and showed encouraging local 
control and overall survival rates when LRRC is treated in a multimodality manner.31-33 
The surgical treatment is technically demanding. Pelvic exenterative surgery is often 
necessary to achieve complete surgical margins but comes with a high complication and 
morbidity rate.34
The first chapters of this thesis focus on local staging. Previously mentioned, local 
staging is an essential part of high quality rectal cancer treatment. The accuracy of 
rectal cancer staging has greatly improved since the introduction of MR imaging. 
Unfortunately, the use of neo-adjuvant (chemo-)radiotherapy has confronted us with a 
new problem. Potentially, (chemo-)radiotherapy provides us the opportunity to perform 
less radical surgery due to the downstaging effect. However, the grade of downstaging 
differs per person and it seems useful to reassess the local tumor extent after (chemo-)
radiotherapy. Unfortunately, the accuracy of MR imaging after (chemo-)radiotherapy is 
poor and this questions the usefulness of local restaging.35,36 Fibrosis and local reactions 
caused by the radiotherapy makes it difficult to differentiate between viable tumor 
and non-malignant tissue. To improve restaging accuracy, it could be useful to add 
Dynamic Contrast Enhanced (DCE) sequences to MRI restaging. DCE may be helpful 
to differentiate between malignant and non-malignant tissue due to different contrast 
enhanced patterns. In chapter 2 of this thesis we evaluated whether the addition 
DCE sequences resulted in an improved tumor, nodal staging and assessment of CRM 
involvement.
Local staging mainly determines the optimal treatment in rectal cancer management. 
However, detecting distant metastases is at least as important in order to offer patients 
optimal treatment. Approximately 20% of the patients are diagnosed with synchronous 
distant metastases at presentation.37 These patients can, in case of limited metastatic 
disease, be offered resection of both metastases and primary tumor. If this is not the 
case, these patients should be referred for palliative care. Fortunately, most patients 
present without distant metastases and are candidates for curative surgery. In case of 
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LARC, patients are scheduled for neo-adjuvant (chemo-)radiotherapy and planned for 
surgery approximately 8-12 weeks after ending (chemo-)radiotherapy. The duration 
of a long course of (chemo-)radiotherapy is approximately 5 weeks and this means 
surgery is performed 4 to 5 months after initial staging. In this period new metastases 
may have developed or may become visible on imaging. This is particularly the case 
in LARC patients as these patients have the highest chance of developing distant 
metastases.27,38,39 It could be of additional value to restage these patients by a thoraco-
abdominal CT-scan after neo-adjuvant (chemo-)radiotherapy to identify patients with 
new distant metastases. This would have clinical impact, since these patients could be 
offered a different surgical approach or these patients could be spared surgery in case 
of extensive metastasized disease and be referred for palliative care. In chapter 3, we 
evaluated the benefit of restaging by thoraco-abdominal CT-scan after a long course 
(chemo-)radiotherapy for LARC.
Despite the poor accuracy of restaging techniques after (chemo-)radiotherapy, it is 
widely used. To evaluate the usefulness, we briefly reviewed the current literature to 
evaluate and question the potential benefit of restaging in chapter 4.
After optimal staging and neo-adjuvant therapy, patients with LARC are planned for 
the most suitable surgical procedure. The downstaging effect of neo-adjuvant therapy 
and beyond TME surgery may result in complete resections in the majority of the 
patients. However, due to the extensiveness of the local tumor some patients may still 
have involved circumferential resection margins (CRM). Involved CRMs leads to poor 
oncologic outcomes with high local recurrence rates and poor overall survival.40 In an 
attempt to improve outcomes for these patients, several institutes across the world have 
implemented intra-operative radiotherapy (IORT) to their multimodality approach. The 
advantage of IORT is that a local radiotherapy boost can be administered at a specific 
area at risk, while other radiosensitive tissue, such as the small intestine and bladder, 
can be shielded from this radiation therapy. One single dose of IORT is considered to 
have a two to three times higher biological equivalent than fractioned radiotherapy. 
Therefore, a 10 Gy radiation dose may be able to eliminate microscopic remnants after a 
microscopically incomplete resection.41,42 In chapter 5, we evaluated the effect of IORT 
in LARC on the local recurrence rate after neo-adjuvant (chemo-)radiotherapy and TME 
surgery.
The multimodality treatment of LARC results in improved oncological outcomes, 
whereas the benefit of a multimodality approach in early stage rectal cancer is limited. 
Moreover, the surgical treatment of early stage rectal cancer is considered to be 
technically less demanding. These factors render early stage and locally advanced rectal 
cancer to be considered as two different diseases. The most advanced stage (cT4) rectal 
cancer is relatively rare. In this stage radical surgical procedures are often necessary 
and these procedures are accompanied by high complication and morbidity rates. These 
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1patients may potentially benefit the most from a dedicated and experienced (surgical) multidisciplinary team. Therefore, the benefit of treatment in dedicated high volume 
hospital may be more apparent in cT4 rectal cancer than in the more common cT1-3 
rectal cancer. In chapter 6, we hypothesized that the effect of hospital volume in the 
treatment of cT4 rectal cancer was more important than in cT1-3 rectal cancer. We have 
analyzed the overall survival in a large population based study according to the hospital 
volume for cT4 and cT1-3 rectal cancer separately. A previous population based study did 
not find evidence that hospital volume regardless of the tumor stage was associated with 
a long-term overall survival in the Netherlands.43
Approximately 20% of the colorectal cancer patients are diagnosed with synchronous 
distant metastases.44,45 Patients with limited metastatic disease can be treated with 
curative intent by a synchronous resection of primary tumor and metastases, by a ‘liver 
first’ approach or a resection of the metastases in a later stage.46 Unfortunately, the 
majority of the patients is not suitable for a curative resection. For these patients, the 
best treatment strategy remains unclear. They can undergo a palliative resection of the 
primary tumor, which is frequently performed worldwide or they can be treated with 
palliative systemic therapy.47 In case of disabling symptoms, there may be an indication 
for resection. In asymptomatic or mildly symptomatic tumors, the effect of primary 
tumor resection is questionable. Some advocate primary tumor resection, as it would 
lead to a prolonged survival. However, the studies suggesting a beneficial effect of 
primary tumor resection are often limited by selection bias. In these studies only patients 
in good clinical condition were considered candidates for surgery. High level evidence 
(e.g. randomized controlled trials) is lacking. Therefore, in chapter 7, we reviewed 
the current evidence of primary tumor resection in stage IV colorectal cancer with 
unresectable metastatic disease.
The introduction of TME surgery and pelvic radiotherapy introduced a new problem 
of treating this new ‘type’ of LRRC. The optimal LCCR treatment includes neo-adjuvant 
(chemo-)radiotherapy to improve local control.48 However, when the primary tumor has 
already been treated with radiotherapy, the radiation dose for LRRC treatment is limited. 
Additionally, previous TME-surgery makes complete resection of the local recurrence 
more demanding due to the fact that local recurrences after TME surgery may not be 
limited to an anatomical compartment. These factors render treatment of LRRC after TME 
surgery and previous radiotherapy more difficult. Furthermore it makes it questionable 
whether these patients still should be offered surgical treatment. In chapter 8, we have 
evaluated the outcome of LRRC in patients who received pelvic radiotherapy and TME 
surgery and compared it to the outcome of patients who did not receive previous pelvic 
radiotherapy.
In LRRC treatment, the single most important prognostic factor for overall survival 
and disease free survival is the resection margin status.49 A complete resection (R0) 
14
Chapter 1
can lead to 5-year survival rates up to 60%, while incomplete resections (R1/2) lead to 
significantly poorer outcomes.50,51 All efforts should be made to achieve a R0-resection 
by tumor downstaging by neo-adjuvant therapy and performing more radical surgery. 
In primary rectal cancer, it is unclear whether to consider 1mm or 2mm as an involved 
resection margin. Some authors plea to consider margins less or equal to 1mm to 
be involved, while others advice to consider margins less or equal to 2mm to be 
involved27,52,53. Nonetheless, there is consensus that close margins, either 1 or 2 mm, are 
associated with poorer oncological outcomes. If this is also the case in LRRC is unknown 
as it has never been evaluated. This may be important, because this could determine 
the extensiveness of the surgical resection and it may be helpful to inform patients more 
accurately after surgery about their prognosis. In chapter 9, we have evaluated the 
association between width of the tumor-free resection margin and the long term outcome 
after LRRC surgery.
Although surgical resection is the only durable option for long-term overall survival and 
local control, only 31-40% of the LRRC patients are considered to be suitable candidates 
for a curative surgical resection.33,54 The majority of the patients have metastatic disease 
or an advanced local recurrence till such an extend that surgical resection is technically 
impossible or futile. These patients can be treated by pelvic radiotherapy in case of pain 
or may be offered chemotherapy which may prolong overall survival. Currently, a high 
number of patients diagnosed with LRRC have already received pelvic radiotherapy for 
the primary tumor. These patients represent an even more challenging group to treat 
palliatively. The radiation dose is limited and chemotherapy may not be as effective 
due to radiation induced fibrosis and scarring. The poorer response of chemotherapy 
in irradiated area has been previously demonstrated in recurrent cervical cancer. A 
meta-analysis found that the proportion of women who responded to treatment was 
significantly lower for recurrences within the pelvic field compared with disease outside 
of the pelvic radiotherapy field.55 Whether this is also the case in LRRC is unknown and 
in chapter 10, we have evaluated the response of chemotherapy on the local recurrence 
in previously irradiated area and compared it to distant metastases outside the radiation 
field in that patient.
That study found that the proportion of women who responded to treatment was 
significantly lower for recurrences within the pelvic field compared with disease outside of 
the pelvic radiotherapy field
Due to the rarity of LRRC and the complexity of the optimal curative and palliative 
treatment, the treatment options for physicians in the Netherlands are relatively 
unknown. A multimodality approach can lead to a relatively good oncological outcome. 
On the other hand, even for patients with LRRC without curative options, there are 
several options to alleviate symptoms. In chapter 11, we have reviewed the current 
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1literature to evaluate the outcome of the surgical treatment and explored the possibilities of both curative and palliative treatment of LRRC.
Summarizing, the treatment of rectal cancer has drastically improved over the last 3 
decades. The treatment has shifted towards a more personalized treatment. LARC and 
LRRC represent a challenging group of patients who require a multimodality approach to 
achieve optimal oncological outcome. The current thesis aimed to further improve this 
multimodality treatment.
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Abstract
Purpose
The usefulness of restaging by MRI after chemoradiotherapy (CTxRTx) in patients with 
locally advanced rectal cancer has not yet been established, mostly due to the difficult 
differentiation between viable tumor and fibrosis. MRI with dynamic contrast-enhanced 
(DCE) sequences may be of additional value in distinguishing malignant from non-
malignant tissue. The aim of this study was to assess the accuracy of tumor, nodal 
staging and CRM involvement by MRI with DCE sequences after CTxRTx.
Methods
The accuracies were assessed by MRI on T2-weighted MR images with DCE sequences in 
patients with locally advanced rectal cancer after long course CTxRTx. MR images were 
assessed by two independent radiologists.
Results
For tumor staging and CRM involvement, MRI with DCE sequences had an accuracy of 
45% and 60%, respectively. The accuracy for nodal staging was 93%. On MRI, malignant 
lymph nodes had a median diameter of 8 mm (range, 4 – 18 and benign lymph nodes a 
median diameter of 4mm (range, 3 – 11). A significant indicator for benign nodes was 
hypointensity on T2 weighted images (p < 0.001) and early complete arterial phase 
enhancement on dynamic contrast-enhanced weighted images (p < 0.001). A significant 
indicator for malignant nodes was heterogeneity on T2 weighted images (χ² p < 0.000) 
and early incomplete arterial phase enhancement on dynamic contrast-enhanced (p < 
0.001).
Conclusions
MRI with DCE is a useful tool for nodal staging after CTxRTx. The addition of DCE 
sequences did not improve the accuracy of determining the tumor stage, CRM 
involvement and in detecting complete response.
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Introduction
Colorectal cancer is the third most common cancer among men and women worldwide.1 
Rectal cancer accounts for 30% of these colorectal malignancies. Surgery with total 
mesorectal excision (TME) is the cornerstone of treatment in rectal cancer and has led 
in combination with neo-adjuvant radiotherapy to a decrease in local recurrences.2-4 
Predictive factors for recurrence are depth of tumor invasion, number of malignant lymph 
nodes and involvement of the circumferential resection margin (CRM).4,5  Therefore, 
patients with locally advanced rectal cancer (e.g. large T3 or T4 tumors or involved 
lymph nodes) have a higher recurrence rate. Currently, these patients are usually treated 
with long course radiotherapy in combination with chemotherapy followed by TME or 
multivisceral resections.2,3,6,7
Magnetic Resonance Imaging (MRI) is the most accurate imaging modality for 
assessment of T-stage and CRM for locally advanced tumors. MRI can accurately predict 
an involved CRM and the transmural invasion of the tumor.8-10 An involved CRM is a 
reason to administer long course chemoradiotherapy (CTxRTx). Nodal disease may 
also be a reason to administer CTxRTx. However, nodal disease remains a difficult 
radiologic diagnosis.11 New techniques such as high spatial MRI and ultra-small particles 
iron oxide (USPIO) enhanced MRI showed promising results in the detection of nodal 
involvement.12,13
The usefulness of restaging after CTxRTx by MRI has not yet been established. After 
CTxRTx the tumor can be downstaged to 60% and approximately 20% of the tumors 
show a pathological complete response (pCR).14,15 Additional imaging may render the 
patient, in case of downstaging and N0 status, operable with a less extensive resection. 
On the other hand, in patients in whom the CRM is still involved, more aggressive 
surgery is justified. Unfortunately, the accuracy of MRI after CTxRTx in predicting tumor 
and nodal stage is poor, mostly due to the difficult differentiation between viable tumor 
and fibrosis.11,16-18 Dynamic Contrast-Enhanced (DCE) MRI may be of additional value 
in distinguishing malignant from non-malignant tissue. Malignant tissue shows specific 
contrast-enhanced patterns due to the neoangiogenesis, which gives elevated perfusion 
and permeability, in patients without neo-adjuvant therapy.19 The aim of this study is to 
assess the accuracy of DCE MRI with DCE sequences for tumor, nodal staging and CRM 
involvement after CTxRTx in patients with locally advanced rectal cancer.
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Methods and Materials
Patients
Between June 2005 and March 2009, 101 patients with locally advanced rectal cancer 
were treated with neo-adjuvant long course radiotherapy followed by rectal surgery. 
Thirty-three patients were treated by radiotherapy without chemotherapy and 13 patients 
were restaged in the referring hospital, leaving 55 patients treated with CTxRTx, who 
were all restaged by MRI with DCE sequences.
All patients had biopsy proven adenocarcinoma of the rectum within 15 cm of 
the anal verge. Locally advanced rectal cancer was defined on imaging prior to the 
chemoradiatherapy. According to  local standard of care, tumors greater than 5 cm at 
colonoscopy (clinically large T3), a clinically fixed tumor, tumor invasion in an adjacent 
organ, tumors with an involved CRM (margin <2 mm) and node positivity (lymph node 
larger than 8 mm on CT-scan or MRI) were considered as locally advanced rectal cancer.
All patients were evaluated including a complete history and physical examination, 
colonoscopy, tumor biopsy, computed tomography (CT) scan of the abdomen, magnetic 
resonance imaging (MRI) of the pelvis and a chest X-ray or chest CT scan.
Therapeutic regimen
Capecitabine was administered orally at a dose of 825 mg/m2 twice a day during 
radiotherapy days. The first daily dose was given two hours before radiotherapy and 
the second dose twelve hours later. Patients received a dose of 50-52 Gy radiotherapy 
delivered in 25-26 fractions of 2.0 Gy. Radiotherapy was administered by a three-field 
technique, using one posterior and two lateral beams, a four-field box or with five fields 
using intensity modulated radiotherapy.7
Radiology
Imaging was performed after CTxRTx after median interval of 5 weeks (interquartile 
range, 4 – 6). Magnetic resonance imaging was performed using thin-section (3 or 5 
mm) high-spatial resolution, phased array coils on a 1.5 T MR systems (Siemens Vision, 
Erlangen, Germany; Philips Intera, Best, The Netherlands). Patients were scanned supine 
without gastro-intestinal tract preparation, rectal insufflation or relaxants. The following 
sequences were used in all patients: transverse, coronal and sagittal Surv Haste (TSE, 
18877/100, 90°), transverse T2W (TSE, 4661/80, 90°), transverse T2W/ Spir (TSE, 
4586/80, 90°), transverse T1W (FFE in/out, 184/2.3- 4.0, 80°), transverse Sense Dyn 
(TFE, 136/1.16, 90°), transverse and sagittal 3D TFE (TFE, 3.4/1.68, 15°).
Dynamic imaging was performed before and after intravenous injection of 20 ml of 
gadopentetate dimeglumine in the arterial dominant, venous dominant and 2-minute 
delayed phases.
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Image interpretation
All images were assessed by a radiologist prior to surgery for determination of the 
operation strategy. Surgery was performed with a median of 4 weeks (interquartile 
range, 3-5) after restaging. Two radiologists: reader 1 (R.D.) and reader 2 (F.W.) 
retrospectively assessed all images independently. Both readers had over 5 years of 
experience in rectal cancer imaging and were blinded to the pathologic and surgical 
findings.  The following parameters were recorded by the readers:
Tumor stage
The distance of the lower and upper border of the tumor to the anal verge, maximum 
axial diameter, CRM, T-stage and tumor invasion, for T2-weighted images and Dynamic 
contrast-enhanced images were assessed.
Nodal stage
N-stage was determined by location, size (only nodes >3 mm were evaluated), shape 
(round or oval), border (irregular or sharp), signal intensity (SI) on T2 weighted images 
(hyperintens, hypointens SI) and homogeneous or heterogeneous SI. On dynamic 
contrast-enhanced images the arterial phase (early or late and complete or incomplete) 
and possible washout effects (complete or incomplete) were evaluated. Criteria for 
suspect malignant lymph nodes were size ≥ 5 mm, round shape, irregular border, 
heterogeneity on T2 images and incomplete arterial phase and washout effects.20,21 A 
lymph node was considered malignant when ≥ 3 criteria were positive.
Circumferential Resection Margin (CRM)
An involved CRM was defined as a margin ≤2 mm to the mesorectal fascia or in case of 
tumor invasion through the mesorectal fascia into surrounding structures.
Surgery and histopathology
Total mesorectal excision was performed in all patients. In patients whose circumferential 
resection margin (CRM) were considered at risk (CRM <2mm) intraoperative radiotherapy 
(IORT) was applied. 4,22 Pathologic examination of the histology specimen was evaluated 
according to the protocol of Quirke et al. 23 The report noted the depth of tumor invasion 
into the bowel wall and surrounding tissue, differentiation grade of the tumor, lymph 
node involvement and resection margin involvement.
Radiologic-pathologic comparison
The tumor, nodal status and CRM involvement determined by MRI were compared to 
pathologic staging of the surgical specimen.
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Statistical analysis
All statistical analyses were performed using SPSS for Windows, version 15.0.  The data 
used when appropriate were mean, median, (interquartile) range and standard deviation. 
The diagnostic accuracy, sensitivity, specificity, negative predictive and positive predictive 
value of MRI was computed in determining the post-chemoradiation nodal stage. The 
interobserver agreement was calculated by using K statistics. K values of less than 0 
indicated poor agreement, 0-0.20 indicated slight agreement, 0.21-0.40 indicated fair 
agreement, 0.41-0.60 indicated moderate agreement, 0.61-0.80 indicated substantial 
agreement and 0.80-1.00 indicated almost perfect agreement.  The χ²-test was used 
to determine the correlated factor to predict the nodal positivity, if the assumption of 
adequate cell sizes (≥5) was not met; the Fisher’s exact test was applied. The results are 
significant at a P-value of less than 0.05.
Results
Surgery and histopathology
Surgery was performed in 41 males and 14 females with a median age of 61 years 
(range 33 – 78)  The median interval of surgery after CTxRTx was 9 weeks (interquartile 
range, 8 – 10) Surgical and pathologic characteristics are depicted in table I.
Table I. Characteristics of 55 patients with locally advanced rectal carcinoma after CTxRTx
Number of patients (%)
Surgery
LAR 25 (46)
APR 20 (36)
Total exenteration 4 (7)
Posterior exenteration 6 (11)
Tumor staging
T0 6 (11)
Tis 2 (4)
T1 0 (0)
T2 10 (18)
T3 32 (58)
T4 5 (9)
Nodal staging
N0 45 (82) 
N1 5 (9)
N2 5 (9)
LAR, Low anterior resection; APR, abdominoperineal resection
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A pathological complete response was found in 6 (11%) patients. Five patients 
underwent a resection with viable tumor within 1 mm of the CRM. One patient had a 
positive lymph node <1 mm from the mesorectal fascia. Four patients received IORT 
after resection due to CRM of <2 mm. 22 In resection specimens a median of 9 (range 
1 – 21) lymph nodes were retrieved. Ten (8,8%) patients had a total of 42 tumorpositive 
lymph nodes.
Radiologic-pathologic comparison
A comparison of preoperative MRI staging and histopathological staging for both readers 
is depicted in table II.
Tumor stage
The readers both understaged 4 (7%) patients. Reader 1 had an accuracy of 40% (22 
patients) and overstaged 29 (53%) patients. Reader 2 had an accuracy of 45% (25 
patients) and overstaged 26 (47%) patients. The k statistics show fair agreement (k = 
0.37) for T-staging.
Table II. Comparison of T-staging by DCE MRI and histopathology
 
Histopathology
 T0 Tis T2 T3 T4
Reader 1
 
T2 3 1 3 3 0 10
T3 3 1 6 15 1 26
T4 0 0 1 14 4 19
Total 6 2 10 32 5 55
Reader 2
 
T2 0 0 4 3 0 7
T3 5 1 5 17 1 29
T4 1 1 1 12 4 19
Total 6 2 10 32 5 55
Nodal stage
The accuracy of both readers in nodal staging is noted in table III. Both readers 
accurately diagnosed the same 8 patients node positive on MRI.  The accuracy for 
reader 1 for nodal staging 89%, sensitivity 80%, specificity 91%, a positive predictive 
value (PPV) of 66% and a negative predictive value (NPV) of 95%. Reader 2 showed an 
accuracy of 93%, sensitivity of 80%, specificity of 96%, a PPV of 80% and a NPV of 96%. 
K-statistics showed almost perfect agreement (k = 0.89).
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Table III. Comparison of N-staging by DCE MRI and histopathology
 pN0 pN+  
Reader  1
 
 
cN0 41 2 43
cN+ 4 8 12
Total 45 10 55
Reader 2
 
 
cN0 43 2 45
cN+ 2 8 10
Total 45 10 55
Characteristics of lymph nodes
The median diameter of the lymph nodes was as follows: malignant lymph nodes 8.1 mm 
(range 4.2 - 16.2) and 8.0 mm (range 4.0 - 18.0) for reader 1 and 2 respectively, benign 
lymph nodes 4.8 mm (range 3.0 – 11.0) and 4.4 mm (range 3.0 - 11.0) for reader 1 and 
2 respectively.
Circumferential resection margin (CRM)
The accuracy of both readers in predicting CRM involvement is depicted in table IV. The 
accuracy for reader 1 was 60%, sensitivity 86%, specificity 49%, PPV of 38% and a 
NPV of 91%. Reader 2 showed an accuracy of 56%, sensitivity 79%, specificity 48%, 
PPV of 34% and a NPV of 91%. K-statistics showed moderate agreement (k = 0.59) for 
predicting CRM involvement.
Table IV. Comparison of CRM involvement by DCE MRI and histopathology
Histopathology
CRM involved CRM not involved
Reader  1 CRM involved 12 20 32
CRM not involved 2 21 23
Total 14 41 55
Reader 2 CRM involved 11 21 32
CRM not involved 3 20 22
Total 14 41 55
CRM; Circumferential resection margin
There was a significant difference in shape of malignant and benign nodes. Reader 1 
showed that a round shape is associated with benign nodes (p=0.026) and reader 2 
showed that an oval shape is associated with benign nodes (p=0.008).
The border of lymph nodes did not give a significant difference in the assessment 
of lymph nodes for reader 1, but reader 2 showed that a sharp border is associated 
(p=0.005) with benign nodes. Concerning hyperintensity on T2 weighted images, both 
readers found no significant differences. Hypointensity was an significant indicator 
for benign nodes (reader 1 p=0.000; reader 2  p=0.000) and heterogeneity was an 
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significant indicator for malignant nodes (reader 1 p=0.000; reader 2 p=0.000) for both 
readers.
There were no washout effects detected and only the following characteristic on DCE 
images gave a significant difference for both readers;  early complete arterial phase 
(Fig I.) was a significant characteristic of benign nodes (reader 1 p=0.000; reader 2 
p=0.000). Early incomplete arterial phase (Fig II.) was a significant characteristic of 
malignant nodes (reader 1 p=0.000; reader 2 p=0.000).
Figure I. DCE-weighted image with early complete arterial phase
Figure II. DCE-weighted image with early incomplete arterial phase
Interval between CTxRTx, surgery and restaging
The accuracy of tumor and nodal staging in patients having surgery <9 weeks after 
CTxRTx compared to patients having surgery ≥9 week was not significantly different.  
The accuracy of tumor staging was 42% vs. 37% (p=0.85) and the accuracy of nodal 
staging was 87% vs. 92% (p=0.53), The accuracy of tumor and nodal staging when 
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restaging was performed <4 weeks compared to ≥4 weeks prior to surgery was not 
significantly different either. The accuracy of tumor staging was 29% vs. 46% (p=0.08)  
and the accuracy of nodal staging 92% vs. 87% (p=0.53)
Discussion
This study was conducted to evaluate the additional value of MRI with DCE sequences 
in restaging after CTxRTx in patient with locally advanced rectal cancer. Although the 
accuracy for T-stage was poor, the addition of DCE sequences showed a high accuracy 
in detecting malignant lymph nodes. Complete arterial phase on DCE was a significant 
indicator for benign nodes and incomplete arterial phase (enhanced rim) was significant 
for malignant nodes. Complete pathologic response, carcinoma in situ and T1 stage 
tumor could not be correctly detected.
The addition of DCE to determine T-stage after CTxRTx has not proven its usefulness 
in this study. The poor accuracy of the T-stage could be explained by the fact that rectal 
cancer has a high level of maturation of vessels, which show relatively low permeability, 
thus less enhancement on DCE MRI.24 The accuracy of MRI for T-stage was 45% in this 
study. Other studies, using MRI with additional DCE sequences showed accuracies of 44-
77%.16,25,26 However, these studies divided patients into two T-stages to define accuracy 
(T0 vs. >T1 or T0-2 vs. T3-4).16,25 MRI without additional DCE sequence, showed 
comparable accuracy results of 34-60%.18,27-31
The poor accuracy in predicting T-stage and CRM after CTxRTx is in great contrast 
to the high accuracy of MRI-staging in patients with rectal cancer treated without 
neo-adjuvant CTxRTx. A recent meta-analysis reported a sensitivity and specificity in 
tumor staging of 87% and 75% in patients treated without neo-adjuvant CTxRTx.32 The 
tendency of post-chemoradiotherapy MRI to overstage the T-stage and CRM involvement 
was reported previously and may be caused by the inability of MRI to distinguish 
between viable tumor cells and fibrosis. Recently, Patel et al. analysed the value of MRI 
after CTxRTx in rectal cancer patients to analyse good versus poor responders with the 
histopathological standards of T stage (ypT) and tumor regression grading (TRG). Even 
using only 2 different t-stages (T0-T3a vs. T3b-4) 19% of the patients were under- or 
overstaged.33
The time span from the end of chemoradiotherapy to surgery has slowly increased over 
the years. Delaying surgery may reduce postoperative morbidity without compromising 
prognosis.34 Moreover, several studies showed a higher percentage of pathological 
complete response and downstaging after a longer interval between ending CTxRTx and 
surgery.35-37 This downstaging effect may influence the accuracy of the restaging MRI. 
However, we found no differences in accuracies of tumor and nodal staging between 
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patients in whom surgery was performed < 9 weeks or ≥9 weeks after ending CTxRTx. 
In addition, it has been suggested that the restaging by MRI shortly before surgery may 
improve the accuracy of tumor staging.38 In our study restaging was performed with a 
median interval of 4 weeks before surgery. We found no higher accuracy of tumor and 
nodal staging for patients restaged <4 weeks compared to patients restaged after ≥ 4 
weeks.
The addition of DCE to high-spatial MRI showed a high accuracy in nodal staging 
compared to other studies that also applied DCE. They reported accuracies of 62-
65%.16,25,26 This difference could be explained by the fact that we included different 
enhancement patterns to distinguish between benign and malignant nodes. One study 
staged a node malignant if it was bigger than 5 mm,16  while the other 2 studies did not 
describe any criteria for malignant nodes.25,26 Studies without additional DCE sequences 
reported accuracies of 68-71%.28,31 One study only used the criteria > 5 mm to stage 
a node malignant while the other study did not note any criteria for malignant nodes. 
Brown et al.21 reported that by assessing morphologic features of lymph nodes on MRI, 
malignant nodes can be detected with a greater degree of sensitivity and specificity 
compared to nodal size measurement. Studies using the morphologic criteria stated by 
Brown in addition to size cut-off values (> 5mm mesorectal, > 10mm extramesorectal) 
still showed lower accuracies of 70-78%.27,29 Accuracies were even lower even when 
cut-off values were not used 75-88%39-41. We used the same morphologic features 
described by Brown et al. with a cut-off value of >3 mm. Approximately 9% of the 
malignant nodes are missed on MRI with a cut-off value of 3 mm in patients treated 
without neo-adjuvant therapy.20 Recently, prospective assessment of imaging with MRI 
without DCE after preoperative chemoradiotherapy for rectal cancer showed an accuracy 
for nodal staging of 68% with a NPV of 78%.30 MRI with ultra small particles iron oxide 
showed promising results for nodal staging with a sensitivity of 93% and a specificity 
of 96% when an estimated area of white region within the node that was larger than 
30%.13 This sensitivity and specificity were slightly higher than in our study. However, the 
study mentioned above excluded all patients who were treated with chemoradiotherapy. 
Therefore, these results may not be comparable to ours.
The accuracy of MRI with DCE for nodal stage was 93% with a PPV of 80% and a 
NPV of 96%. There was good agreement between the two readers. Nonetheless, both 
missed the same two histopathology node positive patients. In one patient no benign or 
malignant nodes were detected on MRI. In the other patient, two nodes were detected, 
which were staged benign on MRI with confirmation on histopathology. However, the 
tumor incarcerated a malignant node, undetectable on MRI. Even with the knowledge of 
the presence of malignant lymph nodes, both radiologists were not able to detect any 
suspect lymph nodes after reassessment of the MRI.
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Two histopathology node negative patients were overstaged by both readers. In these 
two patients nodes had an axis of more than 8 mm (9.0 mm and 11.0 mm, respectively). 
Although the median diameter of the malignant nodes was bigger than that of the benign 
nodes in this study (8.0 and 4.4 mm respectively), it shows size is not a single reliable 
criteria to diagnose malignant nodes, which was confirmed in results by other studies.20,21
MRI with DCE has a good predictive value for malignant nodes. Generally, complete 
early arterial phase was a significant indicator of benign nodes, whereas incomplete 
arterial phase was a significant predictor of malignant nodes. Malignant nodes showed 
an intense border and hypointense core on DCE. This difference in intensity could be 
explained by that as tumors grow in size, their metabolic demands become too great for 
existing vasculature. At this stage, the centre of the mass becomes necrotic, leading to 
the common situation of a necrotic core and an active tumor periphery. This finding has 
been previously described in patients with a squamous cell carcinoma of the head or the 
neck. MRI with additional DCE sequences showed significantly different results in contrast 
intensity for their core and rim in malignant cervical lymph nodes. Benign nodes did not 
show significant differences, which is in concordance with our findings.42
Complete pathologic response, carcinoma in situ and T1 stage tumor could not be 
correctly detected on MRI even with the addition of DCE sequence. MRI with DCE 
sequences showed similar poor results in predicting pCR compared to conventional MRI.  
Predicting pCR after CTxRTx can be of great value for patients with rectal cancer. Patients 
could be spared unnecessary surgery with high morbidity. Promising results in predicting 
pCR are shown in adding diffusion weighted (DW) MRI to conventional MRI. Their 
diagnostic accuracy for the evaluation of pCR increased to 85%.14,43,44
Due to the retrospective nature of this study, we were not able to directly assess 
whether lymph nodes detected on MRI are the same lymph nodes assessed with 
histopathology. With prospective research a node-by-node correlation is capable to 
accurately link lymph nodes detected on MRI with DCE to lymph nodes retrieved at 
histopathology. Another drawback is the relative small amount of patients included in this 
study. Many of our patients were restaged by MRI without additional DCE sequences and 
therefore could not be included in this study.
In conclusion, the addition of DCE sequences improved the accuracy of nodal staging 
after chemoradiotherapy. However, additional DCE sequences did not improve the 
accuracy for tumor staging, CRM involvement or detecting a pathological complete 
response. In our opinion, the addition of DCE sequences is a significant step forward 
towards more accurate staging by MRI after chemoradiotherapy. We think that further 
development and introduction of such highly accurate preoperative staging modalities will 
enable us to identify those patients who are candidates for less invasive surgery for rectal 
cancer or even for watchful waiting.
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Abstract
Background
There is no evidence regarding restaging of patients with locally advanced rectal cancer 
after a long course of neoadjuvant radiotherapy with or without chemotherapy. This study 
evaluated the value of restaging with chest and abdominal computed tomographic (CT) 
scan after radiotherapy.
Methods
Between January 2000 and December 2010, all newly diagnosed patients in our tertiary 
referral hospital, who underwent a long course of radiotherapy for locally advanced rectal 
cancer, were analyzed. Patients were only included if they had chest and abdominal 
imaging before and after radiotherapy treatment.
Results
A total of 153 patients who met the inclusion criteria and were treated with curative 
intent were included. A change in treatment strategy due to new findings on the CT scan 
after radiotherapy was observed in 18 (12 %) of 153 patients. Twelve patients (8 %) 
were spared rectal surgery due to progressive metastatic disease.
Conclusions
Restaging with a chest and abdominal CT scan after radiotherapy for locally advanced 
rectal cancer is advisable because additional findings may alter the treatment strategy.
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Introduction
Colorectal cancer is the third most commonly diagnosed cancer in men and the second 
in women.1 At the time of diagnosis, approximately 25 % of patients already have 
liver metastases.2,3 The lungs represent the second most common site of metastases 
from colorectal cancer. According to non-population-based studies, lung metastases 
are present in 10–15 % of patients with colorectal cancer.4,5 A population-based study 
reported that lung metastases are present in 2 % of patients with colorectal cancer.6
Distant metastases have implications on the treatment options. For the screening of 
liver metastases, the Dutch Association of Comprehensive Cancer Centres (ACCC), the 
National Institute for Health and Clinical Excellence (NICE), and The American Society 
of Colon and Rectal Surgeons (ASCRS) recommend a computed tomographic (CT) scan 
or magnetic resonance imaging (MRI). For the screening of lung metastases, they 
recommend the use of a chest X-ray or a chest CT scan.7-9
Locally advanced rectal cancer has a higher risk of developing lung metastases than 
colon cancer.6,8,10 In patients with locally advanced rectal cancer, improved local control 
can be achieved with a long course of preoperative radiotherapy in combination with low-
dose neoadjuvant chemotherapy as a radiosensitizer.11 However, no advice is provided by 
ACCC, NICE, or ASCRS in any guideline regarding restaging of patients after neoadjuvant 
treatment of locally advanced rectal cancer—that is, repeating the imaging, after a long 
course of neoadjuvant radiotherapy treatment, to ensure that in the intervening time no 
metastases have developed. This study evaluated the value of restaging patients with 
locally advanced rectal cancer with a CT scan.
Patients and Methods
Between January 2000 and December 2010, data from all newly diagnosed patients 
who received a long course of radiotherapy for locally advanced rectal cancer in our 
tertiary referral hospital were analyzed. Patients were included if they had a chest and 
abdominal CT scan before and after radiotherapy treatment. An MRI was used for local 
staging before and after radiotherapy. Neoadjuvant treatment was provided with curative 
intent. Patient characteristics were collected retrospectively. The database comprised 
data on age, gender, radiation time and dose, simultaneous chemotherapy, pre- and 
postradiotherapy chest and abdominal CT scan, pathological primary tumor stage, lymph 
node stage, and type of surgery.
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CT Scan
All CT scans were assessed by radiologists in regular clinical practice. Whenever there 
was any doubt concerning lesions found on the CT scans, then these scans were 
reassessed by a panel of radiologists and discussed in a multidisciplinary meeting.
Images were acquired after intravenous injection of 150 mL contrast material at 
3.5 mL/s with a delay of 80 s. In addition, an arterial phase scan of the liver was 
acquired at a delay of 30 s. Positron emission tomography scan is not used as standard 
protocol in our center.
Locally Advanced Rectal Cancer
Locally advanced rectal cancer was defined in our center as a histological proven 
adenocarcinoma with one of the following characteristics: tumor >5 cm at colonoscopy 
and MRI (clinically large T3); clinically fixed tumor or with ingrowth in adjacent organ 
on MRI (T4); N+ tumor (lymph node >8 mm and/or >4 nodes >5 mm on CT scan or 
MRI). T4 tumors, but also advanced T3 tumors with a close relation to the circumferential 
margin, were considered as locally advanced rectal cancer. Regardless of size criteria, 
any lymph node depicted on MRI with an irregular border or mixed signal intensity was 
considered suspicious for metastasis.
All patients with locally advanced rectal cancer were discussed in a multidisciplinary 
team that consisted of colorectal surgeons, hepatobiliary surgeons, gastroenterologists, 
surgical oncologists, medical oncologists, radiation oncologists, radiologists, pathologists, 
and nurse practitioners.
Chemoradiotherapy
In our center, patients with locally advanced rectal cancer have been treated with a long 
course of neoadjuvant radiotherapy: 45–50 Gy (in fractions of 1.8–2 Gy) with or without 
chemotherapy (capecitabine 825 mg/m2 twice a day only on radiotherapy days).12 We 
selected patients who did not receive chemotherapy as a result of their comorbidities. 
Radiotherapy was followed by surgery with a delay of 6–10 weeks. Intraoperative 
radiotherapy was applied if the circumferential margin was <2 mm. 13 No laparoscopic 
resections were performed.
Statistical Analysis
Descriptive statistics are expressed as median (interquartile range [IQR]). Pre- and post-
CT variables are expressed as binary variables and compared with the McNemar test for 
paired data. If fewer than 25 cases change values from the first variable to the second 
variable, the binomial distribution is used to compute the probability. The SPSS statistical 
software package (version 17.0; SPSS, Chicago, IL) was used for statistical analysis, 
where a P-value of ≤0.05 was considered statistically significant.
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Results
Between January 2000 and December 2010 over 2000 patients were treated with 
neoadjuvant radiotherapy for rectal cancer. Patients were excluded for receiving 
radiotherapy for recurrence, palliative radiotherapy, primary radiotherapy treatment, 
postoperative radiotherapy treatment, and liver-first treatment14; and for not have 
imaging studies available.
A total of 153 patients with primary locally advanced rectal cancer had imaging studies 
available before and after radiotherapy treatment. A chest CT scan before radiotherapy 
treatment was not performed in 36 patients; they received a chest X-ray. All other 
patients had an abdominal and chest CT scan. The majority of patients were men 
(61 %), and the median age was 62 (IQR 53–69.5) years. All 153 patients had a chest 
and abdominal CT scan after radiotherapy.
The median time between the staging scan and the start of radiotherapy was 6 weeks 
(IQR 5–8).The time between end of radiotherapy and the postradiotherapy staging scan 
was 3 weeks (IQR 2–5). The median time between the two scans was 15 weeks (IQR 
12.5–17). The median time between the end of radiotherapy and surgery was 9 weeks 
(IQR 8–10). The median time between the postradiotherapy scan and surgery was 
5 weeks (IQR 3–6) (Fig. 1).
Figure I. Time interval of treatment
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Chest and abdominal CT scans after radiotherapy demonstrated significant additional 
findings of metastases compared to the scans before radiotherapy, 11 patients (five 
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and lung metastases) (P = 0.001). Details of the CT scan findings before and after 
radiotherapy are described in Table I. 
 
 
 
 
 
 
 
Chest and abdominal CT scans after radiotherapy demonstrated significant additional 
findings of metastases compared to the scans before radiotherapy, 11 patients (five 
liver metastases, five lung metastases, and one with both liver and lung metastases) 
versus 25 patients (14 liver metastases, seven lung metastases, and four with both 
liver and lung metastases) (P = 0.001). Details of the CT scan findings befor  nd after 
radiotherapy are described in Table I.
42
Chapter 3
Table I: Diagnostic findings of restaging after radiotherapy
Before RTx After RTx No. of patients
Normal Normal 96
Normal LrM 6
Normal LrM + lung IL 1
Normal LrM + lung LNS 1
Normal LrM + LnM 1
Normal LnM 3
Normal Liver IL 6
Normal Lung IL 5
Normal Lung LNS 3
Liver IL Normal 5
Liver IL Liver IL 1
Liver IL LrM 2
Liver LNS Normal 1
Liver LNS Liver LNS 2
LrM LrM 2
LrM LrM + LnM 2
LrM LrM + lung LNS 1
LrM + LnM LrM + LnM 1
Lung IL LrM 1
Lung IL Lung IL 1
Lung IL Lung LNS 2
Lung IL Normal 3
LnM Normal 1
LnM LnM 4
Liver IL + lung IL Lung LNS 1
Liver LNS + lung LNS Liver LNS + lung LNS 1
RTx radiotherapy, LrM liver metastases, LnM lung metastases, IL indeterminate lesions, LNS lesions not 
suspicious
Of the 153 patients treated with neoadjuvant radiotherapy with curative intent, 107 
received a long course of chemoradiotherapy and 46 a long course of radiotherapy only. 
In ten patients, metastases were detected on the staging scan before radiotherapy, and 
in 143 patients, the scan before radiotherapy did not reveal any metastases. Of the 
143 patients without metastases on the staging scan before radiotherapy, 15 patients 
(10 %) had metastases on the restaging scan after radiotherapy. A change in treatment 
strategy due to new findings was carried out in 13 patients (9 %). A resection for rectum 
carcinoma was not performed in 7 (5 %) of 143 patients (Table II).
43
Chapter 3
3
Table II. Metastases found on restaging scan in 143 patients with previously undetected metastases
Before 
RTx RTx After RTx Treatment
Change in 
treatment strategy
Normal RTx LrM + lung IL Palliative CTx Yes
Normal CTx, RTx LrM + LnM Palliative CTx Yes
Normal CTx, RTx LrM LAR + liver resection Yes
Normal CTx, RTx LrM LAR + liver resection Yes
Normal CTx, RTx LrM Palliative CTx Yes
Normal CTx, RTx LrM LAR + liver resection Yes
Normal RTx LrM Palliative CTx Yes
Normal CTx, RTx LrM + lung 
LNS
LAR + liver resection Yes
Normal RTx LrM Palliative CTx Yes
Normal CTx, RTx LnM APR + SRx Yes
Normal CTx, RTx LnM APR (palliative) + palliative CTx Yes
Normal RTx LnM + other LAR (palliative) No
Liver IL CTx, RTx LrM LAR + liver resection Yes
Liver IL RTx LrM + other Palliative CTx Yes
Lung IL CTx, RTx LrM Laparotomy, peritoneal 
carcinomatosis → palliative CTx
No
RTx radiotherapy, CTx chemotherapy, LAR low anterior resection, APR abdominal perineal resection, LrM 
liver metastases, LnM lung metastases, SRx stereotactic body radiation, IL indeterminate lesions, LNS 
lesions not suspicious
In the ten patients with metastases detected on the staging scan before radiotherapy, a 
change in treatment strategy was carried out in 5 (50 %) as a result of new findings on 
the postradiotherapy staging scan. A resection for rectum carcinoma was not performed 
in 5 (50 %) of ten patients (Table III).
Table III. Metastases found on restaging scan in 10 patients with previously detected metastases
Before RTx RTx After RTx Treatment
Change in 
treatment
LrM RTx Progression of LrM Palliative CTx Yes
LrM CTx, RTx LrM LAR + liver resection No
LrM CTx, RTx LrM LAR + liver resection No
LrM CTx, RTx LrM + LnM Palliative CTx Yes
LrM RTx LrM + LnM Palliative CTx Yes
LnM CTx, RTx LnM APR No
LnM CTx, RTx LnM LAR No
LnM RTx Progression of LnM Supportive care Yes
LnM CTx, RTx LnM APR + lobectomy No
LrM + LnM RTx LrM + progression of LnM Palliative CTx Yes
RTx radiotherapy, CTx chemotherapy, LAR low anterior resection, APR abdominal perineal resection, LrM 
liver metastases, LnM lung metastases
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In the total group of 153 patients, a change in treatment strategy due to new findings 
was carried out in 18 (12 %). None of the patients had false-positive metastases on 
pathology and/or follow-up. Twelve (8 %) of 153 patients were spared rectal surgery as a 
result of new findings.
Discussion
We evaluated the value of restaging with CT scan for distant metastases after 
neoadjuvant radiotherapy with or without chemotherapy in patients with locally advanced 
rectal cancer. A change in treatment strategy due to new findings was observed in 
12 % of the patients. In the total group, 8 % of patients were spared rectal surgery 
due to progressive metastatic disease.Local staging of rectum carcinoma has important 
implications for the choice of optimal treatment. In patients with locally advanced 
rectum cancer, improved local control can be achieved with a long course of preoperative 
radiotherapy in combination with neoadjuvant chemotherapy.15
Distant metastases have implications on the treatment options. For the screening of 
liver metastases, there consensus among oncologists that CT or MRI be performed. For 
the screening of lung metastases, they recommend the use of a chest X-ray or a CT 
scan.7-9
It is known that locally advanced rectal cancer has a higher risk of developing 
metastases than colon cancer.5,6,8,10 The recommended treatment for locally advanced 
rectal cancer is a long course of radiotherapy with or without chemotherapy.8 Surgery is 
usually planned 6–10 weeks after finishing neoadjuvant therapy. During these 3 months, 
metastases can develop that previously were too small to be detected or were not 
present at all. Therefore, it seems prudent to restage the patient for distant metastases 
after radiotherapy and before commencing surgery because new findings in this relatively 
long period might alter the treatment options. In case of unresectable metastatic disease, 
resection of the primary tumor is unnecessary from an oncological point of view.16-19 
Through restaging, patients might therefore be spared an unnecessary extensive pelvic 
operation.
We found a large interval between the staging scan and the beginning of radiotherapy. 
Most patients were referred to our hospital, and this wide interval is a consequence of 
logistic management. We do not know whether this wide range has an influence on the 
outcome of our study.
Local staging techniques have previously been described for locally advanced rectal 
cancer.20-25 To our knowledge, this is the first study describing restaging for distant 
metastases after radiotherapy and before commencing surgery in patients with locally 
advanced rectal cancer.
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Restaging is only necessary if there are consequences for the treatment strategy 
in case of additional diagnostic findings. Additional findings can result in treatment of 
metastases, or in case of unresectable metastases, no resection of rectal tumor and 
optional treatment with palliative chemotherapy. In our series, 12 % of the total group of 
153 patients had a change in the treatment due to findings on the postradiotherapy CT 
scan. A resection for locally advanced rectal cancer was prevented in 67 % of the latter 
patients as a result of findings on the postradiotherapy CT scan.
Several studies have demonstrated the abdominal CT scan to be a reliable diagnostic 
tool for detecting liver metastases, and CT scan has proven to be better than 
ultrasound.26-28 There are limited data describing the optimal chest staging strategy 
for these patients.29  Some authors conclude that the low incidence of pulmonary 
metastases and minimal consequences for the treatment plan limits the clinical value 
or routine staging chest CT before operation.29,30 It has several disadvantages such 
as cost, radiation exposure, and prolonged uncertainty due to the frequent finding of 
indeterminate lesions.30  However, these results were not assessed in the selected group 
of patients with locally advanced rectal cancer. Choi et al. demonstrated that staging 
before neoadjuvant radiotherapy with a chest CT for patients with locally advanced 
rectal cancer seems reasonable.4 Moreover, these patients can benefit from resection 
of pulmonary metastases because resection can significantly improve survival.31 In 
our specific patient population, all patients will have two CT scans at a median interval 
of 15 weeks. In case of indeterminate lesions, this will help differentiate between 
metastases and benign lesions.
We recognize the limitations of this retrospective study in our single-center database; 
patients were not randomized to have a restaging scan or not, with all inherent biases. 
Only patients who had complete imaging before and after radiotherapy were included. 
However, more patients received restaging scans but not all preoperative imaging was 
available. Not including these patients can cause bias in this study.
In conclusion, this study demonstrated that restaging with a CT scan after radiotherapy 
is a worthwhile step in the treatment of locally advanced rectal cancer because additional 
findings may alter the treatment strategy.
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Primary staging
Primary staging in rectal cancer is essential for determining the optimal treatment 
strategy and consists of local staging and screening for distant metastases. Local staging 
is important to determine the surgical approach and to identify individual risk factors for 
recurrence, such as depth of extramural spread, lymph node involvement, mesorectal 
fascia (MRF) involvement and extramural vascular invasion.1-4 Patients with low risk 
for recurrence can be treated by surgery alone, whereas patients with a high risk for 
recurrence must be treated with neoadjuvant (chemo-)radiotherapy to decrease the 
chance of local recurrence.5,6
Screening for distant metastases is important to identify metastasized patients who 
require a different treatment approach. Patients with resectable synchronous distant 
metastases should be treated with curative intent by resection of the distant metastases 
and primary tumor. Patients with unresectable distant metastases can be safely spared 
rectal surgery and treated with systemic chemotherapy with a low chance of emergency 
surgery.7
For primary local staging, magnetic resonance (MR) imaging is superior compared to 
other imaging modalities currently available. Accuracies of tumor staging, nodal staging 
and MRF-involvement by MR imaging are higher compared to the accuracies of Computed 
Tomographic (CT) scans and endoscopic ultrasound sonography (EUS).8-10 Moreover, the 
multicenter Mercury study with 12 colorectal units in 4 European countries showed MR 
imaging to be highly accurate and reproducible.11 Therefore, MR imaging is recommended 
in all guidelines as preferred imaging modality in the preoperative assessment of rectal 
cancer.12-14  For screening for distant metastases, most guidelines advise a thoraco-
abdominal CT-scan.12,14
Chemoradiotherapy and potential benefits of restaging
Neoadjuvant chemoradiotherapy (CTxRTx) is administered to reduce local recurrence 
rates, to facilitate  tumor downstaging and additionally leads to a pathological complete 
response (pCR) in 11-19%.3,6,15-17 The identification of good versus poor responders 
before definitive surgery is important, because patients may be offered less radical or 
rather more radical surgery. Therefore, patients are increasingly being restaged after 
administering CTxRTx and many advocate to perform restaging routinely.18 Restaging 
could have implications for surgical management. For example, tumor shrinkage may 
lead to sphincter sparing surgery instead of an abdominoperineal resections with a 
permanent stoma. Furthermore, there is a growing interest in selecting those patients 
who are likely to have achieved a pCR, because these patients could be offered a ‘wait 
and see policy’ and spared rectal surgery at all.
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Does restaging alters treatment strategy and is it safe?
The most important problem of restaging is that generally the accuracy of predicting 
tumor stage is poor. This is mainly caused by the difficulty differentiating between vital 
tumor and radiation induced fibrosis. Other radiation-induced changes, such as edema, 
inflammation and necrosis also contribute to a poor accuracy. Especially, the sensitivity 
of tumor staging in patients after CTxRTx is concerning. A recent meta-analysis reported 
a poor mean sensitivity of 50% and a mean specificity of 91%, while only discriminating 
between T0-2 vs. T3-4.19 Accuracies predicting exact tumor stage are even poorer.20,21 On 
the other hand, the accuracy of predicting lymph node involvement in restaging is higher 
compared to primary staging, but still the specificity nodal restaging is concerning. The 
same meta-analysis reported a mean specificity of 60% and a mean sensitivity of 76%.19
One of the most important questions regarding the clinical use of restaging remains 
unanswered: Does restaging indeed alter surgical treatment? Theoretically, tumor 
downstaging caused by CTxRTx may result in more sphincter saving procedures, which 
could explain the increase of the sphincter sparing procedures in the last decades from 
17% in the early 80s22 to 79% in 2011.23 However, none of the randomized controlled 
trials evaluating the effect of CTxRTx was able to demonstrate a significant increase in 
the rate of sphincter saving surgery. This suggests that the increase is more likely to be 
caused by advances in the surgical practice than by administering CTxRTx.24 Moreover, 
it remains unclear whether performing less radical procedures in downstaged patients is 
safe, keeping in mind that imaging is insufficient to detect possible vital tumor remnants 
in the radiation induced fibrosis.25 Another problem is the considerable change of under- 
and overstaging. Obviously, the risk of overstaging is higher due to the replacement 
of vital tumor into fibrosis, but understaging of tumor status occurs in 7-22% of the 
patients.20,21,26 Surgeons should be cautious performing less radical resections based on 
restaging imaging, because understaging may lead to incomplete resections and these 
are disastrous for oncologic outcome.2
A potential interesting aspect of restaging is that in case of complete tumor 
disappearance treatment plan could be altered into a wait and see policy. Although the 
results of studies with a wait and see policy are promising,27,28 it is important to realize 
that omitting surgery is no standard practice. The results of a wait and see policy are 
based on few studies and the majority of the studies originates from one single center 
with limited long term follow up. Based on these data, a wait and see policy is not proven 
to be safe. Therefore, restaging with the idea to alter treatment plan into a wait and 
see policy should only be performed in clinical trials. Moreover, due to the very poor 
sensitivity of predicting a pCR of 19%, restaging in a wait and see policy should only 
be performed as an integrated part of several examinations, including endoscopy and 
digital examination.19 The diagnostic accuracy of predicting a pCR may be increased 
by performing local excisions by transanal endoscopic microsurgery (TEM). In the 
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near future, the CARTS trial will provide the answer whether this approach is safe and 
feasible.29 However, not only accurate determination of tumor stage is important to safely 
alter treatment into a wait and see policy. Accurate assessment of possible malignant 
lymph nodes is at least even important. Unfortunately, the specificity of 60% of nodal 
restaging shows there is a considerable chance of missing malignant lymph nodes.
Benefits of local restaging
A potential involved circumferential resection margin (CRM) or the relationship of the 
tumor to the MRF has emerged as one of the most powerful predictors of outcome. 
Surgical dissection outside of this fascia has become central in the efforts to achieve 
CRM negativity and is possible in many cases. This is the concept behind the beyond 
total mesorectal exicion (TME) approach.30 The accuracies of predicting MRF-involvement 
after CTxRTx are acceptable with a sensitivity of 76% and a specificity of 86%.19 This 
makes restaging is useful for determining MRF-involvement in patients and to assess the 
need for resections beyond the TME plane. However, surgeons should keep in mind that 
there is a considerable change of overtreatment by performing unnecessary multivisceral 
resections or undertreatment by performing incomplete resections.
Another interesting and potentially useful aspect of restaging is that radiologically 
determined tumor response can be used as early prognostic factor. The mercury study 
group has demonstrated that radiologically determined poor tumor response was 
associated with poorer overall survival and disease free survival.31 In these patients, 
post-operative follow up could be intensified to detect distant metastases in an early 
stage or could be offered more aggressive (neo)adjuvant therapy.
Improvements in accuracy of  local restaging
Although accuracies of restaging are generally poor, there have been gains in restaging 
accuracies in the hands of dedicated and experienced radiologists. Recent studies have 
reported accuracies up to 80%.25,32,33 This is caused by the use of high resolution MRI 
techniques, the use of validated reporting criteria and by diffusion weighted (DW) 
imaging. DWI-MRI significantly improves accuracies in tumor staging and also seems to 
improve the sensitivity of predicting a pCR.19,34
Restaging for distant metastases
Generally, rectal surgery is scheduled after an interval of 6 weeks after ending CTxRTx. 
However, rectal surgery is now often postponed to 9 or even 12 weeks as longer intervals 
may enhance tumor downstaging, increase pCR rates and reduce complication rates.35,36 
Currently, the interval between initial staging and surgery may take up to 4-5 months. 
Due to this long interval, restaging by a thoraco-abdominal CT-scan could detect distant 
metastases, which developed during CTxRTx. Also considering that only the advanced 
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stages of rectal cancer with subsequently the highest risk of developing of distant 
metastases are treated with CTxRTx. Two recently published studies have demonstrated 
the development of distant metastases in 7-12% of the patients being restaged by a 
thoraco-abdominal CT-scan.21,37 This is essential information, because the development 
of distant metastases alters the optimal surgical strategy. Patients with resectable 
metastases can undergo resections of both rectal tumor and distant metastases, while 
patients with unresectable metastases can be spared rectal surgery.
Conclusions
Currently, the actual benefits of local restaging for clinical practice are limited. Accuracies 
of tumor and nodal staging after administering CTxRTx are too low to safely alter 
definitive surgical procedure or to apply a wait and see policy. However, restaging is 
useful to evaluate MRF-involvement in locally advanced rectal cancer and to assess 
whether resections beyond the TME plane are necessary. Furthermore, restaging can 
evaluate tumor response, which can be used as early prognostic factor. Restaging by 
thoraco-abdominal CT-scan is valuable to detect distant metastases developing during 
CTxRTx. A considerable proportion develops distant metastases during CTxRTx and 
these patients require a different surgical strategy. Moreover, some patients develops 
unresectable distant metastases and these patients can even be spared rectal surgery. 
Future research should focus on improvement of restaging accuracies and on evaluating 
the safety of performing less radical surgery in downstaged patients.
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Abstract
Purpose
Intraoperative radiotherapy (IORT) is advocated by some for patients with locally 
advanced rectal cancer (LARC) who have involved or narrow circumferential resection 
margins (CRM) after rectal surgery. This study evaluates the potentially beneficial effect 
of IORT on local control.
Methods
All surgically treated patients with LARC treated in a tertiary referral center between 
1996 and 2012 were analyzed retrospectively. The outcome of patients treated with IORT 
with a clear but narrow CRM (≤2mm) or a microscopically involved CRM was compared to 
patients who were not treated with IORT.
Results
A total of 409 patients underwent resection of LARC and 95 patients (23%) had a CRM 
≤2mm. Four patients were excluded from further analysis due to a macroscopically 
involved resection margin. In 43 patients with clear but narrow CRMs, there was no 
difference in the cumulative 5-year local recurrence-free survival of patients treated 
with (n=21) or without IORT (n=22) (70 vs. 79%,p=0.63). In 48 patients with a 
microscopically involved CRM, there was a significant difference in the cumulative 5-year 
local recurrence-free survival in favor of the patients treated with IORT (n=31) compared 
to patients treated without IORT (n=17) (84 vs. 41%,p=0.01). Multivariable analysis 
confirmed that IORT was independently associated with a decreased local recurrence rate 
(HR 0.24, 0.07–0.86). There was no significant difference in complication rate of patients 
treated with or without IORT (65% vs. 52%,p=0.18)
Conclusion
The current study suggests that IORT reduces local recurrence rates in patients with 
LARC with a microscopically involved CRM.
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Introduction
Local control is an important goal of the surgical treatment of rectal cancer. Local 
recurrences are usually accompanied by severe pain and poor quality of life.1 One of the 
most important predictive factors for local recurrence is the circumferential resection 
margin (CRM).2 The recognition of an involved CRM as one of the main causes of local 
recurrences has led to the introduction of total mesorectal excision (TME), resulting 
in less involved margins and consequently less local recurrences. A further decrease 
of CRM-involvement was caused by introducing neoadjuvant (chemo-)radiotherapy. 
Unfortunately, despite using neoadjuvant (chemo-)radiotherapy followed by TME, 
CRM-involvement is still reported in 17–20% of the patients with locally advanced rectal 
cancer (LARC) and results in local recurrence rates of 55–62% in these patients.3,4
Several institutes worldwide have integrated intraoperative radiotherapy (IORT) to 
the multimodality approach of LARC to improve outcome. IORT refers to the delivery 
of a boost of radiation at the time of surgery. One single IORT dose results in a two 
to three times higher biological equivalent than the same dose given by conventional 
fractionation.5 The rationale behind IORT is that this extra radiation boost, if preceded 
by neoadjuvant radiotherapy, may be able to eradicate microscopic remnants after an 
incomplete resection. In addition to patients with microscopically involved CRMs, IORT 
may also be beneficial in patients with a clear but narrow CRM (≤2mm), because these 
patients are also known to have a higher risk of local recurrence.6
In the literature, the results of the effect of IORT on local control in patients with LARC 
are contradictory. Some retrospective studies reported a beneficial effect 7-11, but others, 
including a recently published randomized controlled trial, did not find any beneficial 
effect.12-14 However, these studies report on patients that in the majority of cases had 
radical resections and some describe both LARC and locally recurrent rectal cancer 
patients. Comparative studies focusing on LARC with involved or clear but narrow CRMs 
specifically are lacking. The aim of the current study is to evaluate whether IORT after 
neoadjuvant radiotherapy decreases the local recurrence rate in patients with LARC with 
a microscopically involved CRM or a clear but narrow CRM after TME.
Patients and methods
Between 1996 and August 2012, all patients undergoing curative TME for LARC in the 
Erasmus Cancer institute, a tertiary referral center for T4 colorectal cancer for the 
southwest region of The Netherlands, were entered in a database. LARC was defined as 
large T3 or T4 rectal tumors with clinical suspicion of narrow or involved CRMs with or 
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without potentially malignant lymph nodes, or rectal tumors with potentially malignant 
lymph nodes outside the TME plane.
Based on the final pathology report, all patients with a CRM equal or less than 2 mm 
were retrospectively analyzed. These patients were divided into two groups; a group 
with resections with a clear, but narrow CRM (≤2mm) and a group with a microscopically 
involved CRM. In these groups, we compared the local recurrence-free survival and 
overall survival of the patients who were treated with and without IORT.
Neoadjuvant (chemo-)radiotherapy
All patients received preoperative (chemo-)radiotherapy, either as a short course (25Gy) 
delivered in 5 fractions or as a long course (44,6–50Gy) delivered in 19-25 fractions. 
From 2006 onwards, patients received chemoradiotherapy with capecitabine administered 
orally at a dose of 825 mg/m2 twice a day during radiotherapy days as reported 
previously.15 Before 2006, no patient received concomitant chemotherapy. Radiotherapy 
was administered by a three-field technique, using one posterior and two lateral portals, 
a four-field box or with five fields using intensity modulated radiotherapy. The lateral 
pelvic borders were defined as 1.5cm lateral of the bony pelvis, the cranial border was 
the promontory, and the caudal border was below the foramina obturatoria to 2cm under 
the anus, depending on tumor position.
Surgery, intraoperative radiotherapy and adjuvant 
treatment
Surgical strategy was planned preoperatively in a multidisciplinary tumor board. TME was 
performed in all patients and multivisceral ‘beyond TME’ resections were performed in 
those with tumor ingrowth into surrounding structures. Patients in whom a CRM ≤2mm 
was expected were planned in an operation theatre with IORT facilities. During surgery, 
CRM status was evaluated on frozen sections. When the CRM was ≤2mm, IORT was 
applied to the resection area involved. Patients in whom a CRM >2mm was expected 
were planned in an operation theatre without IORT facilities and no standard frozen 
sections of the specimen were taken.
IORT was delivered by high dose rate (HDR) brachytherapy. The area where the 
resection margin was considered to be at risk was marked with surgical clips. IORT was 
administered to this area by a flexible intraoperative template (FIT), which was described 
previously.16 a 5mm-thick pad made of flexible silicon with 1cm-spaced parallel source 
guide tubes running through the center of the template. The size and shape of the FIT 
were adjusted by surgeon and radiation oncologist. Thereafter, it was placed on the 
target surface. Treatment planning was performed using the standard geometries present 
in the treatment planning system. A dose of 10Gy was delivered, usually at 1cm depth 
from the applicator surface. Peri-operative morbidity was divided into surgical and non-
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surgical morbidity and was graded according to the Dindo-Clavien classification.17 Our 
treatment protocol for LARC does not include adjuvant chemotherapy or postoperative 
radiotherapy. Nevertheless, some patients received adjuvant chemotherapy or underwent 
postoperative radiotherapy.
Follow up
Patients visited the outpatient clinic every 3 months during the first two years. 
Thereafter, patients were examined biannually. The first two years CEA determination 
was performed every 3 months and thoracic and abdominal imaging biannually. After 
2 years of follow up, CEA determination was performed biannually and thoracic and 
abdominal imaging yearly. Patients were usually discharged from further follow up after 
5 years. During follow up, a local recurrence was established by symptoms, CEA increase 
or imaging. All suspected recurrences were confirmed by CT or MR imaging. Biopsies 
were attempted routinely.
Statistical analysis
Statistical analysis was carried out using SPSS (version 20.0.0). Data was reported as 
median (interquartile range). Categorical data was reported as count (percentage). 
The Chi-square, Fisher’s exact and Mann-Whitney U test were used for comparison 
of both groups as appropriate. Univariate local recurrence-free survival and overall 
survival analyses were carried out by means of Kaplan–Meier curves and log rank tests. 
Univariate and multivariable analyses by Cox hazard regression models were performed  
to determine the prognostic value of covariates.
Results
A total of 409 patients underwent TME surgery for LARC between 1996 and August 2012. 
Neoadjuvant (chemo-)radiotherapy was administered to 399 patients. Of these patients, 
95 patients had a CRM ≤2mm on final pathology report. Forty-three patients had a 
clear but narrow CRM ≤2mm and 48 patients had a microscopically involved CRM. Four 
patients underwent a macroscopic irradical resection and were not included in this study. 
(Fig. I)
64
Chapter 5
Figure I. Study flowchart of all patients
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Resections with a clear but narrow CRM (≤2mm)
Patient and tumor characteristics of the patients with radical resections with a clear 
but narrow CRM ≤2mm are depicted in table I. Twenty-one patients were treated with 
IORT (49%), whereas 22 patients (51%) did not receive IORT. The main reasons for 
not administering IORT was preoperative understaging (n=14). In these patients, 
perioperative frozen sections were not performed and IORT was not considered. The 
other cause for omitting IORT was a false-negative result of the perioperative frozen 
sections, while the CRM proved to be ≤2mm on final pathology report (n=8).
Surgery, perioperative results and adjuvant treatment
The interval between ending radiotherapy and surgery was 9 (interquartile range, 7–12) 
weeks for the patients treated with IORT and 8 weeks  (interquartile range, 7–11) for 
the patients treated without IORT (p=0.91). There were no differences in the surgical 
procedures and TNM stage (table II). Operation time was significantly longer and there 
was significantly more blood loss in patients treated with IORT. One patient treated with 
IORT received adjuvant chemotherapy compared to 2 patients who were not treated with 
IORT.
Local recurrence-free survival and overall survival
The median follow up was 38 (interquartile range, 15-66) months for patients treated 
with IORT and 39 (interquartile range, 11–73) months for patients treated without IORT. 
The estimated 3- and 5-year local recurrence-free survival of the 21 patients treated with 
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IORT was 82% and 70% respectively. This did not significantly differ from the 3- and 
5-year local recurrence-free survival of 79% and 79% respectively of patients treated 
without IORT (p=0.63) (figure IA). Further univariate analysis for local recurrence-free 
survival is outlined in table III. Five-year overall survival did not differ significantly 
between patients treated with or without IORT (63 vs. 81%,p=0.28). The only 
independent prognostic factor for overall survival was synchronous metastatic disease 
(HR 5.18, CI95%: 1.27–21.2).
Resections with a microscopically involved CRM
Patient and tumor characteristics of 48 patients with a microscopically involved CRM are 
depicted in table I. IORT was administered to 31 patients (65%), whereas 17 patients 
(35%) did not receive IORT. In 12 patients the reasons for not administering IORT was 
preoperative understaging, whereas 5 patients had false-negative frozen section results. 
In patients not treated with IORT, stage IV disease was more common than in patients 
treated with IORT (52 vs. 13%,p=0.01).
Table I. patients and tumor characteristics
Clear but narrow CRM ≤2 mm
Resections with a microscopically 
involved CRM
Non IORT 
(%)
IORT  
(%) p-value
Non IORT 
(%)
IORT  
(%) p-value
Total 22 21 17 31
Gender
Male 15 (68) 18 (86) - 11 (65) 23 (74) -
Female 7 (32) 3 (14) 0.28* 6 (35) 8 (26) 0.73**
Age ₸ 59 (17–76) 66 (43–76) 0.08*** 56 (23–75) 61 (18–77) 0.84***
Neoadjuvant treatment
Short course RTx 1 (5) 1 (4) - 3 (18) 2 (6) -
Long course RTx 9 (41) 12 (50) - 9 (53) 13 (42) -
Chemoradiotherapy 12 (55) 8 (33) 0.55** 5 (21) 16 (52) 0.24**
Tumor localization
≤ 5 cm 12 (55) 11 (52) - 9 (53) 16 (52) -
> 6 cm 10 (45) 10 (48) 0.69** 8 (47) 15 (48) 0.93**
Clinical tumor stage
T3 13 (59) 6 (29) - 8 (47) 10 (32) -
T4 9 (31) 15 (71) 0.04 9 (53) 21 (68) 0.31
Clinical nodal stage
N0 10 (46) 13 (62) - 7 (41) 13 (42) -
N+ 12 (54) 12 (38) 0.65 10 (59) 18 (58) 0.96
CRM, Circumferential resection margin, IORT, intra-operative radiotherapy ₸, Years (interquartile 
range); RTx, Radiotherapy, CTx, Chemotherapy; * using Fisher’s exact test; **, Using χ²; ***, using 
Mann-Whitney U test
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Surgery, perioperative results and adjuvant treatment
The interval between ending radiotherapy and surgery was 8 (interquartile range, 6–11) 
weeks for the patients treated with IORT and 7 (interquartile range, 6–9) weeks for the 
patients treated without IORT (p=0.18). Surgical procedures were similar in both groups 
(table II). Operation time was significantly longer in the IORT group. Two patients treated 
without IORT received an adjuvant radiation boost of 20–30Gy and one patient received 
adjuvant chemotherapy. No patients treated with IORT received adjuvant therapy.
Local recurrence-free survival and overall survival
The median follow up was 23 (interquartile range, 11–46) months for patients treated 
with IORT and 12 (interquartile range, 6–22) months for patients treated without IORT. 
Of the patients treated with IORT, 4 patients developed a local recurrence, whereas 14 
Table II. Surgical, pathological results and adjuvant therapy
Clear but narrow CRM ≤2 mm
Resections with a microscopically 
involved CRM
Non IORT 
(%)
IORT (%) p-value Non IORT 
(%)
IORT (%) p-value
Total 22 21 17 31
Surgical procedure
LAR 8 (40) 4 (19) - 6 (35) 4 (13) -
APR 6 (27) 9 (43) - 6 (35) 14 (45) -
Intersphinteric 1 (5) 1 (5) - 0 1 (3) -
Posterior exenteration 5 (23) 3 (14) - 3 (9) 5 (16) -
Total exenteration 2 (9) 4 (19) - 2 (6) 4 (13) -
Abdominoperineal sacral 0 0 0.55** 0 3 (10) 0.40**
Operation time (minutes) ₸ 317  
(145–672)
481  
(258–662)
0.003*** 293  
(220–343)
495  
(433–580)
<0.001***
Blood loss (milliliters) ₸ 1650  
(200– 12.500)
3.300  
(300 –20.000)
0.016*** 1750  
(790–3290)
3000  
(1700–5350)
0.10***
Tumor stage
T3 16 (72) 17 (81) - 9 (52) 11 (35) -
T4 6 (28) 4 (19) 0.72* 8 (48) 20 (65) 0.40**
Nodal stage
N0 10 (45) 11 (52) - 7 (41) 19 (61) -
N+ 12 (55) 10 (48) 0.65** 10 (59) 12 (39) 0.18**
Distant metastases 4 (18) 3 (15) 1.00* 9 (52) 4 (13) 0.01*
Pulmonary 0 0 - 1 (5) 1 (3) -
Liver 4 (18) 3 (15) - 8 (47) 3 (10) -
Adjuvant therapy
Chemotherapy 1 (5) 2 (10) - 1 (6) 0 -
Radiotherapy 0 0 - 2 (12) 0 -
CRM, Circumferential resection margin, IORT, Intra-operative radiotherapy; LAR, Low anterior resec-
tion; APR, Abdominoperineal resection ₸,Interquartile range; *, Using Fisher’s exact test; **, Using χ²; 
***, Using Mann Whitney U test
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Table III. Univariate analysis of local recurrence-free survival and overall survival of resections with 
a clear but narrow CRM ≤2mm
Local recurrence-free survival Overall survival
Number 
of 
patients
Hazard ratio 
local recurrence 
(95%CI)
P-value Hazard ratio 
overall survival 
(95%CI)
P-value
Gender
Male 33 1 1
Female 10 2.50 (0.56 – 11.21) 0.23 1.55 (0.39 – 6.22) 0.63
Neo-adjuvant Treatment
RTx (25-50Gy) 23 1 1
CTxRTx (50Gy) 20 0.21 (0.09 – 11.09) 0.23 0.48 (0.10 – 2.35) 0.37
Period of surgery
1996-2004 18 1 1
2005-2012 25 0.26 (0.20 – 1.39) 0.18 0.92 (0.24 – 3.50) 0.91
Surgical resection
LAR 15 1 1
APR 28 3.05 (0.36 – 25.41) 0.27 1.81 (0.38 – 8.70) 0.52
Tumor stage
T3 32 1 1
T4 11 1.75 (0.34 –- 9.12) 0.51 2.12 (0.53 – 8.53) 0.66
Nodal stage
N- 21 1 1
N+ 22 0.96 (0.19 – 4.72) 0.96 0.63 (0.14  - 2.81) 0.54
CRM
>0 and ≤1 mm 14 1 1
>1 and ≤2 mm 29 0.77 (0.18 – 3.56) 0.67 2.16 (0.45 – 10.42) 0.32
Metastatic disease
No 36 1 1
Yes 7 1.54 (0.18 – 13.14) 0.69 5.18 (1.27 – 21.22) 0.02
Tumor differentiation 
grade
Well and moderate 36 1 1
Poor 7 1.11 (0.13 - 9.58) 0.92 2.00 (0.40 – 9.98) 0.40
Vasoinvasion
No 32 1 1
Yes 11 1.77 (0.32 – 9.56) 0.51 1.70 (0.32  – 9.16) 0.53
Tumor localization
≤ 5 cm 25 1 1
> 6 cm 18 2.13 (0.42 – 10.75) 0.36 0.79 (0.15 – 4.06) 0.77
IORT
No 22 1 1
Yes 21 1.44 (0.32 – 6.47) 0.63 2.10 (0.53 – 8.42) 0.29
CRM, Circumferential resection margin; RTx, Radiotherapy; CTxRTx, Chemoradiotherapy; LAR, Low 
anterior resection; APR, Abdominoperineal resection; IORT, Intraoperative radiotherapy
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Table IV. Univariate local recurrence free survival and overall survival of resections with a micro-
scopically involved CRM
Local recurrence-free survival Overall survival
Number 
of 
patients
Hazard ratio 
local recurrence 
(95%CI)
P-value Hazard ratio 
overall survival 
(95%CI)
P-value
Gender
Male 34 1 1
Female 14 2.82 (0.86 – 9.26) 0.09 0.86 (0.38 – 1.95) 0.72
Neo-adjuvant Treatment
RTx (25-50Gy) 27 1 1
CTxRTx (50Gy) 21 0.51 (0.14 – 1.93) 0.32 0.46 (0.19 – 1.13) 0.08
Period of surgery
1996-2004 21 1 1
2005-2012 27 1.05 (0.32-3.45) 0.94 0.76 (0.37 – 1.58) 0.47
Surgical resection
LAR 14 1 1
APR 34 0.46  (0.14 – 1.52) 0.20 1.2 (0.53 – 2.72) 0.66
Tumor stage
T3 20 1 1
T4 28 0.63 (0.19 – 2.09) 0.45 1.82 (0.80 – 3.73) 0.17
Nodal stage
N0 26 1 1
N+ 22 1.32 (0.36 – 5.01) 0.66 1.1 (0.49 – 2.41) 0.82
Metastatic disease
No 35 1 1
Yes 13 2.86 (0.86 – 9.27) 0.10 1.98 (0.92 – 4.28) 0.08
Tumor differentiation 
grade
Well and moderate 37 1 1
Poor 11 4.88 (1.46 – 15.12) 0.004 1.65 (0.75 – 3.6) 0.21
Vasoinvasion
No 35 1 1
Yes 13 1.09 (0.27 – 4.36) 0.90 1.1 (0.49 – 2.53) 0.80
Tumor localization
≤ 5 cm 25 1 1
> 6 cm 23 1.67 (0.45 – 6.21) 0.45 1.25 (0.56 – 2.78) 0.56
IORT
No 17 1 1
Yes 31 0.23  (0.07– 0.81) 0.016 0.39 0.19– 0.81) 0.01
CRM, Circumferential resection margin; RTx, Radiotherapy; CTxRTx, Chemoradiotherapy; LAR, Low 
anterior resection; APR, Abdominoperineal resection; IORT, Intraoperative radiotherapy
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patients died without developing a local recurrence. Of the patients treated without IORT, 
7 patients developed a local recurrence, whereas 7 patients died without developing a 
local recurrence. This resulted in significant difference in 5-year local recurrence-free 
survival in favor of the patients treated with IORT (84% vs. 41%,p=0.01). This is 
shown in figure IB. When 2 two patients who received a post-operative radiotherapy 
boost were excluded, the difference in 5-year local recurrence-free survival was more 
pronounced (84% vs. 33%, p=0.004). Further univariate analysis is depicted in table IV. 
Figure IA: local recurrence-free survival of patients with clear but narrow CRMs (≤2mm)
Figure IB: Local recurrence-free survival of patients with microscopically involved CRMs
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Multivariable analysis confirmed that IORT (HR 0.24, 95%CI: 0.07–0.86) and poor tumor 
differentiation (HR 4.82, 95%CI: 1.46–15.94) were independently associated with local 
recurrence-free survival. There was also a significant difference in 5-year overall survival 
in favor of the patients treated with IORT (41 vs. 13%,p=0.008). Further univariate 
analysis demonstrated that IORT was the only significant prognostic factor for overall 
survival (HR 0.39, CI95%: 0.19–0.81) (table IV).
Perioperative morbidity and mortality of all patients
The perioperative morbidity and mortality is outlined in table V. In 52 patients treated 
with IORT, 38 complications occurred in 34 patients (65%). In 39 patients treated without 
IORT, 23 complications occurred in 20 patients (52%). There was no significant difference 
in number of patients with complications (p=0.18), nor in grade of complications between 
patients treated with or without IORT. A relaparotomy was performed in 2 patients (4%) 
treated with IORT compared to 1 patient (3%) not treated with IORT.
Table V. Peri-operative morbidity and mortality of all patients
Non IORT (%) IORT (%) p-value
Total 39 52
Peri-operative morbidity
Surgical
Abdominal/perineal wound infections 9 (23) 18 (31) 0.14*
Presacral abscess 5 (13) 3 (6) 0.28**
Relaparotomy 1 (3) 2 (4) 1.00**
Anastomotic leakage † 1 (3) 1 (2) -
Wound dehiscence 0 1 (2) -
Non-surgical
Pneumonia/atelectasis 4 (10) 8 (15) 0.76**
Cardiac 1 (3) 2 (6) 1.00**
Urinary tract infection 3 (8) 5 (8) 1.00**
Grading of complications (Dindo-Clavien)
Grade ≥2 10 (25) 17 (33) 0.16**
Grade ≥3 6 (15) 8 (15) 1.00**
Grade ≥4 1 (3) 1 (2) 1.00*
Mortality
In hospital mortality 1 (3) 0 -
IORT, Intraoperative radiotherapy; †, Only in patients with an anastomosis without a diverting
Ileostoma; *, using Fischer’s exact; **, using χ²
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Discussion
The current study suggests that IORT reduces the local recurrence rate in patients with a 
microscopically involved CRM after neoadjuvant radiotherapy for LARC. This study did not 
find evidence that IORT reduces local recurrence rates in patients with a clear but narrow 
CRM (≤2mm). The complication rate is not increased in patients treated with IORT.
Patients with a microscopically involved CRM who were treated with IORT had a 
significantly improved 5-year local recurrence-free survival of 84% compared to 41% 
for the patients who were treated without IORT. This suggests that administering IORT 
can eradicate microscopic remnants after incomplete resections and thus improve local 
control.
The reduction of the local recurrence rate by IORT contradicts the results of a recently 
published randomized controlled trial, which demonstrated no beneficial effect of IORT 
after neoadjuvant radiotherapy.12 However, that study included mostly patients with 
radical resections, thus providing evidence that standard administration of IORT in 
patients with a radical resection is not beneficial. This is in line with our finding that IORT 
had no beneficial effect on patients with radical resections with a clear but narrow CRM. 
Although the recurrence rate in these patients is increased, the recurrence rate is not as 
high as in patients with involved resection margins. Consequently, many more patients 
would be required to confirm a beneficial effect of IORT in this specific patient group; 
neither the randomized controlled trial, nor our study can answer this question
The literature is scarce on the effect of IORT in relation with the resection margin 
status and in particular in patients with R1-resections of LARC. In patients with a 
microscopically involved CRM, local recurrence rates of 41-100% are reported after 
neoadjuvant radiotherapy without administering IORT.3,4,18,19 One comparative study 
demonstrated that IORT improved 5-year local control in patients with a microscopically 
involved CRM.20 Non-comparative studies reported 5-year local control rates after IORT 
for LARC of 55-77% in patients with an involved CRM.9,21-23 These rates are relative low 
compared to our 5-year local recurrence-free survival of 84%, which may be explained 
by the fact that we excluded patients with macroscopically involved margins. Others 
demonstrated that IORT did not result in a similar increase in local control after IORT for 
macroscopically involved resection margins as in patients with microscopically involved 
resection margins.9,11,14 This suggest that IORT may be less or uneffective in patients with 
macroscopic involved resection margins.
Preoperative understaging and false-negative frozen section evaluation resulted in the 
omission of IORT in patients with involved or narrow margins. However, the erroneous 
omission of IORT made it possible for us to make a unique comparison of patients treated 
with or without IORT, which was impossible in other studies from centers that apply IORT 
routinely in LARC patients. Our false-negative rate of CRM-involvement on preoperative 
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imaging and on frozen sections seems high, but one should keep in mind that only 
patients with a CRM ≤2mm were selected. The overall false-negative CRM-involvement 
rate of 409 surgically treated patients was 6% (24/409) which is in line with a 5% false-
negative rate of CRM-involvement in the Mercury trial.24 The 7% (13/196) false-negative 
rate of frozen sections was slightly higher and was probably caused by sampling error. 
Still, this latter finding has led us to change our protocol. Currently, patients in whom 
we judge the risk of sampling error to be high are treated with IORT regardless of frozen 
section results.
Although the operation time was longer and the estimated blood loss was higher in 
patients who were treated with IORT, there was no significant difference in complication 
rate between patients who were treated with or without IORT. Administering an extra 
dose of radiotherapy could contribute to an increased toxicity or a higher complication 
rate. However, administering radiotherapy intraoperatively provides the ability to 
treat a specific area at risk under direct visual control with the possibility to shield 
surrounding structures from radiation. Previous studies from other institutes confirmed 
that administering IORT is safe and feasible and does not result in a higher complication 
rate.10,12 Our overall complication rate of 65% in patients treated with IORT is higher 
compared to other institutes, reporting complications rates of 15-35%.12,20,25 This 
difference may be explained by the fact that we included patients with more advanced 
tumors (≤2mm) and patients undergoing multivisceral resections (33%).
Due to the retrospective nature of this analysis, this study has drawbacks. Different 
neoadjuvant radiotherapy regimes were used in this study. Although the nature of the 
neoadjuvant treatment did not differ significantly, more patients who had microscopically 
involved CRMs treated with IORT had received neoadjuvant chemoradiotherapy. 
This is caused by the fact that chemoradiotherapy was introduced in 2006 and IORT 
was applied with an increasing frequency after 2006. Several randomized controlled 
trials demonstrated that adding chemotherapy during radiotherapy reduces the local 
recurrence rate.26 However, these results were mainly based on radical resections. 
Furthermore, it could be hypothesized that patients with an involved CRM after 
chemoradiotherapy may have an even more aggressive tumor behavior, because 
this group consists of poor responders. This assumption is supported by the study of 
Nagtegaal et al.2 Patients with an involved CRM after (chemo-)neoadjuvant radiotherapy 
had a higher chance on local recurrence than patients with a involved CRM who were 
treated without neoadjuvant (chemo-)radiotherapy.
Another remarkable finding was that in the group of patients who did not receive 
IORT for a microscopically involved CRM, significantly more patients had stage IV 
disease. Patients with stage IV disease were generally referred to our hospital for 
metastatic surgery and not for LARC specifically. Stage IV patients with involved CRMs 
on pathological staging were understaged preoperatively. On the other hand, patients 
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with a compromised CRM on preoperative clinical staging were specifically referred 
for IORT to our hospital, whereas the patients who were understaged preoperatively 
underwent surgery in other hospitals. This may explain the higher number of patients 
with understaged rectal cancer in the group of patients with stage IV disease. Stage IV 
disease was not the reason for omitting IORT; all patients were planned for a curative 
resection by a ‘liver first’ approach, synchronous resection of rectum and metastases or 
resection of the metastases in later stage.27
The presence of metastatic disease explains the shorter length of follow up in patients 
with an involved CRM not treated with IORT. Regardless of this shorter follow up time, 
patients who were not treated with IORT had a higher local recurrence rate compared 
to patients treated with IORT, who were followed longer. Nevertheless, metastasized 
disease may indicate more aggressive tumor behavior, which may also be associated with 
a higher local recurrence rate, even though the presence of synchronous metastases was 
not a significant risk factor for local recurrence in the univariate analysis. The difference 
in stage IV patients makes it inappropriate to draw any conclusions about the effect of 
IORT on overall survival, despite a significant difference between patients treated with or 
without IORT, because distant metastases are the most important prognostic factor for 
overall survival.
Several studies advocated a randomized controlled trial for definitive evidence of the 
effect of IORT in patients with incomplete resections. The accrual of a sufficient number 
of patients for such a trial would be challenging. This is illustrated by the small number of 
patients treated with an involved CRM over a long period of time in a high volume center 
in the current study. Furthermore, it is questionable whether not administering IORT 
in patients with involved margins may be considered acceptable in institutes currently 
performing IORT. Nevertheless, this study is the result of a retrospective analysis and 
therefore all known drawbacks of retrospective studies apply.
In conclusion, IORT does not have a benefit for patients who undergo radical resections 
of rectal cancer. However, our results suggest that IORT reduces the local recurrence 
rate in patients with microscopically involved CRMs. Patients who are at risk for a 
microscopically involved CRM should undergo surgery in centers with IORT facilities.
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Abstract
Background
The treatment of rectal cancer mainly depends on the tumor stage. Clinically staged 
T1-3 rectal cancer (cT1-3) is treated by total mesorectal excision (TME) with or without 
neoadjuvant therapy, whereas cT4 rectal cancer requires a multimodality approach and 
often multivisceral surgery. The current study evaluates the outcome of cT1-3 and cT4 
rectal cancer according to hospital volume.
Methods
This population-based study includes patients undergoing rectal cancer surgery between 
2005 and 2013 in the Netherlands using data from the NCR. Cox-proportional hazards 
model was used for multivariable analysis of overall survival according to hospital 
volume. Hospitals were divided into low(1-20), medium(21-50) and high(>50 resections/
year) volume for cT1-3 and into low(1-4), medium(5-9) and high(≥10 resections/year) 
volume for cT4 rectal cancer.
Results
A total of 14.050 confirmed cT1-3 patients and 2.104 cT4 patients underwent surgery. In 
cT1-3 rectal cancer, there was no significant difference in 5-year overall survival related 
to high, medium and low hospital volume (70% vs. 69% vs.69%). In cT4 rectal cancer, 
treatment in a high volume cT4 hospital was associated with a survival benefit compared 
to low volume cT4 hospitals (HR 0.81 95%CI 0.67-0.98) adjusted for non-treatment 
related confounders. There was increase in referral of cT4 rectal cancer to high volume 
hospitals, but the majority of patients was still treated in low volume hospitals.
Conclusion
Hospital volume was not associated with survival in cT1-3 rectal cancer. In cT4 rectal 
cancer, treatment in high volume cT4 hospitals was associated with an improved survival 
compared to low volume cT4 hospitals.
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Introduction
Colorectal cancer is the third most common malignancy in the Western world and rectal 
cancer accounts for approximately one third of the colorectal cancer patients.1 Outcome 
of rectal cancer has improved over the last two decades, mainly due to the introduction 
of improved imaging modalities, total mesorectal excision (TME) and neoadjuvant 
(chemo-)radiotherapy.2-5
Optimal treatment of rectal cancer is dependent on local tumor stage and the presence 
of distant metastases. Local tumor stage determines whether neoadjuvant (chemo-)
radiotherapy should be administered to reduce local recurrence rate. In lower stages of 
rectal cancer, the effectiveness of neoadjuvant (chemo-)radiotherapy is limited, whereas 
in more advanced stages of rectal cancer (chemo-)radiotherapy is an essential part of the 
treatment.6 It leads to tumor shrinkage, thereby facilitating complete resections and a 
decrease in local recurrence rate.3,7
Local tumor stage is also important to determine the optimal surgical treatment. Lower 
stages of rectal cancer can be treated by standard TME procedures or even rectal sparing 
surgery in selected patients.8 Advanced stages of rectal cancer with tumors invading the 
mesorectal fascia often require a more radical surgical approach to achieve a complete 
resection. These procedures, such as extralevatory abdominoperineal resections and partial 
or total exenterations, require a surgical dissection beyond the standard TME plane.9
To improve the outcome of rectal cancer, the current Dutch standard indicates a 
minimum of 20 surgical resections of rectal cancer per year per hospital and the Dutch 
guideline advises centralization of care for patients with advanced stages of rectal cancer 
(i.e. clinically staged T4 and locally recurrent rectal cancer) in specialized colorectal 
cancer hospitals.10 Due to the more complex treatment of the advanced stages of rectal 
cancer, a personalized ‘tailor made’ multimodality treatment is needed. Moreover, cT4 
rectal cancer is relatively rare and exenterative surgery is technically demanding with 
higher amounts of blood loss, operation time and increased morbidity and mortality.11 We 
hypothesize that hospital volumes may be more important in cT4 rectal cancer than in 
patients with cT1-3 rectal cancer. This study analyses the long-term results of cT1-3 and 
cT4 rectal cancer according to hospital volume in the Netherlands.
Patients and methods
Data collection
Data of all rectal cancer patients diagnosed between 2005 and 2013 in the Netherlands 
were retrieved from the nationwide population-based Netherlands Cancer Registry 
(NCR). Registration is mainly based on notification by the automated pathological archive 
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(PALGA) and the National Registry of Hospital Discharge Diagnosis. Trained registrars of 
the NCR collected data from the medical records of the different hospitals. The population 
based NCR database has a 95% completeness of cancer registrations.12 Information 
concerning the cause of death was not available.
Study population
All patients undergoing surgery for rectal cancer were included. The following patient/
tumour related variables were available: year of diagnosis, age, gender, clinical and 
pathological TNM stage, histopathology and the presence of synchronous distant 
metastases. Treatment related variables that were available were: neoadjuvant 
treatment, adjuvant treatment, hospital volume based on number of rectal cancer 
resections per year, type of surgical procedure (low anterior resection, abdominoperineal 
resection or proctocolectomy). Involvement of circumferential resection margin (CRM) 
was available from 2008 onwards.
Clinically staged T1-3 and T4 rectal cancer were analyzed separately. Patients with an 
unknown cT-stage were excluded from analysis, but were included in the determination 
of rectal cancer hospital volume. For cT1-3 rectal cancer, hospitals were divided into 
low volume hospitals (1-20 resections), medium volume hospitals (21-50 resections) 
and high volume hospitals (>50 resections), based on the total number of rectal cancer 
resections performed annually in one hospital. For cT4 rectal cancer, hospitals were 
divided into low (1-4 resections) medium (5-9 resections) and high (≥10 resections) 
volume based on cT4 rectal cancer resections performed annually in one hospital.
The TNM-classification was used according to the edition valid at the time of cancer 
diagnosis (6th edition for 2005-2009 and 7th edition for 2010-2013). The 7th edition included 
a distinction between cT4a (tumor penetrates the surface of the visceral peritoneum) and 
cT4b tumors (tumor invades or is adherent to surrounding organs or structures).
Endpoints
The primary endpoint was overall survival according to the total hospital volume for 
cT1-3 and cT4 rectal cancer.
Follow up
Vital status of patients was retrieved by linkage of the NCR to the nationwide municipal 
population registries network.
Statistical analysis
Data were reported as median (interquartile range) or mean (standard deviation) as 
appropriate. Categorical data were reported as count (percentage). The Chi-square was 
used for comparison of groups. For survival analysis, follow-up time was calculated from 
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date of diagnosis until date of death or end of follow-up. Patients who were alive at the 
end of follow-up were censored. Three and five-year survival rates were calculated by 
Kaplan-Meier analysis and comparisons between groups were made using log-rank tests. 
Multivariable Cox’s proportional hazards analysis was performed to analyze differences 
in overall survival according to hospital volume. Variables with p-values <0.10 in the 
univariate analysis were included in the multivariable analysis. Only variables available 
for the whole study period were included in the multivariable analysis.
Results
16.154 patients underwent rectal cancer surgery and had a confirmed clinical T-stage, 
while in 6394 patients the cT-stage was unknown. Of those patients with a known cT-stage 
14.050 patients (87%) had a cT1-3 tumor and 2.104 patients (13%) had a cT4 tumor.
cT1-3 rectal cancer
The baseline characteristics of the 14.050 patients with cT1-3 rectal cancer are outlined 
in table I. The majority of these patients underwent surgery in medium volume hospitals 
(62%), followed by high volume hospitals (21%) and low volume hospitals (17%). An 
increase was seen in patients treated in high volume hospitals (2005-2007: 13% vs. 
2011-2013: 23%, p <0.001). Neoadjuvant chemoradiotherapy was administered more 
often to patients in high volume hospitals compared to medium volume and low volume 
hospitals (43% vs. 37% and 32%, p<0.001). High volume hospital hospitals performed 
less abdominoperineal resections (32% vs. 36% vs. 36%, p=0.002) and had a higher 
percentage of ypT0 stage (9% vs. 7% vs. 8%, P=0.01). There was no difference in nodal 
stage and CRM-involvement. Patients treated in low volume hospitals received adjuvant 
chemotherapy less often (11% in high and medium volume hospitals compared to 8% in 
low volume hospitals, p <0.001).
Outcomes
The median follow up was 31 months (IQR 15 – 54 months). The estimated 5-year 
survival rate of patients with cT1-3 rectal cancer who were treated in low, medium or 
high volume hospitals was similar (70%, 69%, 69% respectively; p=0.88). Survival 
curves are shown in figure I. Univariate Cox regression analysis showed no significant 
difference in survival between different hospital volumes. Univariate hazard ratios for 
survival of medium and high volume hospitals compared to low volume hospitals were 
1.01 (95%CI: 0.92 – 1.11) and 1.03 (95%CI: 0.92 – 1.16) respectively.
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Table I. Baseline characteristics cT1-3 rectal cancer patients
Total patients
Low volume 
hospitals
1-20/year
2452
Medium volume 
hospitals
20-50/year
8708
High volume 
hospitals
≥50/year
2890 P-value
Gender
Male 1526 (62) 5573 (64) 1824 (63) 0.25
Female 926 (38) 3135 (36) 1066 (37)
Median age 67 67 67 0.10
Year of diagnosis *
2005-2007 685 (24) 1791 (63) 380 (13) < 0.001
2008-2010 780 (16) 2985 (62) 1017 (21)
2011-2013 987 (15) 3932 (61) 1493 (23)
Neo-adjuvant treatment
None 252 (10) 1007 (12) 280 (9) < 0.001
Radiotherapy 1408 (57) 4448 (51) 1359 (47)
Chemotherapy 7 (1) 48 (1) 16 (1)
Chemoradiotherapy 785 (32) 3205 (37) 1235 (43)
Type of surgery
LAR/Hartmann 1569 (64) 5575 (64) 1952 (68) 0.002
APR 854 (35) 2980 (34) 892 (31)
Proctocolectomy 12 (1) 65 (1) 27 (1)
Not otherwise specified 17 (1) 88 (1) 19 (1)
Pathological tumor stage 0.010
T0 190 (8) 648 (7) 269 (9)
T1 183 (7) 627 (7) 209 (7)
T2 824 (34) 2788 (32) 929 (32)
T3 1174 (48) 4270 (49) 1384 (48)
T4 50 (2) 191 (2) 57 (2)
TX 31 (1) 184 (2) 42 (1)
Pathological nodal stage
N0 1592 (65) 5519 (63) 1863 (64) 0.17
N+ 835 (34) 3087 (36) 993 (35)
NX 25 (1) 102 (1) 34 (1)
Pathological distant metastases
M0 2381 (97) 8317 (96) 2767 (96) 0.002
M+ 71 (3) 391 (4) 123 (4)
Tumor grade
Well differentiated 70 (3) 259 (3) 168 (2) < 0.001
Moderately differentiated 1009 (41) 3466 (40) 1040 (36)
Poorly differentiated/
undifferentiated
161 (7) 532 (6) 159 (6)
Unknown 1212 (49) 4451 (51) 1623 (56)
CRM-involvement #
Involved 125 (7) 477 (7) 180 (7) 0.50
Not involved 1292 (73) 4967 (72) 1779 (71)
Unknown 349 (20) 1470 (21) 551 (22)
Adjuvant chemotherapy 201 (8) 980 (11) 326 (11) < 0.001
LAR; Low anterior resection, APR, Abdominal perineal resection, CRM; Circumferential resection margin, *, 
percentages are calculated within years of diagnosis. #, CRM was reported in the database starting from 2008
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Figure I. Overall survival in cT1-3 patients according to hospital volume.
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cT4 rectal cancer
The baseline characteristics of 2.104 patients with cT4 rectal cancer are depicted in 
table II. The majority of patients (60%) underwent surgery in low volume cT4 hospitals, 
followed by high volume hospitals (25%) and medium volume hospitals (15%). Eight 
hospitals performed less than one surgical procedure for cT4 rectal cancer per year on 
average (2005-2013). There was an increase in referral of cT4 rectal cancer patients for 
resection to any other hospital from 23% in 2005 to 38% in 2013 (p=0.003) (figure IIa). 
CT4 patients were most often referred by low volume hospitals, followed by medium and 
high volume hospitals (figure IIb) and most often referred to high volume hospitals, but 
also to medium volume hospitals and even to other low volume hospitals (figure 2c).
The percentage of patients who received neoadjuvant therapy was higher in high 
volume cT4 hospitals (98%) than in medium and low volume cT4 hospitals (respectively 
91% and 88%, p<0.001). In high volume cT4 hospitals, 83% of the patients received 
chemoradiotherapy, compared to 70% in medium volume cT4 hospitals and 62% in low 
volume cT4 hospitals.
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Figure IIa. Referral of cT4 rectal cancer patients for resection
Figure IIb. Volume of hospital of diagnosis of the referred patients
Figure IIc. Volume of hospital of resection of the referred patients
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Table II. Baseline characteristics of cT4 rectal cancer patients
Low volume 
hospitals
1-4/year
Medium volume 
hospitals
5-9/year
High volume 
hospitals
≥10/yea
P-value
Total patients 1.256 328 520
Gender
Male 622 (50) 175 (53) 294 (57) 0.02
Female 634 (50) 153 (47) 226 (43)
Median age 67 65 63 <0.001
Year of diagnosis *
2005-2007 433 (64) 102 (15) 142 (21) 0.03
2008-2010 442 (59) 120 (16) 188 (25)
2011-2013 381 (56) 106 (16) 190 (28)
Neo-adjuvant treatment
None 156 (12) 29 (9) 13 (2) <0.001
Radiotherapy 308 (25) 53 (16) 58 (11)
Chemotherapy 10 (1) 16 (5) 15 (3)
Chemoradiotherapy 782 (62) 230 (70) 434 (83)
Type of surgery <0.001
LAR/Hartmann 528 (42) 103 (31) 138 (27)
APR 590 (47) 157 (48) 259 (50)
Proctocolectomy 121 (10) 63 (19) 114 (22)
Not otherwise specified 17 (1) 5 (2) 9 (2)
Pathological tumor stage
T0 87 (7) 23 (7) 47 (9) 0.02
T1 26 (2) 10 (3) 19 (4)
T2 198 (16) 43 (13) 59 (11)
T3 610 (49) 142 (43) 239 (46)
T4 287 (23) 95 (29) 143 (28)
TX 48 (4) 15 (5) 13 (3)
Pathological nodal stage
N0 710 (57) 204 (62) 330 (64) 0.04
N+ 512 (41) 113 (34) 179 (34)
NX 34 (3) 11 (3) 11 (2)
Pathological distant metastases
M0 1,174 (93) 294 (90) 461 (89) 0.001
M+ 82 (7) 34 (10) 59 (11)
Tumor grade
Well differentiated 34 (3) 6 (2) 18 (3) <0.001
Moderately differentiated 455 (36) 87 (27) 147 (28)
Poorly differentiated/undifferentiated 116 (9) 25 (8) 38 (7)
Unknown 651 (52) 210 (64) 317 (61)
CRM-involvement #
Involved 160 (19) 45 (20) 63 (17) 0.58
Not involved 466 (57) 131 (58) 213 (56)
Unknown 197 (24) 50 (22) 102 (27)
Adjuvant chemotherapy 172 (14) 52 (16) 54 (10) 0.05
LAR; Low anterior resection, APR, Abdominal perineal resection, CRM; Circumferential resection margin, *, 
percentages are calculated within years of diagnosis. #, CRM was reported in the database starting from 2008
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The proportion of patients with a pathological T4-stage was higher in high volume 
hospitals compared to low volume hospitals (28 vs. 23%). In a subgroup analysis of the 
cT4 patients diagnosed between 2010 and 2013, more patients were staged cT4b in high 
volume hospitals compared to medium volume hospitals (82% vs. 70%, p=0.007) and 
low volume hospitals (82% vs. 68% p<0.001). Low volume hospitals had the highest 
proportion of node positive patients: 41% compared to 34% in both medium volume 
and high volume hospitals. The number of synchronously metastasized patients was 
significantly higher in high volume hospitals compared to low volume cT4 hospitals (11% 
vs. 7%, p=0.001) and was similar in medium cT4 hospitals (11% vs. 10%, p=0.66). In 
the period 2008-2013, there was no significant difference in CRM-involvement between 
high, medium and low volume cT4 hospitals (respectively 19%, 20%, 17%, p=0.58).
Outcomes
There was no difference in 30-days mortality and 90-days mortality according to hospital 
volume. Patients were followed with a median of 33 (IQR 16 - 60) months. The estimated 
overall survival of cT4 patients treated in high volume cT4 hospitals was significantly 
longer than in medium and low volume cT4 hospitals (p=0.001). The estimated 3-year 
survival rate was 76%, 71% and 67% respectively and the 5-year survival rate was 
63%, 53% and 54% respectively (Figure III). Multivariable analysis demonstrated 
that resection in high volume cT4 hospitals was independently associated with a better 
overall survival compared to low volume cT4 hospitals (HR 0.81, 95%CI 0.67-0.98)), 
after adjusting for patient/tumour related confounders (age, pTNM-stage and tumor 
differentiation) (table III).
Figure III. Overall survival of cT4 rectal cancer according to the cT4 hospital volume
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Table III. Univariate and multivariable survival analysis for overall survival of cT4 tumors with and with-
out treatment related confounders
Univariate
Hazard ratio 
(95%CI) p-value
Multivariable
Hazard ratio 
(95%CI)
Multivariable
Hazard ratio 
(95%CI)
Hospital volume (procedure per year) <0.001
1-4 1 1 1
5-9 0.93 (0.76-1.14) 0.97 (0.79-1.19) 0.99 (0.81-1.22)
≥10 0.71 (0.59-0.85) 0.81 (0.67-0.98) 0.87 (0.71-1.05)
Gender 0.98
Male 1 - -
Female 1.00 (0.87-1.15) - -
Age 1.03 (1.02-1.04) <0.001 1.03 (1.03-1.04) 1.03 (1.02-1.04)
Year of diagnosis 0.98 (0.95-1.02) 0.32
Neo-adjuvant therapy <0.001
None 1 -
Radiotherapy 0.58 (0.46-0.73) - 0.70 (0.54-0.88)
Chemotherapy 0.59 (0.35-0.97) - 0.69 (0.41-1.17)
Chemoradiotherapy 0.32 (0.26-0.39) - 0.53 (0.42-0.68)
Type of surgery 0.02
LAR/Hartmann 1 - 1
APR 0.81 (0.69-0.95) - 0.99 (0.84-1.17)
Proctocolectomy 0.95 (0.78-1.16) - 0.95 (0.77-1.18)
Not otherwise specified 1.42 (0.83-2.43) - 1.47 (0.85-2.53)
Pathological tumor stage
T0 1 <0.001 1 1
T1 0.89 (0.35-2.24) 0.92 (0.37-2.32) 0.87 (0.35-2.21)
T2 2.02 (1.20-3.39) 1.84 (1.09-3.10) 1.75 (1.04-2.94)
T3 3.57 (2.22-5.72) 2.73 (1.69-4.41) 2.53 (1.56-4.09)
T4 5.89 (3.65-9.50) 4.30 (2.65-6.99) 3.89 (2.38 (6.37)
TX 2.64 (1.46-4.78) 2.50 (1.38-4.56) 2.42 (1.33-4.41)
Pathological nodal stage <0.001
N0 1 1 1
N1 1.64 (1.38-1.95) 1.34 (1.12-1.61) 1.32 (1.10-1.58)
N2 2.74 (2.29-3.28) 2.06 (1.71-2.49) 1.95 (1.61-2.36)
NX 2.31 (1.62=3.30) 2.06 (1.43-2.97) 2.11 (1.46-3.04)
Pathological distant metastases
M0/X 1 <0.001 1 1
M+ 2.14 (1.71-2.67) 2.12 (1.68-2.69) 1.99 (1.56-2.52)
Tumor grade <0.001
Well differentiated 0.93 (0.62-1.42) 1.04 (0.69-1.60) 1.11 (0.73-1.69)
Moderately differentiated 1 1 1
Poorly differentiated/undifferentiated 1.66 (1.32-2.09) 1.49 (1.18-1.88) 1.47 (1.16-1.86
Unknown 0.83 (0.71-0.97) 1.01 (0.86-1.19) 1.14 (0.96-1.35)
Adjuvante chemotherapy
No 1 - -
Yes 1.06 (0.87-1.30) 0.54 - *
LAR; Low anterior resection, APR, Abdominal perineal resection, CRM; Circumferential resection margin, *, 
percentages are calculated within years of diagnosis. #, CRM was reported in the database starting from 
2008
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When treatment related confounders were included in the multivariate analysis, 
neoadjuvant chemoradiotherapy was associated with improved survival. Adjustment for 
neoadjuvant therapy resulted in the disappearance of a significant difference between 
high, medium and low volume hospitals.
Discussion
The current population-based study found an overall survival benefit of cT4 rectal cancer 
patients treated in high volume cT4 hospitals compared to low volume cT4 hospitals. 
In cT1-3 rectal cancer, we were not able to find an overall survival difference related to 
hospital volume. In the present study patients with locally advanced (cT4) rectal cancer 
treated in high volume hospitals (≥10 resections annually) had a significantly improved 
5-year overall survival of 63% compared to 53% in low volume (1-4 resections). This 
contradicts a previous study executed in the Southern part of the Netherlands, which 
did not found an association between hospital volume and long term overall survival for 
both colon and rectal cancer patients.13 However, that study did not analyze the long-
term outcome of cT4 and cT1-3 separately. This may explain why we found a survival 
difference, while the other study did not. Although the referral of cT4 tumors to high 
volume hospitals has increased during the study period, the majority of patients (56%) 
were still treated in a low volume cT4 hospital in the period 2011-2013
Rectal cancer is a relatively common malignancy and the majority of patients can be 
treated by a standard TME procedure. The Dutch TME-trial, which included a teaching 
program for the TME technique, showed us that this technique can be taught and rolled 
out nationwide and results in low recurrence rates.4 However, only patients with cT1-3 
rectal cancer are suitable candidates for a standard TME procedure, because standard 
TME in patients with tumor invasion through the mesorectal fascia (cT4) leads to an 
involved mesorectal fascia and thus incomplete resections (R1/2-resections). Involved 
circumferential resection margins (CRM) are uncommon in cT1-3 rectal cancer patients 
and reported to be <10%, whereas in cT4 patients positive CRM is demonstrated in 
approximately 20%.14 Incomplete resections are deleterious for oncological outcome 
and all efforts should be aimed at avoiding R1/2-resections.15 This makes more radical 
procedures in patients with cT4 rectal cancer necessary to achieve R0-resections. These 
surgical procedures beyond the TME plane are less straightforward and more technically 
demanding than standard TME surgery.9,16,17 Additionally, the advanced stages of rectal 
cancer have the greatest benefit of a multimodality treatment, including neoadjuvant 
chemoradiotherapy leading to more complete resections and reduces local recurrence 
rates.3,7
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Accurate staging of the rectal tumor is essential in selecting patients who should be 
treated with neoadjuvant therapy and to differentiate between those who can be treated 
by a standard TME procedure and those who require more extended surgery. The quality 
of this assessment may be enhanced by multidisciplinary tumor board meetings (MDT), 
including dedicated radiologists, radiation oncologists, medical oncologists and surgeons. 
Nowadays, almost all rectal cancer patients in the Netherlands are staged by MR imaging 
and are discussed in an MDT.2 In an experienced MDT, cT4 tumors are potentially 
more accurately assessed and a more appropriate surgical procedure may be selected. 
Furthermore, in experienced MDTs, standardized care for patients with advanced stages 
of rectal cancer may result in an improved long-term outcome.
Several studies have reported survival differences according to hospital volume in 
complex surgical procedures in other malignancies, such as esophagus, pancreas and 
bladder cancer.18-20 The hypothesis of this survival benefit is that more exposure and 
experience in the multimodality treatment (staging, neo-adjuvant therapy and surgical 
expertise) of these relatively rare malignancies results in an improved long-term 
outcome. In line with the findings of studies in other malignancies, the current study 
showed a survival benefit in the treatment of cT4 rectal cancer in high volume cT4 
hospitals, but not in the more common cT1-3 rectal tumors. In a previous study from 
data of the NCR no difference in survival was demonstrated between high and low 
volume centers for all colon or rectal patients.13 However, the results from the present 
study, suggest that locally advanced (cT4) rectal cancer requires a minimal number of 
resections per hospital, irrespective of the number of resections performed for cT1-3 
rectal cancer in that same hospital.
The reason for the overall survival benefit of cT4 tumors treated in high volume cT4 
hospitals cannot be defined by this population-based study. Presumably, the overall 
survival benefit is caused by multiple factors. Optimal staging, neoadjuvant therapy, 
surgical treatment and experience of the MDT may lead to superior selection, treatment 
and results when optimally combined. Optimal staging may results in the selection of the 
appropriate neoadjuvant treatment. Experience with extensive rectal resections in high 
volume hospitals may contribute. However, this did not lead to a lower percentage of 
CRM-involvement in high volume cT4 hospital compared to medium and low volume cT4 
hospital in the years evaluated. This may be explained by referral of patients with more 
advanced tumors to high volume cT4 hospitals, which explains the higher pathological 
stage (pT4a and p T4b) in high volume cT4 hospitals, regardless of the higher percentage 
of neoadjuvant therapy administered. Another factor that may have contributed to the 
survival benefit is the availability of intraoperative radiotherapy (IORT). High volume 
cT4 hospitals in The Netherlands have the ability to apply an extra radiation dose during 
surgery. IORT may eradicate remaining tumor cells and this may lead to a survival 
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benefit.21,22 Unfortunately, IORT was not comprehensively registered in the Netherlands 
Cancer Registry making further evaluation of the role of IORT impossible.
Unfortunately, the data available on different aspects of treatment is limited. 
The type of procedure was registered, but is limited to ‘‘low anterior resection’, 
‘abdominoperineal resection’ and ‘proctocolectomy’. Especially in cT4 rectal cancer, data 
on resections outside the TME plane, the need for multivisceral surgery, urinary tract 
reconstructions and the admission of intra-operative radiotherapy may provide more 
insight into what type of tumours were treated in different hospitals. However, these 
data are not available; only the administration of neoadjuvant therapy was registered 
comprehensively and indeed was identified as an independent prognostic factor for 
survival. We argue that when the quality of a multidisciplinary/multimodality treatment of 
rectal cancer is assessed, the singling out of an individual aspect, because that variable 
happens to be available, is inappropriate. The administration of all contributors of the 
multimodality treatment, at the right time, to the right patient is what defines quality 
of care. When important treatment related variables are lacking, a valid multivariate 
analysis of treatment related variables is impossible. The fact that this study identifies 
neo-adjuvant chemoradiotherapy as a prognostic factor for survival when randomized 
clinical trials did not, adds to our skepticism towards the appropriateness of a 
multivariate analysis of treatment related confounders in this study23.
Although referral of cT4 rectal cancer has increased during the study period, further 
centralization of cT4 rectal cancer seems warranted. Remarkably, some of the patients 
diagnosed in low volume hospitals were referred to other low volume cT4 hospitals for 
treatment. To improve care for rectal cancer patients in the Netherlands, it seems logical 
to refer cT4 rectal cancer patients to high volume hospitals only. The total number of 
cT4 rectal cancer diagnosed annually in the Netherlands (approximately 250 patients) is 
limited and the appointment of 4 or 5 cT4 rectal cancer centers would seem appropriate. 
Excluding cT4 rectal cancer from the required total number of rectal cancer procedures 
per hospital can eliminate the stimulus to treat these patients in hospitals without T4 
rectal cancer experience.
As all retrospective studies do, this study has limitations. The younger age of patients 
treated in high volume cT4 hospitals may indicate that the patients referred to high 
volume centers for extensive surgery were the ones in a relatively good clinical condition 
and that may improve their survival significantly. On the other hand, the pathological 
T-stage and the number of metastasized patients was significantly higher in high 
volume cT4 hospitals, suggesting that advanced stages of disease were referred to high 
volume cT4 hospitals, which would decrease overall survival in these patients. This type 
of discussion on the profile of patient groups in different hospitals is often referred to 
as the ‘case mix’ discussion. Unfortunately, for reasons described earlier, we cannot 
91
Chapter 6
6
conclude whether case mix is the driver behind the differences that we did and did not 
find. We stress, however, that earlier studies that suggested improved outcome in high 
volume centers for complex surgery also relied on retrospective data and were flawed 
by the same confounders. The observation that in a cohort of more than 14.000 cT1-3 
rectal cancer patients, no relationship between hospital volume and overall survival was 
present, stands. This makes it questionable whether such a relationship, should we have 
missed it in this study, could realistically be clinically relevant.
In conclusion, the treatment of cT4 rectal cancer in high volume cT4 hospitals was 
associated with an improved survival compared to low volume cT4 hospitals after 
adjustment for patient and tumour related confounders. Hospital volume in cT1-3 
rectal cancer was not associated with overall survival in the present study. There was a 
small increase in referral of cT4 rectal cancer to high volume cT4 hospitals, but further 
centralization of cT4 rectal cancer seems warranted to further improve outcome for this 
difficult group of patients.
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Abstract
Since patients with incurable metastatic colorectal cancer (CRC) only have a relatively 
limited life expectancy, and resection of the primary tumour is accompanied by both 
morbidity and mortality, it is under debate whether resection of the primary tumour has 
an effect on survival or quality of life. The rationale behind the resection strategy is that 
prophylactic surgery prevents future complications. With current new chemotherapy 
regimens, a relatively low number of patients with metastatic CRC require surgery for 
their primary tumour. Many studies concerning the management of incurable stage 
IV CRC have been performed and most studies suggest a survival benefit for patients 
undergoing surgical resection of the primary tumour compared with those who received 
palliative treatment. However, in stage IV CRC with unresectable metastases, the role of 
a palliative resection of the primary tumour has never been assessed properly. Because 
randomised clinical trials are lacking, it is difficult to draw conclusions from the present 
literature.
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Introduction
Colorectal cancer (CRC) is one of the two most commonly diagnosed cancers, with 
approximately 1.2 million new cases each year and more than 600,000 annual deaths 
estimated to occur worldwide.1 In addition, roughly one-fifth of patients presents 
with incurable disseminated disease.2 In the last decade, development of new 
chemotherapeutic biological agents has significantly improved overall survival (OS) of 
these patients.3-12
A palliative resection of the primary tumor is frequently performed13 and there is a 
clear indication for surgery when patients present with symptoms of the primary tumor. 
However, if patients present with absence or mild symptoms, the indication for resection 
is less obvious. Since patients with incurable metastatic CRC (mCRC) only have a 
relatively limited life expectancy and resection of the primary is accompanied with both 
morbidity and mortality14-16, it is under debate whether resection of the primary tumor 
has an effect on survival or quality of life.17,18 Many studies concerning the management 
of incurable stage IV CRC have been performed; however the advantage of a palliative 
resection of the primary tumor has never been assessed properly.19  Moreover, most 
studies do not even report whether a resection of the primary has been performed.20
In this paper we aim to evaluate the role of surgery of the primary in stage IV CRC 
with unresectable metastases.
Treatment of metastatic colorectal cancer (mCRC)
At diagnosis of CRC, approximately 20% of the patients present with synchronous mCRC, 
and the liver is the predilection site in half these patients.21,22 The lungs represent the 
second most common site of metastases from CRC and according to non population 
based studies lung metastases are present in 10-15% of patients with colorectal 
cancer.23,24
When metastases are limited, a possible curative treatment can be obtained by 
surgical resection, however, only 15-20% of patients is resectable.25 Median 5-year 
survival for patients undergoing an R0 resection of the metastases is approximately 
30% (range 15-67%).26 Despite complete resection and neoadjuvant or adjuvant 
chemotherapy regimens, recurrences occur in 75% of the patients.27 Extrahepatic disease 
in combination with liver metastases was generally considered a contraindication for 
surgery.28 However, resection of both intrahepatic and extrahepatic colorectal metastases 
should be considered if resection of all metastatic sites can be complete and the disease 
is controlled by chemotherapy.29
In patients with unresectable metastases, palliative systemic chemotherapy is the 
treatment of choice. With systemic combination chemotherapy response rates of 40-
70% have been reported resulting in a median overall survival rate of approximately 
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22 months.30-32 Most frequently used combinations are oxaliplatin or irinotecan plus 
capecitabine or 5-fluorouracil (5-FU) with or without bevacizumab. In case of K-RAS 
wild type tumors, anti-epidermal growth factor receptor (EGFR) antibodies such as 
panitumumab and cetuximab are being used.33
Resection of the primary tumor in patients with 
unresectable synchronous mCRC
Traditional surgical teaching promotes resection of the primary tumor in patients with 
unresectable metastases, even if the primary is asymptomatic. The rationale behind 
this strategy is that prophylactic surgery prevents future complications of intestinal 
obstruction, perforation and haemorrhage.34 However, resection does not provide 
immediate palliative benefit in case of an asymptomatic primary tumor, and surgery 
is associated with high mortality (5-13%) and morbidity (23-48%) in patients with 
metastatic disease.34-37 Some studies tried to selectively apply prophylactic surgery in 
patients with a low metastatic tumor burden because these patients are presumed to 
be at risk for obstruction because of long survival. If the metastatic tumor burden is 
extensive, resection of the primary is unlikely to benefit the patient and is associated 
with a high risk of postoperative complications. These patients are probably better served 
by focusing on the disseminated component of their disease and start with systemic 
treatment early on in their course, reserving surgery for when and if symptoms from the 
primary tumor are substantial.36,38
Other studies have shown no association between the incidence of complications and 
the extent of metastatic disease.39,40 Due to recent advances in systemic chemotherapy, 
the risks and benefits of immediate or deferred surgical strategy are under debate.
Some clinicians in favor of the surgical approach argue that if the asymptomatic 
primary cancer is not resected, patients will develop disabling symptoms such as 
weight loss and nutritional depletion (secondary to “near” obstruction) and anemia 
due to bleeding of the primary tumor. Arguments supporting surgery include a lower 
reported operative mortality for elective surgery in patients with stage IV disease 
(3-6%), compared with the more threatening operative mortality rates for non-elective 
resections in patients with advanced and symptomatic disease (20-40%).34,41,42 Another 
argument supporting this concept, is that preoperative staging is sometimes unclear 
and that surgery is considered the last and most effective diagnostic tool for the correct 
staging of abdominal tumors before treatment.19 In addition, patients are provided with 
psychological comfort who feel that the “cancer” has been removed.36
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Chemotherapy first in patients with unresectable 
synchronous mCRC
The advocates of a chemotherapy first approach prefer to avoid complications at least 
in non symptomatic patients. The argument of those who prefer “elective” surgery due 
to higher mortality if emergent surgery is required, was addressed in several studies, 
were the risk of death was found to be extremely low.39,43-45 In fact, Poultsides et 
al. compared their study population with studies with elective colon resection in the 
metastatic setting and found that it appears that this deferred approach is associated 
with at least comparable perioperative mortality.46 Another argument for chemotherapy 
first, is that chemotherapy will not only treat the metastases but also the primary 
tumor; many patients will have improvements of their symptoms and therefore evading 
a possible resection.35,47 Chau et al. demonstrated that overall, 86% of patients had an 
improvement in symptoms. Of the patients with symptoms, 71% had diminished pelvic 
pain/ tenesmus, 90% had improvement in diarrhea/constipation, 100% had reduced 
rectal bleeding, and 93% had weight stabilization or weight gain.
Advocates of the deferred surgical approach argue that surgery at diagnosis can 
delay or even preclude systemic chemotherapy, and that most patients will never 
develop symptoms and these patients could be spared an unnecessary operation. 
Additionally, primary CRC surgery may alter the host immune response in such a way 
that tumor growth is increased in the post operative period.56,57 An argument against 
resection is that patients with unresectable metastasis from colorectal cancer who have 
undergone palliative resection of the primary still face the prospect of further intestinal 
complications, which may require further surgery (Table I).34,48 After resection of the 
primary tumor, these patients may develop local recurrence or adhesions which can 
result in obstruction and require subsequent surgery.
A decade ago, when patients were treated with single agent 5-FU chemotherapy, 
approximately 20% of patients with mCRC treated with chemotherapy required palliative 
surgery for symptoms related to their intact primary CRC.39,40,46,48,51 In recent years, 
combinations with modern chemotherapy like FOLFOX, XELOX and FOLFIRI have attained 
response rates of 50% and disease control rates of 85% in prospective clinical trials.58 
With these modern chemotherapy regimens, approximately 7% (range 3-22%) of 
patients with mCRC required surgical palliation for their intact primary CRC, as stated in 
an elegant review by Poultsides.43-46 These data suggest that with effective chemotherapy 
almost 14 asymptomatic patients need to undergo prophylactic resection of their 
primary tumor in order to save one patient a subsequent operation for obstruction 
or perforation.46 There are indications that this has led to a decrease over time in 
the percentage of resection of the primary tumor in case of unresectable metastatic 
colorectal disease.13
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Survival
Several studies have been performed to analyze overall survival of patients with stage 
IV CRC and unresectable metastases to examine whether to resect the primary or not. 
Recently, Venderbosch et al. performed a retrospective analysis of two phase III studies 
(CAIRO and CAIRO2)7,59 and investigated the prognostic and predictive value of resection 
Table I. Study results on colorectal cancer and unresectable metastases, in which the non-resection 
arm was treated with chemotherapy
Author Years of study
Number 
of 
patients
Received 
chemotherapy 
(%)
Secondary 
palliative surgical 
interventions
Palliative 
Resection of 
primary
Scoggins 
40
1985-
1997
resection 66 0 2 (3%) -
chemo 23 100 2 (9%) 0
Tebbutt 48 1990-
1999
resection 280 100 14 (5%) -
chemo 82 100 8 (10%) 1 (1%)
Konyalian 
49
1991-
2002
resection 62 58 # -
chemo 47 60 17 (36%) 0
Galizia 50 1995-
2005
resection 42 100 0
chemo 23 100 6 (26%) ¶
Ruo  51 1996-
1999
resection 127 0 6 (5%)
chemo 103 83 30 (29%) 0
Michel  44 1996-
1999
resection 31 97 0
chemo 23 100 5 (22%) 3 (13%)
Serela 39 1997-
2000
resection - - -
chemo 24 88 6 (25%) 4 (17%)
Benoist 43 1997-
2002
resection 32 94 0
chemo 27 100 4 (15%) 3 (11%)
Karoui 52 1998-
2007
resection 85 99 27 (32%)
chemo 123 100 15 (12%) 15 (12%)
Aslam  53 1998-
2007
resection 366 63 ¥
chemo 281 36 128 (46%) 0
Bajwa 54 1999-
2005
resection - - -
chemo 67 100 27 (40%) 25 (37%)
Muratore 
45
2000-
2004
resection - - -
chemo 35 100 1 (3%) 0
Poultsides  
35
2000-
2006
resection - - -
chemo 233 100 16 (7%) 8 (3%)
Seo 55 2001-
2008
resection 144 100 22 (15%)
chemo 83 100 4 (5%) 1 (1%)
# Konyalian53 not described; 12 patients with complications mostly infectious; ¶ Galizia54 not de-
scribed; 2 colon perforations, 1 intestinal hemorrhage, 1 bowel obstruction, 2 surgery owing to bowel 
perforation or stent dislocation ¥ Aslam56 not described; 11 full thickness wound dehiscence, 11 intra-
abdominal collections, 11 anastomotic leak, 7 intra-abdominal sepsis, 5 hemorrhage, 4 postoperative 
ileus, 1 splenic tear, 1 inter-loop fistula
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of the primary tumor in stage IV mCRC patients.60 They demonstrated that resection of 
the primary tumor was a significantly important prognostic factor for survival in these 
patients. They also performed a review of the literature and identified 22 nonrandomized 
studies, most of which showed improved survival for mCRC patients who underwent 
resection of the primary tumor. These results were confirmed in a systemic review by 
Anwar et al.57  An overview of these studies is presented in table 2.
However, in all studies presented a selection bias cannot be excluded. Most studies were 
not randomized, performed in single centers and were retrospective of nature. Patients 
with a good performance status were more likely to undergo surgery whereas those with 
extensive disease were more likely to be offered chemotherapy instead. In the absence of 
randomized controlled trials, the best evidence is obtained from case-matched studies. A 
case-matched study by Benoist et al. compared 27 patients with asymptomatic colorectal 
cancer and irresectable synchronous liver metastases who received chemotherapy, with 
32 matched patients who were treated by initial resection of the primary tumor. They 
found no difference in survival between the operative and the non-operative management.
Prospective studies on this topic are currently planned. Recently a protocol has been 
developed in the Netherlands for stage IV colon cancer patients with unresectable 
metastases.61 In this trial patients will be randomized to either systemic therapy until 
progression or unacceptable toxicity or to resection of the primary tumor followed by 
systemic therapy until progression or unacceptable toxicity. The endpoint of the trial 
is overall survival and the trial is powered to identify a survival benefit of 6 months in 
the surgery group. Also the National Surgical Adjuvant breast and Bowel Project has 
started a phase II Trial using 5-fluorouracil, leucovorin, and oxaliplatin chemotherapy 
plus bevacizumab for patients with unresectable stage IV colon cancer and synchronous 
asymptomatic primary tumor.62  The primary endpoint is the event rate related to the 
intact primary tumor requiring surgery. In both trials only patients with colon cancer will be 
randomized and patients with rectal cancer are excluded. Also a trial from Australia/New 
Zealand “SUPER” is currently running: “A randomized phase III multicentre trial evaluating 
the role of palliative surgical resection of the primary tumor in patients with metastatic 
colorectal cancer”.63 Patients will be randomized to compare chemotherapy followed by 
surgery to surgery alone. The primary outcome is to determine whether surgical resection 
of the primary tumor in patients with stage IV colorectal cancer decreases intestinal 
complications and improves overall survival and quality of life. For patients with rectal 
cancer and unresectable systemic disease a phase III randomized clinical trial is recently 
conducted in the Netherlands. In this trial the role of radiotherapy in providing local control 
will be studied and patients will be randomized to either standard chemotherapy alone 
or short term course radiotherapy (5x5 Gy) on the primary tumor followed by standard 
of care chemotherapy. The primary endpoint is the number of patients requiring an 
unplanned surgical intervention related to symptoms of the primary rectal tumor.
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Table II: Studies Comparing Resection versus Non-resection of the Primary Tumour in Stage IV 
Colorectal Cancer and Unresectable Metastases
Author
Years 
of 
study
Number 
of 
patients
OS 
(months) p value
Postoperative 
Mortality % p-value
Makela 34 1974-
1983
Resection 66 15 — 5 —
non-resection 30 7 17
Scoggins 40 1985-
1997
Resection 66 14.5 0.59 5 —
non-resection 23 16.6 —
Liu 16 1986-
1991
Resection 57 11 — 9 —
non-resection 6 3 17
Tebbutt 48 1990-
1999
Resection 280 14 0.08 — —
non-resection 82 8.2 —
Konyalian 49 1991-
2002
Resection 62 13 <0.0001 5 —
non-resection 47 5 6
Beham 64 1993-
2003
Resection 46 18 <0.001 3 —
non-resection 21 8 0
Costi 19 1994-
2003
Resection 83 9 <0.001 8 0.397
non-resection 47 4 15
Yun 65 1994-
2004
Resection 283 15.3 <0.001 3 —
non-resection 93 5.3 —
Stelzner 66 1995-
2001
Resection 128 11.4 <0.0001 12 0.784
non-resection 58 4.6 10
Galizia 50 1995-
2005
Resection 42 15.2 0.03 — —
non-resection 23 12.3 —
Law 15 1996-
1999
Resection 150 7 <0.001 7 0.01
non-resection 30 3 21
Ruo 51 1996-
1999
Resection 127 16 <0.001 2 —
non-resection 103 9 —
Michel 44 1996-
1999
Resection 31 21 0.718 0 —
non-resection 23 14 —
Mik 67 1996-
2000
Resection 52 21 NS — —
non-resection 82 14 —
Benoist 43 1997-
2002
Resection 32 23 — 0 —
non-resection 27 22 —
Kaufman 68 1998-
2003
Resection 115 22 <0.0001 — —
non-resection 69 3 —
Aslam 53 1998-
2007
Resection 366 14.5 <0.005 8 —
non-resection 281 5.83 —
Bajwa 54 1999-
2005
Resection 32 14 0.005 3 —
non-resection 35 6 —
Evans 69 1999-
2006
Resection 45 11 0.2056 16 —
non-resection 57 7 36
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Table II: Studies Comparing Resection versus Non-resection of the Primary Tumour in Stage IV 
Colorectal Cancer and Unresectable Metastases (continued)
Author
Years 
of 
study
Number 
of 
patients
OS 
(months) p value
Postoperative 
Mortality % p-value
Chan 70 2000-
2002
Resection 286 14 <0.001 — —
non-resection 125 6 —
Frago 71 2000-
2008
Resection 12 39.1 0.008 8 —
non-resection 43 1.0 6
Seo 55 2001-
2008
Resection 144 22 0.076 0 —
non-resection 83 14 —
Venderbosch 
60
2003-
2004
Resection 258 17 0.0001 — —
Non-resection 141 11 —
2005-
2006
Resection 289 21 0.0001 — —
Non-resection 159 13 —
Resection was defined as resection of the primary tumour and non-resection was defined as surgical 
intervention without resection of the primary tumour. NS = not stated.
Summary
In stage IV CRC with unresectable metastases, the role of resection of the primary 
tumor remains unclear. Because randomized clinical trials are lacking, it is difficult to 
draw conclusions from the present literature. With current new chemotherapy regimen, 
including VEGF and EGF inhibitors, a relatively low number of patients with mCRC require 
surgery for their primary tumor. Most studies suggest a survival benefit for patients 
undergoing surgical resection of the primary tumor compared to those who received 
palliative treatment. However, these results are likely to be influenced by selection 
bias and therefore prospective randomized controlled trials are needed to address this 
question.
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Abstract
Background
The widespread use of neoadjuvant radiotherapy (nRTx) followed by total mesorectal 
excision (TME) introduced the problem of treating locally recurrent rectal cancer (LRRC) 
after nRTx and TME. Few data exist on the outcome of the surgical treatment of this type 
of LRRC and the influence of nRTx for the primary tumor on the outcome is unclear.
Methods
All patients receiving multimodality treatment (including intraoperative radiotherapy) for 
LRRC in our center between 1996 and 2012 were retrospectively analyzed. The outcome 
of patients with non-metastasized resectable LRRC who received nRTx and TME for the 
primary tumor was compared to the outcome of patients who did not receive nRTx for 
the primary tumor.
Results
During this period, 139 patients underwent surgery for LRRC; 93 of these patients 
underwent curative surgery for LRRC after TME for the primary tumor. Sixty-five 
patients did not receive nRTx for the primary tumor, while 28 patients received nRTx for 
the primary tumor. There were no significant differences in the number of incomplete 
resections or peri-operative morbidities. There was no significant difference in 5-year 
overall survival (28% vs. 43%,p=0.81), recurrence-free survival (55% vs. 48%,p=0.50) 
and disease-free survival (27% vs. 40%,p=0.59).
Conclusion
Surgical treatment of carefully selected patients with non-metastasized resectable LRRC 
after nRTx and TME for the primary tumor is feasible and can result in sustained local 
control and overall survival. Patients with resectable LRRC who received nRTx for the 
primary tumor do not have a poorer outcome than patients who did not.
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Introduction
Before the introduction of total mesorectal excision (TME) for rectal cancer, local 
recurrence rates after surgery varied between 15 and 45%.1-3 Since the publication of the 
Dutch TME-trial, neoadjuvant radiotherapy (nRTx) followed by TME became the standard 
of care in the Netherlands for stage II and III rectal cancer and has led to a decrease in 
local recurrence rates to 6%.4 The implementation of nRTx and TME as standard therapy 
introduced the problem of treating locally recurrent rectal cancer (LRRC) after nRTx and 
TME.
Surgical treatment of LRRC includes (chemo-)radiotherapy to improve local control.5 
When nRTX was administered for the primary tumor, the radiation dose for treatment 
of the LRRC is limited.6 In addition, recurrences after TME may not be limited to the 
anatomical compartment lined by the visceral rectal fascia. Both factors render radical 
resection of these recurrences more demanding than resection in patients who did 
not undergo nRTx or TME previously. However, literature on the outcome of surgical 
treatment of LRRC after TME with and without nRTx for the primary tumor is scarce.
According to an update of the Dutch TME-trial, patients with LRRC after nRTx for the 
primary tumor have a shorter overall survival than patients who did not receive nRTx for 
the primary tumor.7 This suggests that local recurrences after nRTx for the primary tumor 
have a more aggressive biological behavior than recurrences of rectal cancer that was 
not treated with nRTx primarily.
Because of the factors mentioned above, it is questionable whether curative treatment 
of LRRC in these patients is possible. On the other hand, if curative resection is possible 
the influence of nRTx for the primary tumor on outcome is unclear. The aim of the 
current study was to evaluate the outcome of resectable LRRC after nRTx and TME for 
the primary tumor and to demonstrate whether there is a difference in outcome of the 
curative treatment of resectable LRRC in patients who received nRTx and TME for the 
primary tumor and patients who had TME without nRTx.
Patients and Methods
Between January 1996 and July 2012, all patients undergoing surgery for LRRC in our 
hospital, a tertiary referral center for the southwest region of the Netherlands, were 
entered in a prospective database and retrospectively analyzed. All patients had a 
histologically proven recurrence of rectal cancer in the pelvic area.
Patients were divided into two groups; group A were patients who did not receive nRTx 
for the primary tumor, group B were patients who received nRTx for the primary tumor. 
Only primary resections that were performed by TME were included.
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All LRRCs were scheduled for neoadjuvant (chemo-)radiotherapy followed by surgery. 
Patients who received nRTx for the primary tumor received a neoadjuvant re-irradiation 
dose of 27-30Gy, delivered in 15-18 fractions of 1,8-2Gy. Patients who did not receive 
nRTx for the primary tumor were scheduled for 44.6-52Gy in 19-28 fractions of 1.8-
2.3Gy. (Re-)irradiation for LRRC was administered by a 3- or 4 field-technique or by 5 
fields using intensity modulated radiotherapy. From 2006 onwards, all patients received 
chemoradiotherapy with capecitabine administered orally at a dose of 825 mg/m2 twice 
a day during radiotherapy days as reported previously.8 Before 2006, no patient received 
concomitant chemotherapy.
Before treatment, distant metastases were ruled out by a thoraco-abdominal CT-scan, 
which was repeated after (re-)irradiation.9 In the majority of patients, pelvic MRI was 
performed for localization and progression of the recurrence prior to and after (re-)
irradiation. Resectable LRRC was defined as a recurrence within the pelvic region, without 
distant metastases in which imaging revealed a recurrence with a high chance of a R0/
R1-resection. R0/R1-resection was considered feasible when there was no apparent 
lateral bone-involvement, no sacral involvement above level S3, no extension through 
the greater sciatic notch and no encasement of common or external iliac arteries. Local 
recurrences were classified using the Wanebo classification.10
All surgical procedures were performed by a midline abdominal approach and included 
low anterior resections (LAR), abdominoperineal resections (APR), posterior or total 
exenterations and abdominoperineal-sacral resections. R0-resections were defined as 
resection margins >0mm; R1-resections as microscopically involved resection margins 
and R2-resections as macroscopically involved resection margins. Our multimodality 
approach for LRRC includes intra-operative radiotherapy (IORT) with a single dose of 
10Gy for patients with tumor-free margins ≤2mm, evaluated during surgery on frozen 
sections.11 No patient received adjuvant chemotherapy.
Peri-operative morbidity was divided into surgical and non-surgical morbidity. 
Abdominal wound infections were scored in case there were signs of inflammation. 
Wound healing problems after APR were defined as signs of inflammation of the perineal 
area 30 days after surgery. A presacral abscess was diagnosed by clinical symptoms in 
combination with a CT-scan. Small bowel obstruction and postoperative hemorrhage were 
considered adverse events when a re-laparotomy had to be performed. Post-operative 
complications were graded according to the Dindo-Clavien classification.12 Peri-operative 
mortality was defined as any death occurring within 30 days of surgery. In-hospital 
mortality was defined as any death occurring during admission.
Statistical analysis was carried out using SPSS (version 20.0.0.1). Data was reported 
as median (interquartile range). The Chi-square (χ²), Fisher’s exact and Mann-Whitney 
U test were used for comparison of both groups as appropriate. The survival rates were 
calculated using Kaplan-Meier curves and significance was calculated by a log rank test. 
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Survival rates were calculated from the day of LRRC surgery until death or last follow-up. 
P-values ≤0.05 were considered significant.
Results
A total of 139 patients underwent surgery for LRRC between January 1996 and July 
2012. In 98 patients primary tumor resection was performed by TME. During LRRC 
surgery, 5 of 98 patients were considered incurable due to metastatic disease or 
unresectability of the recurrence, rendering 93 patients eligible for analysis. Of these 
patients, 65 did not receive nRTx for the primary tumor (group A), while 28 patients 
received nRTx for the primary tumor (group B).
Table I. Patient and primary tumor characteristics
No nRTx for primary 
tumor (group A)
nRTx for primary 
tumor (group B) P-value
Total patients 65 28
Age (years) ‡ 66 (59-72) 63,5 (55-70) 0.23*
Gender
Male 46 (65) 18 (64) -
Female 19 (35) 10 (36) 0.54**
Primary tumor stage
Stage I 12 (18) 5 (18) -
Stage II 26 (40) 8 (29) -
Stage III 22 (34) 11 (39) -
Stage IV 3 (5) 4 (14) -
Unknown 2 (3) 0 0.39**
Type resection
LAR 45 (69) 17 (61) -
APR 20 (31) 11 (39) 0.42**
Neoadjuvant treatment
Short course RTx (25Gy) - 10 (36) -
Long course RTx (44.6 -50Gy) - 10 (36) -
Chemoradiotherapy (50Gy) - 8 (28) -
Values in parentheses are percentage unless indicated otherwise; nRTx, neoadjuvant radiotherapy;‡, 
values are median (interquartile range); LAR, Low Anterior Resection; APR, Abdominoperineal Resec-
tion; RTx, Radiotherapy; *, using Mann Whitney U test; ** using χ²-test
Primary tumor and local recurrence
Patient and primary tumor characteristics are depicted in table I. All patients with stage 
IV primary rectal cancer (n=7) had undergone metastasectomy previously (median 14 
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months prior to LRRC, range 12-48 months) and were free of distant metastases at the 
time of diagnosis of LRRC. The median interval between primary tumor resection and 
diagnosis of LRRC was 24 (14-41) months for the patients in group A and 20 (12-30) 
months for patients in group B (p=0.10). The tumor characteristics of LRRC are depicted 
in table II
Table II. Tumor characteristics of locally recurrent rectal cancer
No nRTx for primary 
tumor (group A)
nRTx for primary tumor 
group B) P-value
Total patients 65 28
Wanebo classification
Tr1 7 (11) 1 (4) -
Tr2 6 (9) 3 (11) -
Tr3 24 (37) 12 (39) -
Tr4 23 (36) 11 (36) -
Tr5 5 (8) 1 (4) 0.74**
Location of recurrence
Intraluminal 13 (20) 4 (14) -
Extraluminal 52 (80) 24 (86) 0.51***
Location of LRRC
Presacral 21 (32) 10 (36) -
Lateral 18 (28) 8 (29) -
Anterior 15 (23) 6 (21) -
Anastomic 13 (20) 4 (14) 0.92**
Values in parentheses are percentage; nRTx, neoadjuvant radiotherapy; Tr, Tumor stage recurrent rec-
tal cancer; LRRC, locally recurrent rectal cancer; ** using χ²-test, *** using Fisher’s exact test
Peri-operative results
The surgical procedures and operative results for LRRC are depicted in table III. There 
were no significant differences between both groups in the number of R0, R1 and 
R2-resections, although there tend to be more R1-resections in group B (26% vs. 
43%,p=0.09). Intraoperative radiotherapy (IORT) was administered to all patients with 
an R1-resection or with a tumor-free margin ≤2mm.
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Table III. Operation characteristics for locally recurrent rectal cancer
No nRTx for primary 
tumor (group A)
nRTx for primary tumor 
(group B) P-value
Total patients 65 28
Neoadjuvant treatment LRRC
RTx 41 (63) 11 (39)
CTxRTx 24 (37) 17 (61) 0.03**
Interval nRTx and surgery‡ 8 (6 – 10) 8 (8 – 10) 0.46*
Surgical procedure
LAR 7 (11) 1 (4) -
APR 15 (23) 7 (25) -
Intersphinteric resection 4 (14) 1 (4) -
Posterior exenteration ¥ 17 (26) 10 (36) -
Total pelvic exenteration 17 (26) 8 (29) -
Pelvic recurrence resection 5 (8) 1 (4) 0.76**
Partial sacrectomy 5 (8) 2 (7) 0.93***
Omental flap 43 (66) 18 (64) 0.86**
Resection margin
R0 41 (63) 13 (46) -
R1 17 (26) 12  (43) -
R2 7 (11) 3 (11) 0.26**
IORT
R0† 16/41 (39) 6/13 (46) 0.65**
R1 17/17 (100) 12/12 (100) -
R2 5/7 (71) 3/3 (100) 1.00***
Pathological complete 
response
6 (9) 1 (4) 0.67***
Operation time (minutes) ‡ 408 (268 – 491) 460 (360 – 555) 0.14*
Blood loss (milliliters) ‡ 2200 (1925  – 3900) 3900 (1925 – 8250) 0.16*
Values in parentheses are percentage; †, values in parentheses are interquartile range; RTx, Radiother-
apy; CTxRTx, chemoradiotherapy; LAR, Low Anterior Resection; APR, Abdominoperineal Resection;¥, 
only performed in women, percentage of all patients; R0, resection margin of >0 mm; R1, microscopi-
cally invclved margins; R2, macroscopically involved margins; IORT, intraoperative radiotherapy; † only 
in patients with margins <2mm *, using Mann-Whitney U test; **, using χ²-test; ***, using Fisher’s 
exact test
In group A, 41 surgical complications occurred in 32 patients (49%). Sixteen surgical 
complications occurred in 13 patients (46%) in group B (p=0.80). Seventeen non-
surgical complications occurred in 12 (18%) patients in group A and 11 non-surgical 
complications occurred in 8 patients (29%) in group B (p=0.28). There was no significant 
difference in grade ≥2, ≥3 or ≥4 complications.
Three patients (3%) died during admission in the hospital. There was no significant 
difference in in-hospital or peri-operative mortality between both groups. All deaths were 
caused by cardiac events. The peri-operative morbidity and mortality is further outlined 
in table IV.
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Table IV. Mortality and peri-operative morbidity
No nRTx for primary 
tumor (group A)
nRTx for primary tumor 
(group B) P-value
Total patients 65 28
Peri-operative morbidity
Surgical
Abdominal wound 
infections
11 (17) 5 (18) 1.00***
Presacral abscess 11 (17) 5 (18) 0.91** 
Relaparotomy 10 (15) 3 (11) 0.75***
Small bowel perforation 5 (8) 1 (4) -
Wound dehiscence 1 (4) 0 -
Abscess/hemorrhage 2 (2) 1 (4) -
Negative 2 (4) 1 (4) -
Non-surgical
Pneumonia/atelectasis 9 (14) 4 (14) 0.73***
Cardiac 3 (5) 2 (8) 0.64***
Urinary tract infection 5 (8) 5 (18) 0.19**
Perineal woundhealing 
problems^
12 (70) 8 (66) 1.00**
Grading of complications 
(Dindo-Clavien)
Grade ≥2 45 (78) 22 (81) 0.68**
Grade ≥3 24 (41) 10 (37) 0.70**
Grade ≥4 9 (16) 3 (11) 0.74***
Mortality
In hospital mortality 1 (2) 2 (7) 0.22***
Peri-operative mortality 3 (5) 2 (7) 0.64***
Values in parentheses are percentage; nRTx, neoadjuvant radiotherapy; ^, only in patients with an APR 
**, using χ²-test; ***, using Fisher’s exact test
Survival
In group A, 25 patients (39%) were alive at last follow up. The median survival of 
surviving patients was 41 (range, 3-90) months. In group B, 14 patients (50%) were 
alive at last follow up. Their median survival was 32 (range, 4-86) months. The median 
survival of all patients in group A was 42 (95%CI 27-57) months compared to 38 
(95%CI, 0-77) months for all patients in group B (p=0.81). The estimated 3- and 5-year 
overall survival rates of patients in group A were 50% and 28% respectively and for 
patients in group B 56% and 43%, respectively. (Fig. IA)
In group A, 23 (35%) patients suffered a re-recurrence, while 21 patients (32%) died 
without suffering a re-recurrence. This resulted in an estimated 5-year local recurrence-
free survival of 55%. In group B, 11 patients (39%) suffered a local re-recurrence, while 
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5 patients (18%) died without suffering a re-recurrence. This resulted in an estimated 
5-year local recurrence-free survival of 48%. This did not differ significantly from group 
A. (p=0.50) (Fig. IB)
There was a significant difference in distant metastasis free-survival after 5 years in 
favor of patients in group B (39% vs. 66%,p=0.05). These results are shown in figure IC. 
Disease free-survival did not differ significantly after 5 years (27% vs. 40%,p=0.59) and 
is shown in figure ID.
Figure Ia: Overall survival
Figure IB: Local recurrence-free survival
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Figure IC: Distant metastasis-free survival
Figure ID: Disease free survival
Discussion
Our results demonstrate that in carefully selected patients with non-metastasized 
resectable LRRC who received nRTx and TME for the primary tumor, the overall survival 
is similar to patients who did not receive nRTx for the primary tumor. There may be more 
incomplete resections in patients who received nRTx for the primary tumor, but this does 
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not result in an increased local re-recurrence rate. The peri-operative morbidity is not 
increased in patients who received nRTx for the primary tumor.
These findings are complementary to updates of two large randomized controlled 
trials7,13  These studies demonstrated a poorer prognosis of LRRC in case the primary 
tumor was treated with nRTx. However, both studies included patients that were 
treated curatively and those who were not, while our study focuses on resectable LRRC 
specifically. The poorer prognosis of LRRC after nRTx may lead to the conclusion that 
nRTx alters tumor characteristics resulting in more aggressive biological behavior. 
However, it is more likely that recurrences after nRTx may simply represent a selection 
of patients with unfavorable tumor characteristics. Neoadjuvant radiotherapy probably 
does not prevent recurrence in patients with “bad” disease (e.g. more residual disease, 
positive resection margins, higher tumor load). These patients are likely to have a 
poorer prognosis and this originates in a high rate of distant metastases at diagnosis or 
within 6 months after diagnosis of LRRC after nRTx for the primary tumor.7 These distant 
metastases disqualify patients for surgery and this caused only a minority (17%) of 
the patients after nRTx in the update of the Dutch TME-trial to be selected for curative 
surgery. In our hospital, since 2002, 28% of patients with LRRC after nRTx for the 
primary tumor were scheduled for curative treatment (data not shown). By ruling out 
distant metastases prior to and after (re-)irradiation, we only selected those patients that 
in general have malignancies with a more benign biological behavior and this explains 
why this study did not find a difference in outcome of patients treated with and without 
nRTx for the primary tumor.
Surprisingly, we found a significant difference in 5-year distant metastasis-free survival 
in favor of patients who received nRTx for the primary tumor. This finding should be 
interpreted with caution. It is based on a small number of patients and is probably 
caused by the selection bias mentioned above. However, it may explain why the outcome 
in these patients is comparable to that of patients who did not receive nRTx for the 
primary tumor, even when re-irradiation doses are limited and radical resections are 
technically more demanding. The difference in distant metastasis-free survival did not 
result in a significant difference in overall survival, which is comparable to the overall 
survival in other centers where a multimodality approach for LRRC is adapted.14,15
Because resected LRRC patients in both study groups have a similar local recurrence-
free survival, this implies that previous irradiation for the primary tumor does not result 
in decreased local control after surgery for the LRRC. This is remarkable, because the 
number of R0-resections in patients who received nRTx for the primary tumor was 
lower (although not significant) and radical resection  is the most important prognostic 
factor for local re-recurrence and overall survival after resection of LRRC.16-18 This lower 
number of R0-resections could be explained by the fact that a re-irradiation dose of 
30Gy is less effective than an irradiation dose 50Gy, resulting in less downstaging and 
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more incomplete resections. LRRC in patients who received nRTx for the primary tumor 
may also evolve from radiation-insensitive tumor deposits, rendering re-irradiation 
less effective. Nonetheless, our R0-resection rate of LRRC in patients who did and did 
not receive nRTx for the primary tumor is in line with other studies that report radical 
resection rates of 44-59% in LRRC after TME for the primary tumor. These studies did not 
include patients that had received nRTx or did not differentiate between patients who did 
and did not receive nRTx for the primary tumor.19,20
IORT may be a contributing factor to the relatively low local recurrence rate after 
R1-resections in this study. Although no randomized control trials were published proving 
the value of IORT for LRRC, several retrospective studies suggested a beneficial effect 
of IORT on local control for locally advanced rectal cancer.21-23  In IORT, the biological 
equivalent of a single dose is considered 2 to 3 times the dose given by conventional 
fractioning.24 The biological equivalent dose (BED) of 30Gy re-irradiation is 36Gy, 
resulting in a combined BED of nRTx and IORT of 56-66Gy, which is an adequate dose 
to increase local control in rectal cancer. In patients who received an irradiation dose 
of 50Gy, which has a BED of 60Gy, the addition of IORT leads to a BED of 80-90Gy. 
However, this did not result in a lower local recurrence rate in our study.
Although there was more blood loss in patients with LRRC who received nRTx for the 
primary tumor, peri-operative morbidity and mortality rates were similar in both groups. 
Increased blood loss may be caused by extensive post-radiation fibrosis after previous 
nRTx and re-irradiation. Overall complication rates, the occurrence of wound infections 
and presacral abscesses were similar to those reported in the literature.14,18,19,25
As could be expected in a retrospective analysis, this study has methodological 
drawbacks. Patients eligible for surgery were selected from larger groups of patients 
that were not selected for surgery because of distant metastases, unresectable disease 
or co-morbidity. In the first years of our study period, patients often did not receive 
nRTx for the primary tumor, whereas in later years, neoadjuvant therapy became the 
standard. This resulted in a difference in length of follow-up of 9 months of the surviving 
patients between groups A and B (41 vs. 32 months). Despite this difference, we think 
both groups were followed for an adequate length of time, since no re-recurrences were 
reported after 32 months of follow up. Furthermore, during the study period imaging 
modalities have improved, possibly resulting in more accurate staging and improved 
patient selection.
In conclusion, surgical treatment of carefully selected patients with resectable LRRC 
without metastatic disease after nRTx and TME is feasible and can result in sustained 
local control and overall survival. Patients with resectable LRRC after nRTx and TME for 
the primary tumor do not have a poorer outcome than patients who did not receive nRTx 
for the primary tumor. Therefore, these patients should be considered candidates for 
curative surgery. However, only a minority of patients with LRRC after previous irradiation 
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are candidates for curative surgery, because the majority has distant metastases or 
unresectable disease. Patients after previous nRTx for the primary tumor are more likely 
to have an incomplete resection of the LRRC, but this does not result in an increased 
local recurrence rate in this series of patients who underwent multimodality treatment.
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Abstract
Background
The importance of the circumferential resection margin (CRM) has been demonstrated in 
primary rectal cancer, but the role of the minimal tumor-free resection margin in locally 
recurrent rectal cancer (LRRC) is unknown.
Objective
To evaluate the prognostic importance of a minimal tumor-free resection margin in LRRC.
Design
This was a single-institution, retrospective study.
Setting
This study was conducted in a tertiary referral hospital
Patients and methods
Based on the final pathology report, surgically treated patients with LRRC between 1990 
and 2013 were divided into 4 groups: 1) Tumor-free  margins of >2mm; 2) tumor-free 
margins of >0-2mm; 3) microscopically involved margins and 4) macroscopically 
involved margins.
Main outcome measures
Local control and overall survival.
Results
A total of 174 patients with a median follow up of 27 months (range, 0-144)  were 
eligible for analysis. There was a significant difference in 5-year local re-recurrence-
free survival in favor of 41 patients with tumor-free margins of >2 mm compared 
to 34 patients with tumor-free margins of >0-2mm (80 vs. 62%,p=0.03) and a 
significant difference in 5-year overall survival (60 vs. 37%,p=0.01). The 5-years local 
re-recurrence-free and overall survival for 55 patients with microscopically involved 
margins were 28% and 16% and of 20 patients with macroscopically involved margins 
0% and 5%, respectively. On multivariable analysis tumor-free margins of >0-2mm were 
independently associated with higher re-recurrence rates (HR 2.76 95%CI1.06 – 7.16) 
and poorer overall survival (HR 2.57 95%CI 1.27-5.21) compared to tumor-free margins 
of >2mm.
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Limitations
This study was limited by its retrospective nature
Conclusion
Resection margin status is an independent prognostic factor for re-recurrences rate and 
overall survival in surgically treated LRRC. In complete resections, patients with tumor-
free resection margins of >0-2mm have a higher re-recurrence rate and a poorer overall 
survival than patients with tumor-free resection margins of >2mm.
Introduction
Developments in the treatment of primary rectal cancer, such as total mesorectal 
excision (TME) and neoadjuvant (chemo-)radiotherapy, have significantly decreased the 
local recurrence rate. Unfortunately, locally recurrent rectal cancer (LRRC) still occurs 
in 6-13% of surgically treated patients.1-4 LRRC is associated with a poor prognosis and 
treatment is challenging.
Multimodality treatment of LRRC, including neoadjuvant radiotherapy and surgical 
resection, can lead to long-term disease-free and overall survival. However, the outcome 
strongly depends on whether a complete surgical resection can be achieved. Recent 
studies have demonstrated that complete resections can result in 5-year overall survival 
rates of 30-57% and local control rates of 50-80%.5-10 On the other hand, incomplete 
resections leads to drastically poorer survival rates and high re-recurrence rates.11 The 
treatment options for re-recurrences are limited and overall survival is usually short when 
re-recurrence occurs. Moreover, the development of re-recurrences has a major impact 
on the patient’s quality of life.
In primary rectal cancer, the optimal cut-off for defining an involved circumferential 
resection margin (CRM) is under debate. Some authors propose a tumor-free margin 
of 1mm, while others propose 2mm. Regardless of this debate, there is consensus that 
narrows CRMs, whether 1mm or 2mm, are associated with a poorer outcome.12-14 It 
is likely that narrow resection margins in LRRC may lead to a poorer outcome as well. 
However, the association between the minimal distance of viable tumor to the nearest 
resection plane and long term outcome of LRRC has not been validated.15 This is clinically 
relevant, because narrow resection margins in LRRC surgery are common. Moreover, 
when this holds true for LRRC, a more aggressive surgical approach may be warranted. 
The goal of this study was to evaluate the association between width of the tumor-free 
resection margin and the long term outcome after LRRC surgery with curative intent.
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Patients and methods
All patients undergoing surgery for LRRC between January 1990 and March 2013 in 
our hospital, a tertiary referral center for the southwest region of the Netherlands, 
were retrospectively analyzed. LRRC was defined as a histopathologically proven local 
recurrence of colorectal cancer within the pelvic region. Demographic data, clinical 
characteristics, operative procedures and histopathology were examined.
Patients were scheduled for neoadjuvant (chemo-)radiotherapy followed by surgery, 
either as a long course of 44.6-52Gy in 19-28 fractions of 1.8-2.3Gy or a short course 
of 25Gy in 5 fractions of 5Gy or were treated by surgery alone. Previously irradiated 
patients were scheduled for a re-irradiation dose of 27-30Gy, delivered in 15-18 
fractions of 1.8-2.3Gy. After 2006, patients were treated with chemoradiotherapy 
with capecitabine administered orally at a dose of 825 mg/m2 twice a day during 
radiotherapy. Radiotherapy for LRRC was administered by a three field technique, using 
one posterior and two lateral portals, a four-field box or with five fields using intensity 
modulated radiotherapy.
Patients were locally staged by pelvic MRI or CT-scan and screened for distant 
metastases by a thoraco-abdominal CT-scan at the time of LRRC diagnosis. The 
majority of patients was restaged after (re-)irradiation to evaluate the response of the 
local recurrence to neo-adjuvant (chemo-)radiotherapy and to detect potential distant 
metastases.
LRRCs were treated by local recurrence excisions, low anterior resections (LARs), 
abdominoperineal resections (APRs), partial exenterations, total exenterations or 
abdominosacral resections. Patients were considered candidates for surgical treatment 
in case of no extensive distant metastases, no apparent lateral bone involvement, no 
sacral involvement above level S3, no extension through the greater sciatic notch, and no 
encasement of common or external iliac arteries.
Our multimodality approach for LRRC included intra-operative radiotherapy (IORT), 
which became available after 1996 for patients with tumor free margins of ≤2mm, 
evaluated during surgery on frozen sections.16 Frozen section evaluation became a 
standard part of the surgical procedure after the introduction of IORT and was taken 
from sites that were potentially at risk for tumor involvement evaluated on pre-operative 
imaging or macroscopic evaluation by surgeon and pathologist.
All resection specimens were assessed by experienced gastrointestinal pathologists, 
inked following a standard procedure, formalin fixed and cutsectioned in slices. The 
minimal tumor-free resection margin was evaluated macroscopically and microscopically 
as the nearest distance of viable tumor cells to the inked resection plane. The minimal 
resection margin of the frozen section evaluation was confirmed by final pathology 
evaluation. For patients where a sampling error occurred (closer or involved margins at 
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another resection plane), the margin of the final pathology report was considered the 
definitive tumor-free resection margin. For patients with a more extended resection as a 
result of the frozen sections, the minimal tumor-free resection margin was measured in 
the additional resected tissue.
Based on the final pathology report, patients with viable tumor were divided into four 
groups: 1) tumor-free resection margins of >2 mm; 2) tumor-free margins of >0-2 mm; 
3) microscopically involved resection margins and 4) macroscopically involved resection 
margins. In these subgroups, we compared the local re-recurrence-free survival and 
overall survival.
Follow up consisted of a program in which patients generally visited the outpatient 
clinic every 3 months during the first two years and biannually after 2 years. The first 
two years CEA determination was performed every 3 months and thoracic and abdominal 
imaging biannually. After 2 years of follow up, CEA determination was performed 
biannually and thoracic and abdominal imaging yearly. Re-recurrences were established 
by symptoms, CEA increase or imaging. All suspected re-recurrences were confirmed 
by CT/MR imaging or biopsies. Confirmation of the date of death was retrieved from 
the death registries of the municipal register. Some patients returned to the referring 
hospitals for follow up. In these patients follow up data was obtained by hospital notes 
and information of the general practitioner.
Statistical analysis was carried out using SPSS (version 20.0.0). Data was reported 
as median (interquartile range). Categorical data was reported as count (percentage). 
Univariate analyses for local re-recurrence-free survival and overall survival were 
performed by using the Kaplan-Meier method and a log-rank test. Univariate and 
multivariable analyses to determine the prognostic value of covariates regarding local 
re-recurrence-free and overall survival were performed by using Cox’s proportional 
hazards model. In these analyses, we excluded patients with a pathological complete 
response or an indeterminable resection margin. Multivariable analysis was stratified 
for period of surgery (1990-1996, 1997-2005 and 2006-2013) to rule out the effect 
of non-measurable covariates. For the multivariate analysis, only parameters with 
P-values ≤0.05 in the univariate model were entered in the Cox regression model. 
Backward elimination was applied and variables were removed if P-values were >0.10. 
Local re-recurrence-free survival and overall survival were calculated from the date of 
LRRC surgery to last follow-up or death. P-values <0.05 were considered statistically 
significant.
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Results
A total of 174 patients underwent surgery for LRRC. During surgery, 9 patients were 
considered incurable due to unresectable metastatic disease or unresectability of the 
local recurrence, leaving 165 patients (59 women and 106 men) eligible for analysis. The 
baseline characteristics are depicted in table I. The median age at LRRC surgery was 65 
years (interquartile range, 56-70).
Histopathological evaluation
Thirteen patients (8%) had a pathological complete response without viable tumor 
in the resected specimen after neoadjuvant therapy. Forty-one patients (24%) had a 
tumor-free resection margin of >2 mm (median 5mm, range, 2.1-25mm), 34 patients 
(21%) a tumor-free margin of >0-2mm (median 1mm, range, 0.1-2), 55 patients (33%) 
a microscopically involved resection margin and 20 patients (12%) a macroscopically 
involved resection margin. In 2 patients (1%) the resection margin could not be 
determined accurately. Tumor-free resection margins of >2mm were most commonly 
achieved in central LRRCs (14/20=70%), followed by anterior LRRCs (10/30=33%), 
lateral LRRCs (10/45=22%) and posterior LRRCs (6/42=14%). Six patients (4%) 
had a well differentiated, 102 patients (62%) a moderately differentiated and 20 
(12%) patients a poorly differentiated adenocarcinoma. In 36 patients (21%) tumor 
differentiation was not specified. Vaso-invasion was found in 30 patients (18%).
Follow up
The median length of follow up was 27 months (range, 0-144). At last follow up, 57 
patients were alive with a median follow up of 43 months (range, 3-144). The estimated 
1-, 3-, 5-year overall survival was 82%, 46%, 32%, respectively. A total of 66 patients 
suffered a re-recurrence during follow up, while 51 patients died without a known 
re-recurrence.
Results of univariate and multivariable analyses of 150 patients for local re-recurrence-
free survival are provided in table II. Univariate and multivariable analyses for overall 
survival are provided in table III. Fifteen patients with a pathological complete response 
or an undeterminable margin were excluded from this analysis. Multivariate analyses 
demonstrated that the resection margin status was an independent prognostic factor 
for local re-recurrence-free survival and overall survival. In addition, interval between 
primary tumor resection and diagnosis of LRRC and vasoinvasion were independent 
prognostic factors for overall survival.
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Table I. Baseline patients and LRRC characteristics
Number of patients (%)
Total patients 165
Primary tumor resection
Sphincter saving 127 (77)
Non-sphincter saving 38 (23)
Previous pelvic radiotherapy
None 134 (81)
(CTx)RTx 31 (19)
Primary tumor resection
Non-TME 65 (39)
TME 100 (61)
Interval primary tumor – LRRC* 24 (12-38)
Neoadjuvant treatment LRRC
None 22 (13)
RTx 81 (49)
CTxRTx 62 (38)
Tumour location
Central 20 (13)
Lateral 45 (30
Anterior 30 (20
Posterior 42 (28)
Unknown 13 (9)
LRRC surgery
LAR 20 (12)
APR 29 (18)
Partial exenteration 61 (37)
Total exenteration 29 (18)
Abdominosacral resection 19 (12)
Recurrence resection 7 (4)
Distant metastases at diagnosis 7 (4)
Metastases-first treatment 2 (1)
Synchronous treatment 1 (1)
Delayed metastases treatment 3 (2)
Adjuvant chemotherapy 3 (2)
Blood loss*** 3.000 (1.750-5.250)
IORT 76 (46)
Operation time 403 (281-499)
LRRC, locally recurrent rectal cancer, RTx, radiotherapy; LAR,
Low Anterior Resection; APR, abdominoperineal resection;
CTxRTx, chemoradiotherapy.; TME, total mesorectal excision,
*, Months (interquartile range)**, Weeks (interquartile range);
***, millilitres (interquartile range); IORT, intraoperative radiotherapy
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Local re-recurrence-free survival
The estimated 3- and 5-year local re-recurrence-free survival of patients with tumor-
free margins of >2mm were 80% and 80% respectively, compared to 62% and 62% 
for patients with tumor-free margins of >0-2mm, 38% and 28% for patients with 
microscopically involved margins and 0% and 0% for patients with macroscopically 
involved resection margins. The re-recurrence-free survival of patients with tumor-free 
margins of >2mm was significantly longer than in patients with tumor-free margins of 
>0-2mm (p=0.03), microscopically involved margins (p<0.001) and macroscopically 
involved margins (p<0.001) (figure I). In a subgroup analysis of the patients with a 
tumor-free resection margin of >0-2mm, there was no significant difference in local 
re-recurrence-free survival of patients with a tumor-free margin of <1mm (n=15) and 
patients with tumor-free margins of 1-2mm (n=19) (66 vs. 59%,p=0.61).
Figure I. Local re-recurrence-free survival of surgically treated LRRC patients
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Figure I. Local re-recurrence-free survival of surgically treated LRRC patients 
Overall survival
The estimated 3- and 5-year overall survival of patients with tumor-free margins of 
>2mm was 78% and 60% respectively, compared to 45% and 37% for patients with 
tumor-free margins >0-2mm, 32% and 16% for patients with microscopically involved 
margins and 16% and 5% for patients with macroscopically resection margins. The 
overall survival of patients with tumor-free margins of >2mm was significantly longer 
compared to patients with tumor-free margins of >0-2mm (p=0.01), microscopically 
involved margins (p<0.001) and macroscopically involved margins (p<0.001) (figure II). 
In a subgroup analysis of the patients with a tumor-free resection margin of >0-2mm, 
there was no significant difference in overall survival of patients with a tumor-free margin 
of <1mm and patients with tumor-free margins of 1-2mm (38 vs. 36%,p=0.57).
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Table II. Univariate analysis of covariates regarding the local re-recurrence-free survival and multivari-
able analysis stratified for period of surgery
Number of 
patients
Univariate
Hazard ratio 
(95%CI) p-value
Multivariable
Hazard ratio (95%CI) p-value
Gender
Male 94 1
Female 56 1.04 (0.63 – 1.72) 0.88 -
Primary tumor resection
Non TME 58 1
TME 92 1.04 (0.62 – 1.73) 0.89 -
Previous pelvic radiotherapy
No RTx 121 1
(CTx)RTx 29 1.26 (0.68 – 2.32) 0.46 -
Age at surgery
<65 year 74 1
≥65 year 76 1.17 (0.72 – 1.92) 0.53 -
Primary tumor resection
Sphincter saving 114 1 1
Non sphincter saving 36 1.89 (1.13 – 3.16) 0.015 1.48 (0.84 - 2.61) 0.16
Interval primary tumor and 
diagnosis of LRRC
<2 years 72 1
≥2 years 78 0.71 (0.43 – 1.16) 0.17 -
LRRC neoadjuvant treatment
No RTx 21 1
(CTx)RTx 129 0.56 (0.30 – 1.05) 0.07 -
LRRC surgery
Non sphincter saving 97 1 1
Sphincter saving 53 1.77 (1.00 – 3.12) 0.05 1.48 (0.84 – 2.61) 0.17
Total exenteration
No 122 1
Yes 28 0.92 (0.46 – 1.80) 0.80 -
Partial sacrectomy
No 132 1
Yes 18 1.80 (0.98 – 3.32) 0.06 -
Resection margin status
>2mm 41 1 1
>0-2mm 34 2.82 (1.09 – 7.27) 0.033 2.76 (1.06 – 7.16) 0.037
Microscopically involved 55 5.22 (2.28 – 11.95) <0.001 4.92 (2.15 – 11.26) <0.001
Macroscopically involved 20 12.52 (4.97 – 31.53) <0.001 11.06 (4.20 – 29.12) <0.001
IORT
No 74 1
Yes 76 1.38  (0.84 – 2.27) 0.20 -
Tumor differentiation grade
Well/moderate 105 1
Poor 18 0.92 (0.42 – 2.03) 0.83 -
Vasoinvasion
No 121 1
Yes 29 2.40 (1.38 – 4.16) 0.002 1.60 (0.89 – 2.89) 0.12
LRRC, locally recurrent rectal cancer; TME, total mesorectal excision, RTx, radiotherapy; CTxRTx, chemoradio-
therapy;  IORT, intraoperative radiotherapy
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Table III. Univariate analysis of covariates regarding the overall survival and multivariable analysis 
stratified for period of surgery
Number of 
patients
Univariate
Hazard ratio 
(95%CI) p-value
Multivariable
Hazard ratio 
(95%CI) p-value
Gender
Male 94 1
Female 56 0.86 (0.56 – 1.32) 0.50 -
Primary tumor resection
Non-TME 58 1
TME 92 0.83 (0.55 – 1.26) 0.38 -
Previous pelvic radiotherapy
No RTx 121 1
(CTx)RTx 29 0.75 (0.43 – 1.33) 0.33 -
Age at LRRC surgery
<65 year 74 1
≥65 year 76 1.21 (0.80 – 1.83) 0.36 -
Primary tumor resection
Sphincter saving 114 1
Non sphincter saving 36 1.17 (0.74 – 1.85) 0.51 -
Interval primary tumor and 
diagnosis of LRRC
<2 years 72 1 1
≥2 years 78 0.60 (0.40 – 0.90) 0.015 0.55 (0.36 – 0.83) 0.006
LRRC neoadjuvant treatment
No RTx 21 1
(CTx)RTx 129 0.89 (0.51 – 1.58) 0.69 -
LRRC surgery
Non sphincter saving 97 1
Sphincter saving 53 1.52 (0.97-2.38) 0.07 -
Total exenteration
No 122 1
Yes 28 1.17 (0.69 – 1.98) 0.56 -
Partial sacrectomy
No 132 1
Yes 18 1.25 (0.70-2.25) 0.45 -
Resection margin status
>2mm 41 1 1
>0-2mm 34 2.56 (1.26 – 5.20) 0.009 2.58 (1.26 – 5.26) 0.009
Microscopically involved 55 3.91 (2.09 – 7.31) <0.001 3.64 (1.89 – 7.00) <0.001
Macroscopically involved 20 5.95 (2.89 – 12.28) <0.001 4.89 (2.29 – 10.45) <0.001
IORT
No 74 1
Yes 76 1.37 (0.91 – 2.07) 0.14 -
Tumor differentiation grade
Well/moderate 105 1
Poor 18 1.29 (0.70 – 2.39) 0.41 -
Vasoinvasion
No 121 1 1
Yes 29 2.38 (1.50 – 3.81) 0.001 1.78 (1.06 – 2.98) 0.029
LRRC, locally recurrent rectal cancer; TME, total mesorectal excision, RTx, radiotherapy; CTxRTx, chemora-
diotherapy; IORT, intraoperative radiotherapy
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Figure II. Overall survival of the surgically treated LRRC patients
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margins of >2mm followed by 42% for tumor-free margins of 0-2mm, 28% for 
microscopically involved margins and 0% for macroscopically involved margins. 
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Discussion
The current study demonstrates that resection margins are the key to successful curative 
surgery for LRRC. Patients with resection margins of more than 2mm suffer less local 
re-recurrences and have an improved overall survival compared to patients with narrow 
resection margins (>0-2mm). Subsequently, patients with narrow resection margins (>0-
2mm) have a more favorable outcome compared to patients with microscopically involved 
margins. Accurate determination of the minimal tumor-free resection margin leads to a 
more accurate assessment of the risk of local re-recurrence and overall survival. These 
data suggest that all efforts should be made to achieve resection margins more than 2 
mm by downstaging with neoadjuvant treatment and by aggressive, multivisceral surgery 
when needed.
The association between the width of the tumor-free resection margin of LRRC and 
the re-recurrence rate is in line with the association of the CRM and recurrence rates 
in primary rectal cancer. However, re-recurrence rates after LRRC surgery are high 
compared to primary rectal cancer, which suggests a more aggressive local tumor 
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behavior of LRRC.12 In primary rectal cancer, recurrences rates after CRMs of >2mm 
are reported in 2-12% of the patients compared to a re-recurrence rate of 20% after 
LRRC surgery. In patients with CRMs of >0-2mm, local recurrence rates of 5-28% are 
reported in primary rectal cancer compared to a re-recurrence rate of 38% in this study. 
Microscopically involved CRMs lead to a recurrence rate of 35-55% in primary rectal 
cancer compared to a re-recurrence rate of 72% after LRRC surgery in this study.12-14,17
The majority of published studies considers any microscopically uninvolved margin 
after LRRC surgery as a R0-resection. The local re-recurrence rates after such R0-
resections are 25-50%.6,10,18,19 These high re-recurrence rates can be explained by the 
fact these R0-resections probably contain a high proportion of patients with tumor-free 
resection margins of >0-2mm. In our series, tumor-free margins of >0-2mm were 
present in 46% of the patients with complete resections. In line with our results, 
authors who consider tumor-free margins of ≥1mm as R0-resections reported lower 
re-recurrence rates of 13-16%.11,20 In the current study, re-recurrence rate and overall 
survival rates of patients with tumor-free margins of <1mm or tumor-free margins of 
1-2mm were similar. We therefore suggest that tumor-free resection margins of >2mm 
should be the goal of curative surgery for LRRC.
The high frequency of narrow and involved resection margins in rectal surgery is 
caused by the anatomy of the pelvis. Moreover, local recurrences in the TME era are 
usually not confined to an anatomical compartment, since the anatomical compartment 
(mesorectum) was resected completely during resection of the primary rectal tumor. 
Consequently, local recurrences usually involve structures such as the pelvic fatty tissue 
and sidewalls, the bony sacrum, iliac and sacral vessels and nerves, ureters, bladder and 
the internal genitalia (prostate, uterus and vagina). Few patients have true intraluminal 
recurrences. These are the recurrences that may result in wide tumor-free resection 
margins as compared to recurrences that occur anterior, lateral and dorsal in the pelvis.21 
In not-centrally located LRRCs wide tumor-free resection margins can only be achieved 
by performing aggressive surgery, such as posterior exenterations, total exenterations or 
abdominosacral resections.11,22,23
Performing more radical surgical approaches may be the key to increase the number 
of patients with wider resection margins and thus improving the long-term outcome. 
Several experienced LRRC centers have shown that more radical surgical approaches 
for LRRC can be carried out with good results. A recent study of Colibaseanu et al.24 
have demonstrated that extended sacropelvic resections, for example with high sacral 
involvement above the level of S2 or resections in combination with hemipelvectomies, 
can be carried out with acceptable morbidity and results in a high complete resection 
rate of 93% and an excellent 5-year survival rate of 46%. Others have demonstrated 
previously that extensive resections of pelvic sidewall recurrences or extensive resections 
including sacrectomy can be carried out with excellent results.25,26
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The introduction of multidisciplinary tumor boards and the improvement of the quality 
of the imaging modalities can further increase the number of complete resections by 
more accurate determination of the required extent of the surgical approach. It should 
be kept in mind that surgical planning should be performed on the initial imaging before 
neoadjuvant (chemo-)radiotherapy to reduce the chance of incomplete resections. 
Restaging imaging is unreliable to differentiate between post-radiation fibrosis and 
malignant tissue.
In general, the type of surgical procedure for LRRC did not change during the study 
period. However, developments in the treatment of primary rectal cancer, such as TME 
and radiotherapy, did influence the surgical treatment of LRRC. Complete resections 
after TME for the primary rectal tumor are considered more difficult and may result 
in an increased number of patients with narrow or involved resection margins. At the 
same time, the introduction of neoadjuvant radiotherapy for primary rectal cancer has 
caused re-irradiation doses for the treatment of LRRC to be limited in those patients who 
received radiotherapy for the primary tumor. This may result in decreased downstaging 
and less complete resections for LRRC. Additionally, the use of re-irradiation is still 
controversial, because of the potential toxicity. To evaluate the possible influence of 
these variables, we performed uni- and multivariable analyses, but none of these factors 
proved significant.
Although others have suggested a beneficial effect of IORT, the univariate analysis did 
not show a similar result.27,28 However, IORT was specifically administered to patients 
with a high risk of local re-recurrence (i.e. involved or narrow margins ≤2mm), thus 
creating a selection bias to the detriment of the value of IORT.
An interval of more than 2 years between primary tumor resection and the diagnosis 
of LRRC was a prognostic factor for overall survival after LRRC surgery. Due to the fact 
that only patients with minimally of non-metastasized LRRC were selected for surgery, 
patients diagnosed with LRRC after an interval of more than 2 years may have tumors 
with a more favorable biological behavior.
Due to the retrospective nature of this analysis, this study has drawbacks. Firstly, the 
number of patients included is low compared to the studies that evaluated the prognostic 
value of the CRM in primary rectal cancer. However, this may be compensated by a 
higher occurrence of patients with tumor-free margins of >0-2mm. Secondly, the current 
study applied no standardized pathological examination to the resected specimens as 
was conducted in primary rectal cancer. Standardized pathological examination of LRRC 
is difficult due to the heterogeneity of the resected specimens, varying from specimens 
of total exenterations to resections of relative small local recurrences. Furthermore, 
the number of pathologists involved was high. The resection specimens were always 
evaluated by a team of 4 designated GI pathologists. However, we found that the 
turnover in this team has been very high, resulting in approximately 20 pathologists 
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evaluating the specimens. Thirdly, the long time span of this study may have introduced 
non-measurable variables and inherent biases, such as the quality of imaging and 
the experience of different surgeons. Although at all times a team of three dedicated 
colorectal surgeons performed resections of LRRCs (total of 8 surgeons during the study 
period). By stratifying for period of surgery in multivariable analysis, the influence of 
these variables was reduced. Fourthly, the median follow up of all patients was relative 
short (27 months), which was caused by a relative short overall survival. A substantial 
proportion of local re-recurrences may develop after this follow up period. However, the 
median follow up of the surviving patients was 43 months and we therefore think these 
patients were followed for an adequate length of time to evaluate the local re-recurrence-
free survival. Fifthly, this study only included patients that underwent surgery. Since 
2002, approximately 40% of the patients referred to our hospital were considered 
candidates for a surgical resection (data not shown). This is a potential selection bias 
and implies that the findings of current study are only applicable for selected patients. 
This may also explain the high number of patients who were treated by sphincter-saving 
procedures for the primary tumor.
In conclusion, resection margin status is an independent prognostic factor for re-
recurrence and overall survival after curative surgery for LRRC. Patients with tumor-free 
resection margins of less than or equal to 2mm have a significantly higher re-recurrence 
rate and a poorer overall survival than patients with tumor-free resection margins over 
2mm. All efforts should be directed at achieving wide tumor-free resection margins of 
more than 2mm.
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Abstract
Background
Tumor lesions in previously irradiated area may have a less favourable response to 
chemotherapy compared to tumor sites outside the radiation field. The aim of the 
present study was to evaluate the response to chemotherapy of locally recurrent rectal 
cancer (LRRC) within the previous radiation field compared to the response of distant 
metastases outside the radiation field.
Patients and methods
All patients with LRRC referred between 2000 and 2012 to our tertiary university hospital 
were reviewed. The response to chemotherapy of LRRC within previously irradiated area 
was compared to the response of synchronous distant metastases outside the radiation 
field according to the RECIST.
Results
Out of 363 cases with LRRC, 29 previously irradiated patients with distant metastases 
were treated with chemotherapy and eligible for analysis. Twenty-six patients (89%) 
suffered a first recurrence and 3 patients (11%) a second recurrence. These patients 
were followed with a median of 22 months (IQR, 9-40 months) and had a median 
survival of 33 months (IQR 14-42). In  23 patients (79%) the local recurrence showed 
stable disease, but the overall response rate of the local recurrences in the previously 
irradiated area was significantly lower than the response rate of distant metastases 
outside the radiation field (10% vs. 41%,p=0.034).
Conclusions
Previously irradiated patients with LRRC have a lower response rate to chemotherapy 
of the local recurrence within the radiation field compared to the response rate of 
distant metastases outside the radiation field. This suggests that chemotherapy for local 
palliation may not have the desired effect.
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Introduction
Preoperative short-term radiotherapy (5x5Gy) has evolved into an integrated part of the 
treatment of stage II and III rectal cancer in the Netherlands, because of the beneficial 
effect on local control.1 Long-term radiotherapy (50Gy) with or without concomitant 
chemotherapy has become standard of care in the treatment of locally advanced rectal 
cancer, because of improved local control and the effect of downsizing/-staging, thereby 
facilitating the possibility of a complete surgical resection.2,3 Despite these advances, still 
5–15% of the patients develop a local recurrence.4 The widespread use of neoadjuvant 
radiotherapy introduced a new problem; the treatment of locally recurrent rectal cancer 
(LRRC) in previously irradiated area.
The treatment of LRRC is a therapeutic challenge. Complete surgical resection 
is considered the only chance of durable local control and long term survival.5,6 
Unfortunately, only 31-40% of the patients with LRRC have resectable disease.7,8 The 
majority is considered unresectable due to the presence of extensive synchronous 
distant metastases or an advanced local recurrence in which complete surgical resection 
is technically not feasible. These patients can only be offered palliative treatment, 
consisting of pelvic radiotherapy in case of pain or chemotherapy in case of metastasized 
disease.
The palliative treatment options in previously irradiated patients with LRRC are 
limited. Due to the previous radiotherapy, only a limited dose of radiation can be 
administered and when treated with chemotherapy, the response of the local recurrence 
might be less favorable due to scarring and fibrosis of the pelvic tissue caused by 
the previous radiotherapy. This assumption is supported by a subgroup analysis of a 
meta-analysis, evaluating the response to chemotherapy for recurrent cervical cancer. 
Tumor recurrences within the previous radiation field showed a lower response rate to 
chemotherapy compared to the tumor recurrences outside the radiation field.9 However, 
whether this also accounts for LRRC and the chemotherapeutic regimens used in this 
disease remains to be established.
The aim of the present study is to evaluate the response to chemotherapy of local 
recurrences in previously irradiated area compared to the response of distant metastases 
outside the radiation field within the same patient.
Patients and methods
All patients with LRRC referred between January 2000 and December 2012 to the 
Erasmus MC Cancer institute, a tertiary University hospital for the southwest region of 
the Netherlands were analyzed. Patients were discussed in a multidisciplinary tumor 
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board to determine the treatment strategy. At the time of diagnosis of LRRC, all patients 
were locally staged by a pelvic computed tomography scan (CT-scan) or by magnetic 
resonance imaging (MRI) and were screened for distant metastases by a thoraco-
abdominal CT-scan. LRRCs were diagnosed by histological biopsies or by imaging. Criteria 
for LRRC on imaging were; a pelvic mass growing on consecutive imaging, a pelvic mass 
causing progressive ureter obstruction or a pelvic mass with sacral or lateral pelvic bone 
invasion.
Previously irradiated patients who presented with a first or second local recurrence with 
synchronous distant metastases outside the radiation field were identified. Patients who 
were not considered candidates for LRRC surgery and were treated with chemotherapy 
were included for analysis. Patients receiving palliative re-irradiation for local pain 
relief prior to chemotherapeutic treatment were excluded, unless re-irradiation was 
administered at least 1 year before the start of the chemotherapeutic treatment and 
the local recurrence had grown in size on radiologic imaging. Data were collected from 
all referring hospitals and included demographics, radiotherapeutic reports, pathological 
reports, radiological imaging and chemotherapeutic information.
Response to chemotherapy was assessed by two experienced medical oncologists and 
was scored according to Response Evaluation Criteria in Solid Tumors (RECIST) version 
1.1.10 Tumor response was classified as a stable disease (SD), progressive disease (PD), 
partial response (PR) or complete response (CR). Overall response rate was defined 
as the sum of the patients with a PR or CR. Response evaluation was assessed after 
the first available follow up CT-scan after start of chemotherapy with a minimum of 3 
and a maximum of 9 completed courses of chemotherapy. Baseline CT-scan had to be 
performed no more than 12 weeks before start of chemotherapy. Response evaluation of 
the local recurrence and the distant metastases was determined separately.
Statistical analysis was carried out using SPSS (version 20.0.0.1). Categorical data 
were reported as count (percentage) or median (interquartile range) as appropriate. 
Evaluation of distribution of response rates were performed by a chi-square test and a 
paired McNemar’s test. P-values <0.05 were considered significant.
Results
A total 363 patients with LRRC were referred to our hospital; 218 patients (60%) were 
not considered candidates for curative surgery and were offered palliative treatment. 
One hundred and seven patients received pelvic irradiation previously of which 74 
had developed synchronous distant metastases outside the previous radiation field. 
Chemotherapy was administered to 39 patients. Ten patients were excluded due to 
missing data (n=5), additional pelvic radiation within one year before the start of 
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chemotherapy (n=3) and death before tumor response evaluation (n=2), leaving 29 
patients evaluable for analysis. (Figure I)
Figure I. Study flowchart of all LRRC patients
LRRC, locally recurrent rectal cancer
Patient and tumor characteristics
Patients and tumor characteristics are outlined in table 1. Twenty-six patients (89%) 
suffered a first local recurrence and 3 patients (11%) suffered a second recurrence after 
LRRC surgery with curative intent. LRRC was histopathologically proven in 16 patients 
(55%). The median interval between primary rectal surgery and LRRC diagnosis was 
23 months (IQR 15-36). Previous pelvic radiotherapy for the primary tumor or first 
local recurrence was a long course radiotherapy (44,6-50Gy) in 12 patients (41%), 
chemoradiotherapy (50Gy) in 9 patients (28%) and a short course radiotherapy (25Gy) 
in 8 patients (28%). The localization of the distant metastases were pulmonary in 16 
patients (55%), hepatic in 7 patients (24%), both pulmonary and hepatic in 3 patients 
(10%) and inguinal lymph nodes in 3 patients (10%).
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Table I. Baseline patients and tumor characteristics
Number of
patients (%)
Total patients 29
Gender
Male 22 (76)
Female 7 (24)
Age at diagnosis 65 (38-84)
Primary or LRRC surgery
LAR 15 (52)
APR 11 (38)
Posterior exenteration 2 (7)
Total exenteration 1 (3)
Primary or LRRC resection margin
R0 25
R1 (≤1mm) 3
R2 (macroscopically incomplete) 1
Tumor Stage
T1-2 2
T3-4 27
Lymph node status
N0 8
N+ 21
Tumor differentiation
Well 0
Moderate 17 (59)
Poor 5 (17)
Unknown 7 (24)
LAR, Low Anterior Resection; APR,  abdominoperineal resection
Follow up and response to chemotherapy
Patients were followed with a median of 22 months (IQR, 9-40). At last follow up, 5 
patients (17%) were alive and 24 patients (82%) died, resulting in a median survival 
of 33 months (IQR 14-42). The used chemotherapeutic regimes are depicted in table 
II. Chemotherapy was administered after a median of 2 months (IQR 1-8) after the 
diagnosis of LRRC and response evaluation was done after a median of 3 cycles. The 
response rates to chemotherapy of the local recurrence and the distant metastases are 
outlined separately in table III. There was a significant difference between the overall 
response rate of local recurrence and distant metastases (10 vs. 41%, p=0.034). 
On individual basis, 2 patients with CR of the distant metastases had PR of the local 
recurrence. Of 10 patients with PR of the distant metastases, 9 patients had SD and 1 
had PD of the local recurrence. Of the 10 patients with SD of the distant metastases, 
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8 patients had SD, 1 patient had PD and 1 patient had PR of the local recurrence. Of 
the 7 patients with PD of the distant metastases, 6 patients had SD and 1 patient had 
PD of the local recurrence. There was no significant difference in SD rate of the local 
recurrences of patients with histologically proven LRRC or radiologically detected LRRC 
(88 vs. 70%, p=0.36).
Table II. Chemotherapeutic variables
Number of
patients (%)
Total patients 29
Number of cycles 6 (3-31)
Type chemotherapy
Capecitabine 11
Capecitabine + Oxaliplatin 6
Iriontecan 4
Fluorouracil + Oxaliplatin + leucovorin 3
Capecitabine + Oxaliplatin + bevacizumab 2
Cetuximab 1
Capecitabine + bevacizumab 1
Fluorouracil + leucovorin 1
Switch to second line chemotherapy
Yes 12
No 17
Discussion
The current study suggests a less favorable response rate (according to the RECIST) 
to chemotherapy of the local recurrence in previously irradiated area compared to 
the response rates of the distant metastases outside the radiation field within the 
same patient. The poor response rates of the local recurrences in previously irradiated 
area suggest that chemotherapeutic options may not have the desired effect for local 
palliation.
The response rate of the local recurrences in previously irradiated area was 10%, 
whereas the 41% response rate of the distant metastases was significantly higher. 
Although there is little data available about the response to chemotherapy of LRRC, the 
poor response is in line with studies evaluating the potential palliative effect of regional 
intra-arterial chemotherapy in LRRC. None of these studies were able to achieve an 
acceptable palliative result.11-14 However, these studies were all conducted in the 70’s 
and 80’s before the introduction of the currently used chemotherapeutics regiments and 
did not solely included LRRC in previously irradiated area. Furthermore, the palliative 
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results of these studies were based on subjective clinical symptoms and not on objective 
imaging. To our knowledge, this study is the first to assess the response of LRRC to 
contemporary chemotherapeutic regiments and evaluating the response of the local 
recurrences and distant metastases separately.
A possible explanation for the difference in response rate could be that previous 
radiotherapy and surgery alters the environment of the pelvis in which the local 
recurrence is located. Previous surgery may affect vascularization of the pelvic region and 
radiotherapy leads to post-irradiation fibrosis and subsequently a reduced vascularization. 
This may prevent adequate local chemotherapeutic tissue levels, which are necessary to 
achieve tumor response. A comparable phenomenon was found in patients with recurrent 
cervical carcinoma. A pooled analysis of patients from multiple randomized controlled 
trials demonstrated a lower response rate to chemotherapy of tumor recurrences within 
the previous irradiated area compared to tumor recurrences outside the radiation field.9 
However, the analysis included studies comparing the response rates of patients with 
local recurrent disease after previous radiotherapy to the response rate patients who did 
not receive previous radiotherapy. Therefore, these results are more exposed to patient 
and tumor biology variability, which was minimalized in current study by comparing the 
response rate of the local recurrence and distant metastases within the same patient.
A second explanation for the difference in response rate may be that previous 
radiotherapy and surgery leads to a very fibrotic and rigid area, which makes the local 
recurrence within unable to  shrink in contrast to the distant metastases outside the 
radiation and operation field. This may explain the remarkable high number of patients 
(79%) with stable disease of the local recurrence, but not the finding that less patients 
had progressive disease of local recurrences in the previously irradiated area compared 
to the distant metastases outside the radiation field. This suggest that chemotherapy 
may have some influence on the local recurrence, but in comparison to the distant 
metastases, the response may be different due to genetic, biological, or environmental 
differences, whether or not caused by the radiotherapy.
The high rate of stable disease of the local recurrences might also be caused by the 
fact that not all LRRCs were histologically proven and that we simply evaluated non-
malignant pelvic masses. However, both histologically proven and radiologically detected 
LRRCs showed a high rate of stable disease and we found no difference in stable disease 
rate of histologically proven and radiologically detected LRRCs.
Generally, the prognosis of patients with LRRC is poor. Moreover, previously irradiated 
patients with LRRC represents a group with even a poorer prognosis than ‘regular’ not 
previously irradiated LRRC. This was demonstrated by an update the Dutch TME-trial. The 
vast majority of the patients who received radiotherapy for the primary tumor had distant 
metastases at diagnosis or developed them within the first 6 months after diagnosis. This 
resulted in a very poor median life expectancy of only 6 months.15 In the current study, 
153
Chapter 10
10
the survival rate of previously irradiated patients was significantly longer. Presumably, 
the patients in the current study are a selection of patients in generally good clinical 
condition and were therefore also considered candidates for chemotherapeutic treatment.
The main therapeutic problem of LRRC are the often disabling- and difficult to treat 
symptoms, such as severe pain and fistulating or bleeding tumors. The low response 
rate to chemotherapy as described in the current series clearly stresses the high need 
for novel treatment options and in particular for those patients with symptomatic local 
recurrences. Pelvic re-irradiation can provide pain relief in 65-83% of the patients. 
Unfortunately, the duration of this pain relief is limited to a median of only 6-9 
months and it can only be offered for a limited number of times.16-18 Moreover, pelvic 
re-irradiation leaves distant metastases untreated and probably does not affect overall 
survival. A possible mechanism to improve the response to chemotherapy is to combine 
it with hyperthermia. Hyperthermia exposed parts of the body to high temperatures 
(42°C), which causes increased intracellular drug uptake, enhanced DNA damage and 
higher intra-tumor drug concentrations caused by an increased blood flow.19 Future 
research should focus on combining hyperthermia and chemotherapy to investigate 
whether this approach  improves the response rates of the local recurrences in previously 
irradiated area.
Chemotherapy is increasingly used in a potential curative preoperative setting for 
LRRC. Pre-operative chemotherapy is administered to facilitate tumor downstaging and 
thus enhancing the chance of a complete resection. Complete resections are the most 
important prognostic factor for overall survival and it is hypothesized achieving wider 
resection margins may improve outcome.6,20 The results of the current study contradicts 
the potential downstaging effect of chemotherapy in previously irradiated patients. 
Therefore, the use of pre-operative chemotherapy to induce tumor downstaging in 
previously irradiated patients needs further investigation.
Due to the retrospective nature of this analysis, this study has limitations. Moreover, 
there was no standard policy regarding the palliative treatment of patients with LRRC. 
Chemotherapy was only considered a suitable option in a small proportion of the 
patients with LRRC. This is illustrated by the fact that only 39 patients out of 74 LRRCs 
with synchronous distant metastases were treated with chemotherapy. This resulted 
in a relative small number of patients eligible for analysis. Furthermore, different 
chemotherapeutic regiments were used in the current study, which could lead to 
differences in response rate. However, this potential bias was ruled out by evaluating 
the response rate of distant metastases and local recurrence within the same individual 
patient.
In palliative treatment of LRRC, chemotherapy is administered to prolong survival and 
to achieve local symptom palliation. However, the current study did not evaluate the 
effect of chemotherapy on local symptom palliation, because evaluating local palliation 
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is subjective and highly patient and clinician dependent. Moreover, evaluating local 
palliation in a retrospective manner is highly unreliable. By using RECIST, we were able 
to evaluate response to chemotherapy in an objective manner.
In conclusion, previously irradiated patients with LRRC have a lower response rate 
to systemic chemotherapy of the local recurrence within the previous radiation field 
compared to the response rates of distant metastases outside the radiation field. This 
suggests that chemotherapeutic therapy for local palliation may not have the desired 
effect. Further studies are needed to improve treatment results, for example by 
combining chemotherapy with hyperthermia.
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Abstract
• Het lokaal recidiverende rectumcarcinoom (LRRC) heeft een slechte prognose.
• De incidentie is in de afgelopen decennia gedaald door verbeteringen in de 
behandeling van patiënten met een primair rectumcarcinoom, maar LRRC komt nog 
steeds bij 6-10% van deze patiënten voor.
• Het LRRC gaat vaak gepaard met hevige en progressieve pijn en heeft een grote 
impact op de kwaliteit van leven.
• Door een chirurgische resectie gecombineerd met chemo-radiotherapie is er een kans 
op curatie.
• Een radicale resectie is de belangrijkste prognostische factor in de curatieve 
behandeling.
• Neo-adjuvante systemische therapie kan mogelijk de uitkomsten van het LRRC verder 
verbeteren.
• Veel patiënten komen niet in aanmerking voor chirurgische behandeling door de 
aanwezigheid van metastasen of een te groot of te uitgebreid lokaal recidief. Zij 
moeten vanwege de invaliderende pijn optimaal palliatief worden behandeld.
• Radiotherapie is effectief tegen lokale pijn bij ongeveer 75% van de patiënten, maar 
de duur van de palliatie is beperkt.
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Casus ter inleiding
Een 66-jarige man wordt via de Spoedeisende Hulp opgenomen met een urosepsis en 
een gestoorde nierfunctie. Hij heeft 2,5 jaar geleden een rectumamputatie ondergaan 
vanwege een rectumcarcinoom. Een echo laat een hydronefrose links zien en een 
aanvullende CT-scan toont een massa aan ter plaatse van de distale ureter. Hij 
wordt behandeld met antibiotica en er wordt een percutane nefrostomiedrain (PCN) 
geplaatst, waarna hij opknapt. De afwijking wordt op geleide van CT aangeprikt en 
blijkt een adenocarcinoom van colorectale origine te zijn. Er is sprake van een lokaal 
recidiverend rectumcarcinoom. Dit artikel bespreekt de diagnostische en therapeutische 
mogelijkheden voor een patiënt met deze aandoening.
Inleiding
De afgelopen decennia is de behandeling van het rectumcarcinoom verbeterd. 
Verbetering van de operatietechniek, preoperatieve chemo-radiotherapie en verbeterde 
beeldvormende technieken hebben geleid tot een sterke daling van het percentage 
lokale recidieven. Desondanks ontwikkelt 6-10% van de patiënten na resectie van een 
rectumcarcinoom een lokaal recidief.1,2 Door de stijgende incidentie van het primaire 
rectumcarcinoom, met name veroorzaakt door de vergrijzing, kan de komende tijd het 
aantal patiënten met een lokaal recidiverend rectumcarcinoom (LRRC) toenemen.
Het LRRC is echter voor velen een onbekend ziektebeeld. De prognose is slecht, maar 
er is tegenwoordig een kans op curatie door chirurgie gecombineerd met pre-operatieve 
en intra-operatieve radiotherapie. Toch komt slechts een deel van de patiënten hiervoor 
in aanmerking; bij de aanwezigheid van afstandsmetastasen of irresectabiliteit van het 
lokale recidief is chirurgische behandeling niet mogelijk. Het huidige artikel bespreekt 
de mogelijkheden, onmogelijkheden en resultaten van de curatieve en palliatieve 
behandeling van patiënten met een lokaal recidiverend rectumcarcinoom.
Het lokaal recidiverend rectumcarcinoom
Het LRRC wordt gedefinieerd als tumorgroei in het kleine bekken na resectie van een 
primair rectumcarcinoom. De meerderheid van de patiënten (65-70%) heeft klachten op 
het moment dat de diagnose wordt gesteld.3,4 De meest voorkomende klachten zijn een 
veranderend ontlastingspatroon, rectaal bloedverlies, mictieklachten en pijnklachten. Bij 
30-35% van de patiënten wordt de diagnose gesteld terwijl zij geen klachten hebben, 
door een rectaal toucher, een stijgende CEA-waarde of beeldvormend onderzoek tijdens 
de follow-up.
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Het natuurlijke beloop van een onbehandeld LRRC kenmerkt zich door progressieve 
pijn als gevolg van ingroei van de tumor in zenuwen van de sacrale plexus of ingroei 
in ossale structuren. Deze pijn is invaliderend; bovendien ontstaan vaak fistels en 
bloedingen uit de tumor. Dit resulteert doorgaans in een slechte kwaliteit van leven en 
een pijnlijke dood.
Een ‘nieuw’ lokaal recidiverend rectumcarcinoom
Er zijn 2 ontwikkelingen in de behandeling van het primaire rectumcarcinoom die de 
uitkomsten na rectumresectie sterk hebben verbeterd: zogenoemde totale mesorectale 
excisie (TME), een nieuwe operatietechniek, en de voorbehandeling met chemo-
radiotherapie.
Totale mesorectale excisie
De introductie van TME is de belangrijkste ontwikkeling van de afgelopen decennia in de 
behandeling van patiënten met een primair rectumcarcinoom. Bij deze techniek wordt 
het anatomische compartiment rondom het rectum, waarin zich meestal alle aangedane 
lymfeklieren bevinden, in zijn geheel gereseceerd. Hierdoor is het percentage lokale 
recidieven sterk gedaald. Ook wordt tegenwoordig bij lage rectumtumoren een deel van 
de bekkenbodemspieren gereseceerd, omdat bleek dat voortzetten van de TME bij lage 
rectumtumoren juist tot een hoog aantal irradicale resecties leidde.
De introductie van TME en resectie van de bekkenbodemspieren heeft ook het 
karakter van het LRRC veranderd, omdat na een TME in het kleine bekken geen duidelijk 
Figuur I. Schematische weergave van de anatomische structuren van (a) de man en (b) de waar 
alwaar een lokaal recidief kan ingroeien
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afgrensbare compartimenten meer bestaan. Dit betekent dat een LRRC vaak direct 
ingroeit in omliggende structuren, zoals prostaat en vesikels bij de man en uterus, 
adnexen en vagina-achterwand bij de vrouw (figuur I). Ook kan de tumor in de blaas of 
het sacrum ingroeien. Hierdoor is een radicale resectie na TME vaak lastig te realiseren 
en zijn uitgebreide resecties nodig.
Preoperatieve chemo-radiotherapie
De tweede verbetering in de behandeling van primair rectumcarcinoom is de introductie 
van preoperatieve chemo-radiotherapie. Nederlands onderzoek heeft aangetoond dat 
preoperatieve radiotherapie het lokale recidiefpercentage vermindert.2 Daarom worden 
tegenwoordig veel primaire rectumcarcinomen voorbehandeld met chemo-radiotherapie. 
Hierdoor manifesteert een LRRC zich tegenwoordig vaak in een gebied dat al eerder 
bestraald is geweest. Dit bemoeilijkt verdere behandeling, omdat er door eerdere 
radiotherapie minder ruimte is voor preoperatieve radiotherapie van het LRRC.
Daarnaast vormen recidieven in eerder bestraald gebied waarschijnlijk een groep 
van tumoren met biologisch ongunstig gedrag. Patiënten met een LRRC na eerdere 
preoperatieve radiotherapie hebben een slechtere overleving en vaker metastasen op 
afstand dan patiënten die geen preoperatieve radiotherapie hebben ondergaan.5
Tot slot wordt bij patiënten met een rectumcarcinoom in een vroeg stadium soms 
volstaan met een beperkte transanale resectie en bij een complete respons op chemo-
radiotherapie kan worden besloten om helemaal geen operatie uit te voeren. Enerzijds 
kan dit leiden tot een verhoogde incidentie van LRRC; anderzijds bevinden die recidieven 
zich dan, in tegenstelling tot na TME, vaak wel in een nog afgrensbaar en resectabel 
compartiment.
Zoekstrategie
Met betrekking tot diagnostiek en behandeling van het LRRC voerden wij een zoekactie 
in PubMed uit met de zoekterm ‘locally recurrent rectal cancer’. Wij beperkten ons tot 
klinisch onderzoek, gepubliceerd in het Engels en verschenen in de periode 2004-2014. 
Van de 200 artikelen die aan deze criteria voldeden waren er 128 niet relevant. Van de 
72 overgebleven artikelen werden de grootste patiëntenseries geselecteerd als referentie, 
mits zij niet in strijd waren met vergelijkbare series. De referenties uit deze artikelen 
werden nagezien om te voorkomen dat belangrijke series over het hoofd gezien werden. 
Gezien de relatieve zeldzaamheid van de ziekte blijkt de bewijskracht van de studies niet 
hoger dan niveau 3 (cohortonderzoek of patiënt-controle-onderzoek van lage kwaliteit).
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Diagnostiek en stagering
Gedetailleerde lokale stagering van het LRRC is essentieel om de resectabiliteit te 
beoordelen. In vergelijking met het primaire rectumcarcinoom is de beoordeling van 
tumoruitbreiding van het LRRC minder accuraat. Dit wordt veroorzaakt door fibrose en 
littekenvorming door eerdere operaties en chemo-radiotherapie. MRI heeft de hoogste 
accuratesse: 73-85%.6 Een PET-CT kan helpen om littekenweefsel te onderscheiden van 
tumorweefsel.7
Disseminatieonderzoek in de vorm van CT van thorax en abdomen is net zo belangrijk. 
Ongeveer de helft van de patiënten heeft afstandsmetastasen op het moment dat de 
diagnose ‘LRRC’ wordt gesteld.8 Of curatie en overlevingswinst bij LRRC met uitgebreide 
afstandsmetastasen mogelijk is, is onzeker.
Het beoordelen van de scans en ander beeldvormend onderzoek en het bepalen 
van de behandeling is vaak complex. Daarom moeten patiënten met een LRRC in een 
gespecialiseerd multidisciplinair overleg besproken worden, zoals dat ook geldt voor het 
primaire rectumcarcinoom.9
Curatieve behandeling
De curatieve behandeling van LRRC is een multimodaliteitsbehandeling, die bestaat uit 
preoperatieve chemo-radiotherapie, chirurgische resectie en eventueel intra-operatieve 
radiotherapie (IORT).
Preoperatieve chemo-radiotherapie
Preoperatieve chemo-radiotherapie is een belangrijk onderdeel van de curatieve 
behandeling. Het leidt tot meer radicale resecties en verlaagt de kans op een volgend 
lokaal recidief.10 Tegenwoordig wordt de meerderheid van de patiënten met een primair 
rectumcarcinoom met preoperatieve chemo-radiotherapie behandeld. Vanwege de 
toxiciteit van radiotherapie voor organen als de blaas en de dunne darm is de maximale 
dosis radiotherapie die daarna nog gegeven kan worden voor het LRRC beperkt. Het lijkt 
echter veilig om het LRRC na eerdere radiotherapie nogmaals te behandelen met een 
dosis van 30 Gy, zonder dat dit resulteert in hoge toxiciteit.11
Chirurgie
Radicale resectie is de basis van de curatieve behandeling.12 Na TME lukt dit bij 
44-59% van de patiënten.13,14 Dit percentage is ongeveer gelijk aan het percentage 
radicale resecties van primaire tumoren vóór de introductie van TME. Dit resultaat is 
waarschijnlijk behaald door een verbeterde patiëntselectie en uitbreiding van chirurgische 
technieken.
De lokalisatie van het LRRC in het kleine bekken is belangrijk voor de chirurgische 
planning en de inschatting of radicale resectie haalbaar is. Daarnaast wordt de locatie 
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gebruikt om het LRRC te classificeren. Hierbij is een indeling gemaakt in centraal, 
anterieur, dorsaal en lateraal gelokaliseerde recidieven (figuur II en III).
Figuur II: MRI-Scan (transversale coupes) van het bekken met (a) een centraal gelegen recidief 
en (b) een anterieur gelokaliseerd recidief van een rectumcarcinoom bij patiënten die een totale 
mesorectale excisie hebben ondergaan
De kans op een radicale resectie is het hoogst bij centraal gelokaliseerd recidieven 
(zie figuur 2a), zoals het naadrecidief. Deze kans is kleiner bij anterieur, dorsaal of 
lateraal gelokaliseerde recidieven.15 Bij een anterieur gelokaliseerd LRRC is er vaak 
ingroei in de interne genitalia. Bij vrouwen zijn dat de vagina-achterwand, de uterus of 
adnexen. Een radicale resectie kan dan bereikt worden door middel van een achterste 
exenteratie, waarbij deze structuren worden gereseceerd. Bij mannen groeit een LRRC 
vaak in de prostaat. Een radicale resectie betekent dan een totale exenteratie, wat ook 
onvermijdelijk is bij uitgebreide ingroei in de blaas. Een totale exenteratie is een resectie 
van blaas en rectum, waarbij bij vrouwen uterus en adnexen worden meegenomen en 
bij mannen de prostaat. Reconstructie van de urinewegen en aanleg van een urostoma 
is noodzakelijk. Totale exenteraties kunnen leiden tot langdurige overleving en curatie, 
maar gaan gepaard met aanzienlijke morbiditeit.16
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Figuur III: MRI-scans (transversale coupes) van het bekken met (a) een dorsaal gelokaliseerd re-
cidief en (b) een lateraal gelokaliseerd recidief van een rectumcarcinoom die een totale mesorectale 
excisie hebben onderdaan.
Dorsaal gelokaliseerde recidieven hebben een nauwe relatie met of groeien in het sacrum 
(zie figuur 3a). In dat geval is het mogelijk een deel van het sacrum te reseceren; dit is 
de abdominosacrale resectie. Het sacrum, bestaande uit 5 vergroeide wervellichamen, 
kan relatief veilig gereseceerd worden vanaf wervelniveau S2. Het probleem bij partiële 
sacrumresecties is dat de uittredende zenuwwortels worden meegereseceerd. Dat 
leidt doorgaans tot blaasfunctiestoornissen, waardoor katheterisatie vaak levenslang 
nodig blijft. Bij een totale sacrumresectie worden ook de wortels van S1 doorgenomen, 
wat leidt tot motorische uitval van de benen. Deze procedure is vanwege de ernstige 
morbiditeit slechts bij hoge uitzondering gerechtvaardigd. Ook abdominosacrale resecties 
kunnen leiden ook tot langdurige ziektevrije overleving, maar het complicatiepercentage 
is hoog.17
Lateraal gelokaliseerde recidieven hebben vaak een nauwe relatie met de iliacale 
vaatbundel en de ureter. Soms kan een radicale resectie alleen bereikt worden door een 
deel van deze vaten of de ureter te reseceren. Het is mogelijk de A. iliaca communis 
en externa, die essentieel zijn voor de circulatie in de benen, te reconstrueren met een 
interponaat om daarmee een radicale resectie te behalen. Dit soort procedures zijn goed 
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uitvoerbaar en veilig.18 Resectie van een ureter wordt doorgaans opgelost door de blaas 
te mobiliseren en de ureter dan opnieuw met blaas te anastomoseren.
Intraoperatieve radiotherapie (IORT)
Enkele ziekenhuizen in Nederland hebben de mogelijkheid om tijdens de operatie een 
extra dosis radiotherapie toe te dienen. Met IORT kan een specifiek doelgebied extra 
bestraald worden zonder dat andere radiotherapiegevoelige structuren onbedoeld 
beschadigd worden. Het toedienen van IORT resulteert in een 2-3 keer hogere 
biologische dosis dan conventioneel toegediende radiotherapie. Een intra-operatieve 
dosis van 10 Gy leidt dus tot een biologische dosis van 20-30 Gy. In combinatie met een 
herbestralingsdosis van 30 Gy kan zodoende toch een effectieve dosis van 50-60 Gy op 
een specifieke locatie behaald worden, terwijl conventionele herbestraling met een dosis 
van 50-60 Gy zou leiden tot onacceptabele weefseltoxiciteit. Verschillende studies hebben 
aangetoond dat het toedienen van IORT veilig is. Het is daarnaast aannemelijk dat 
achtergebleven vitale tumorcellen op deze manier gedood kunnen worden.19
Preoperatieve en adjuvante systemische therapie
Adjuvante systemische therapie kan worden toegevoegd aan de 
multimodaliteitsbehandeling.20 Dit is in Nederland ongebruikelijk, omdat er geen 
bewijs is dat adjuvante systemische therapie leidt tot overlevingswinst. Daarnaast is 
adjuvante systemische therapie niet altijd haalbaar, vanwege de hoge postoperatieve 
morbiditeit. Wel wordt steeds vaker preoperatieve systemische therapie toegepast om 
maximale tumorreductie te bereiken. Daarnaast kan een goede respons op preoperatieve 
systemische therapie duiden op een gunstig biologisch tumorgedrag, wat mogelijk tot 
betere patiëntselectie leidt. Of preoperatieve systemische therapie daadwerkelijk de 
uitkomsten verbetert, is niet bekend.
Prognose en morbiditeit
Radicale resecties gecombineerd met een multimodaliteitsbehandeling leiden tot een 
5-jaarsoverleving van 43-55%.12,13,20-22 De overleving is slechter na een irradicale 
resectie. Microscopische irradicale resecties hebben een 5-jaars overleving van 0-27% 
en macroscopisch irradicale resecties hebben een overleving die vergelijkbaar is met die 
van palliatief behandelde patiënten.12,13,20-23 Het complicatiepercentage na chirurgische 
resecties van LRRC is hoog. Het betreft voornamelijk infectieuze complicaties, zoals 
perineale wondinfecties en presacrale abcessen, maar ook naadlekkages komen voor.
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Palliatieve behandeling
Bij veel patiënten is resectie niet mogelijk of niet zinvol door de aanwezigheid van 
uitgebreide afstandsmetastasen, irresectabiliteit van het lokale recidief of onvoldoende 
fitheid van de patiënt. Deze patiënten kunnen palliatief behandeld te worden.
Radiotherapie, hyperthermie en systemische therapie
Het kenmerkende probleem van LRRC is de pijn die veroorzaakt worden door het 
lokale tumorproces. De effectiefste manier om deze pijn te behandelen is palliatieve 
radiotherapie. Dit leidt tot verlichting bij ongeveer 75% van de patiënten, maar de 
duur van deze pijnverlichting is beperkt tot slechts 3-9 maanden.24 Patiënten met 
recidiverende klachten van pijn kunnen wel opnieuw bestraald worden, net als patiënten 
die voor het primaire rectumcarcinoom al radiotherapie ontvingen.25
Het effect van herbestraling kan versterkt worden door hyperthermie. De temperatuur 
van het tumoreuze weefsel wordt daarbij verhoogd tot 40-43°C door microgolfstraling. 
Hyperthermie heeft een schadelijk effect op tumorcellen en versterkt het effect van 
radiotherapie.26
Palliatieve systemische therapie kan overwogen worden. Er is echter weinig bekend 
over het effect hiervan op pijnklachten. Oudere studies laten teleurstellende resultaten 
zien en de verwachting is dat ook moderne systemische therapie weinig effect op de pijn 
heeft. Systemische therapie leidt waarschijnlijk wel tot overlevingswinst bij patiënten met 
een gemetastaseerd LRRC, vergelijkbaar met de resultaten van systemische therapie bij 
het primaire gemetastaseerde colorectale carcinoom.
Mogelijk kunnen nieuwe therapeutische ontwikkelingen voor het primaire colorectale 
carcinoom, zoals de ontwikkeling van ‘targeted agents’, ook waardevol blijken voor de 
behandeling van LRRC. Daarmee is wellicht toch winst te behalen, hoewel het opzetten 
van gerandomiseerd onderzoek naar behandeling van patiënten met LRRC vaak niet 
haalbaar is.
Huisarts
De huisarts vervult een belangrijke rol in de behandeling van patiënten met een LRRC. 
Uiteindelijk zullen voor een groot deel van de chirurgisch behandelde en de palliatief 
behandelde patiënten geen behandelingsopties meer zijn. Deze patiënten kan ‘best 
supportive care’ worden aangeboden, waarbij de huisarts onmisbaar is voor adequate 
pijnbestrijding, vaak in samenwerking met de pijnspecialist. Daarnaast vragen deze 
patiënten met oncontroleerbare en progressieve pijn hun huisarts nogal eens om 
euthanasie.
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Conclusie
Het LRRC is een lastig klinisch probleem met ingrijpende gevolgen voor de patiënt. De 
chirurgische behandeling is uitdagend, maar in gespecialiseerde centra kan met een 
multimodaliteitsbehandeling een relatief goed oncologisch resultaat bereikt worden bij 
geselecteerde patiënten. Veel patiënten komen niet in aanmerking voor chirurgische 
behandeling en kunnen palliatief behandeld worden met radiotherapie, hyperthermie en 
systemische therapie. Iedere patiënt met een LRRC dient te worden besproken in een 
gespecialiseerd centrum voor een optimale curatieve en palliatieve behandeling.
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Discussion
This thesis focused on several aspects to further improve locally advanced and recurrent 
rectal cancer management. During last decade, rectal cancer treatment has shifted 
increasingly towards a personalized treatment depending on the local tumor and the 
presence of distant metastases. A multimodality treatment can result in relatively good 
long-term outcomes for both LARC and LRRC. This thesis aimed to further improve the 
multimodality treatment in order to offer patients the best oncological care. Briefly, the 
first part of this thesis, focusing on staging, showed a beneficial effect of restaging by 
thoraco-abdominal CT-scan after (chemo-)radiotherapy. It resulted in newly discovered 
distant metastases altering treatment in a substantial number of patients. Unfortunately, 
the beneficial effect of adding DCE sequences to local restaging by MR imaging after 
(chemo-)radiotherapy was limited. The second part, which focused on LARC, suggested 
that applying IORT leads to improved local control in patients with a microscopically 
involved circumferential resection margin (CRM). Furthermore, the treatment of cT4 
rectal cancer in high volume cT4 hospitals may lead to an improved overall survival, 
while the effect of the hospital volume in cT1-3 rectal cancer is limited. The third part, 
focusing on LRRC, demonstrated that patients with local recurrences after previous pelvic 
radiotherapy and TME surgery should also be considered candidates for curative surgery. 
Additionally, it showed that complete resections with close margins between 0-2mm have 
a poorer outcome than wider resection margins of >2mm and that the effect of systemic 
therapy on the local recurrence in previously irradiated area was limited.
The first part of this thesis focused particularly on restaging of patients with LARC 
after a long course of (chemo-)radiotherapy. Accurate staging is essential for high quality 
rectal cancer management. The accuracy of Magnetic Resonances (MR) imaging of 
tumor staging and CRM involvement is high in those who did not receive neo-adjuvant 
treatment. MR imaging can accurately differentiate between low tumor stage (T1-2) 
and high tumor stage (T3-4) with a high sensitivity of 87%.1 Moreover, a specificity 
of 94% in CRM involvement shows that MR-imaging can accurately detect patients at 
risk for incomplete resections when performing a standard TME procedure. Given the 
knowledge that (chemo-)radiotherapy does not only leads to a reduced local recurrence 
rate, the fact that it leads to tumor downstaging made it interesting to reassess the local 
tumor extent after (chemo-)radiotherapy.2,3 Potentially, these patients can be offered 
less radical resections in case of a good response to (chemo-)radiotherapy. Additionally, 
(chemo-)radiotherapy may lead to a complete pathological response (pCR). A pCR is 
seen in 11-19% of the patients after chemoradiotherapy.4-7 Accurate determination of 
patients with a pCR may be valuable, because these patients can be offered a ‘watch 
and wait’ approach. In a ‘watch and wait’ approach, rectal cancer surgery is omitted and 
patients are closely surveilled. The results of close surveillance after a complete clinical 
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response are promising.8-10 However, when considering applying a ‘watch and wait’ 
approach or performing less radical surgery, it is important to accurately stage rectal 
cancer after (chemo-)radiotherapy. For this reason patients, are increasingly restaged 
after neo-adjuvant (chemo-)radiotherapy. Unfortunately, the accuracy of restaging is 
poor. The sensitivity of differentiating between low tumor stage (T1-2) and high tumor 
stage (T3-4) tumor staging drops from 87% without neo-adjuvant therapy to 50% after 
(chemo-)radiotherapy.1,11 Therefore, new techniques are necessary to accurately reassess 
the local stage or to predict a pCR. Dynamic Contrast Enhanced (DCE) sequences may 
improve the accuracy of MR restaging. Malignant tissue shows specific contrast-enhanced 
patterns due to the neoangiogenesis, resulting in elevated perfusion and permeability.12 
This may help in differentiating between malignant and non-malignant tissue. 
Unfortunately, adding DCE sequences did not improve accuracy of tumor restaging, 
CRM-involvement or predicting a pCR. The accuracy of Tumor staging (45%) was similar 
to other series without the addition of DCE sequences (34-60%).13-18 Moreover, the 
accuracy of CRM-involvement was low and the radiologists were unable to detect a pCR. 
On the other hand, the accuracy of nodal staging was high. It is known that nodal staging 
after chemoradiotherapy is more accurate than at primary staging. This is caused by the 
lower prevalence of positive nodes, leading to a higher negative predictive value and 
thus a more accurate selection of the node negative patients after chemoradiotherapy.19 
Nonetheless, the accuracy of nodal staging in this study was high compared to other 
restaging studies. The fact early incomplete arterial phase enhancement was predictive 
for malignant nodes, makes DCE MR imaging promising for selecting patients for less 
radical surgery, such as Transanal Endoscopic Microsurgery (TEM) procedures. In TEM-
procedures nodal staging is important to prevent local tumor regrowth due to positive 
lymph nodes, since a lymph node dissection is omitted in TEM procedures. Despite of 
the high accuracy of nodal staging, it is doubtful to carry out standard DCE MRI’s in 
LARC restaging due to its poor accuracy of T- staging, CRM-involvement and predicting 
a pCR. MR imaging with extra DCE sequences is time-consuming and brings extra costs. 
The results of diffusion weighted (DW) MRI sequences are more promising. DW MRI 
has a sensitivity of 70% and a specificity of 98% in detecting a complete pathological 
response.20 Future research should focus on the combining different MR techniques to 
increase restaging accuracy and on finding new tumor labeling agents to more accurately 
detect vital tumor. Furthermore, the optimal timing to perform restaging by MR imaging 
should be evaluated. It could be hypothesized that restaging shortly prior to surgery may 
improve diagnostic accuracy, because downstaging is an ongoing process after ending 
chemoradiotherapy.
Although the accuracy of local restaging after (chemo-)radiotherapy is generally poor, 
it is widely used as it seems to be a logical step in improving rectal cancer management. 
In line with local restaging, it also seems logical to restage by a thoraco-abdominal 
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CT-scan after chemoradiotherapy to detect distant metastases. Surprisingly, the 
number of studies concerning the effectiveness of local restaging are numerous, but 
studies assessing the usefulness of restaging by a thoraco-abdominal CT-scan after 
chemoradiotherapy are extremely rare. The chance of developing distant metastases 
is associated with the local tumor stage. LARC has the highest risk of developing 
distant metastases, since higher tumor and nodal stage are associated with distant 
metatases.21-23 In LARC, the time interval between diagnosis and surgical resection is 
approximately 4 to 5 months. In this period occult metastases on primary imaging may 
become visible or new metastases may have evolved. Restaging could identify these 
patients. Our study found new metastases altering the treatment in 12% of the patients 
and surgery was cancelled in 8% of the patients. After publication of this study, other 
studies have reported their results of restaging to detect distant metastases during 
neo-adjuvant treatment. Even though new distant metastases were detected in all these 
studies, the reported percentages varied between 3 and 12%.24-27 Some supported 
our findings concerning the usefulness of restaging to detect distant metastases24. 
However, others state that the yield was too low.25,27 Davids et al.25 found distant 
metastases in 5% of the restaged patients. Surprisingly, it did not lead to an alteration 
of the surgical plan. This is remarkable, as there are several options for patients with 
distant metastases opting for curation.28 The fact that others studies did not find a 
beneficial effect of restaging by thoraco-abdominal CT-scan give room for a thought. 
Presumably, thoraco-abdominal restaging is only beneficial for patients with an advanced 
stage of disease. Our institute is a tertiary referral center for the Southwest region of 
Netherlands and this possibly explains the higher yield in our study compared to others 
studies with less advanced stage of disease. There are several well-known prognostic 
factors for developing distant metastases, such as T-, N-stage and extramural venous 
invasion.21-23 These prognostic factors could identify patients at high risk for developing 
distant metastases during neo-adjuvant treatment. Future research should evaluate 
whether these prognostic factors are also applicable for the development of early distant 
metastases evolving during neo-adjuvant treatment. It would be interesting to develop 
a nomogram to select only those patients with a high chance of early metastases during 
neo-adjuvant therapy. This will save costs, radiation exposure and uncertainty concerning 
the curability of their disease.
Due to the fact that restaging is often common practice in most Western countries, it is 
important to critically appraise the benefit of local restaging. Theoretically, patients could 
be offered less radical surgery in case of tumor downstaging. However, as mentioned 
earlier, the accuracy of local restaging is poor.1,11 Commonly, radiologists overstage 
rectal cancer after neo-adjuvant radiotherapy due to the difficulty to differentiate 
between viable tumor and fibrosis. However, 7-22% of the patients are understaged at 
restaging.17,26,29 Surgeons should be cautious on performing less radical surgery based on 
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restaging imaging, as this could result in incomplete resections. Moreover, MR imaging is 
not able to detect microscopic remnants in radiotherapy induced fibrosis. Furthermore, 
it is important to realize that none of the Randomized Controlled Trials concerning the 
effect of chemoradiotherapy were able to demonstrate a significant increase in the rate 
of sphincter saving surgery.30 This makes it even more doubtful to assume that restaging 
may contribute to less radical surgery when even chemoradiotherapy itself does not 
lead to less radical procedures. Momentarily, the ‘watch and wait’ is much debated as 
an option for patients with a complete clinical response. Unfortunately, MR imaging is 
unable to accurately identify patients with a complete clinical response.31 However, when 
combining MR imaging with a digital examination and endoscopy, it leads to a probability 
of predicting a complete response of 98%.32 This makes MR imaging an essential part 
of a set of examinations for a complete clinical response to be diagnosed. Restaging can 
be used as an early prognostic factor. Radiologically detected poor response is a strong 
prognostic factor for overall survival and disease free survival.33 It should be evaluated 
whether these patients could benefit from a more intensified neo-adjuvant regime by 
adding an extra radiation boost or by adding induction chemotherapy after neo-adjuvant 
chemoradiotherapy. Furthermore, radiologically detected tumor response should be 
evaluated as a predictive factor for early distant metastases, since these patients may 
benefit from thoraco-abdominal restaging. Summarizing the current literature, there 
is limited evidence that local restaging is beneficial for patient or surgeon and there is 
conflicting literature that restaging by thoraco-abdominal CT-scan is useful to detect 
distant metastases. According to our data, restaging by thoraco-abdominal CT-scan is 
advisable.34
Even though rectal cancer management has improved drastically, patients remain with 
such advanced tumors, that complete resection is not possible. Incomplete resections 
are less common than 10 or 20 years ago due to the use of neo-adjuvant therapy and an 
improved surgical technique. However, CRM-involvement was still found in approximately 
6% of the surgically treated patients in 2013 in The Netherlands.35 Additionally, we are 
increasingly able to accurately select those patients at risk for incomplete resections. 
Intra-operative radiotherapy (IORT) may be beneficial when complete resection is not 
possible. IORT was first described in 1937.36 Since the 1980s several institutes across 
the world published their experience with IORT.37-39 The rationale behind IORT is that 
the biological equivalent of one single dose of IORT is two to three times higher than 
fractioned radiotherapy.40 For example, an IORT dose of 10 Gy results in a biological 
equivalent of 20-30 Gy. This results in a total dose of 70-80 Gy when combined with a 
long course pre-operative radiotherapy of 50 Gy. This radiation dose cannot be achieved 
by external beam radiotherapy alone, since this would lead to extensive radiotherapy 
induced toxicity. The advantage of IORT is that an extra boost of radiotherapy can be 
administered at a specific area, while other radiotherapy sensitive structures, such as 
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small bowels, can be shielded from the radiotherapy. Previous studies have shown that 
IORT can be safely administered during surgery.41,42 Although several studies suggested 
a beneficial effect of IORT on local control, comparative studies focusing on LARC and 
R1-resections are scarse. Our study suggests a beneficial effect on local control in 
patients with a microscopically involved CRM (tumor invading the resection planes on 
microscopic assessment), while no benefit was found in patients with a clear but narrow 
CRM (0.1-2mm). This finding is conform to previous studies from our institute.43,44 The 
estimated 5-year local recurrence free survival of 84% in our study was higher than 
the local recurrence free survival rate of 65% reported in the previous study from our 
institute. This can be explained by the fact that our study only included R1-resections, 
while R2-resections were included in the previous studies as well. IORT is unlikely to 
be beneficial in R2-resections and these were therefore excluded from our analysis. 
Others studies have suggested a benefit of IORT on outcome, which is in line with our 
results,.45,46 However, some did not find any evidence of a beneficial effect and skepticism 
about the effect of IORT remains.47,48 Similar to our study, most published studies are 
retrospective with a relatively small amount of patients. This results in the lack of high 
level evidence of the benefit of IORT, making a future prospective randomized controlled 
trial necessary. Unfortunately, the accrual for such trial would be difficult. Since only R1-
resections may benefit of IORT, solely 6% of all rectal cancer patients in the Netherlands 
would be candidates to participate in such trial. Moreover, results from retrospective 
studies indicate that it would be unethical to withhold IORT for patients with a R1-
resection. Furthermore, incomplete resections are becoming less common due to the 
current high quality surgery.35 Although our study focused on LARC, LRRC may also profit 
from IORT since incomplete resections are more frequent in LRRC surgery. Previously, 
others have found a benefit of adding IORT to the multimodality treatment compared to 
historical controls.49
Rectal cancer is a relatively common malignancy with approximately 3500 new patients 
in The Netherlands per year. However, there is a big difference between the treatment of 
the early stages of rectal cancer or the advanced stages of rectal cancer. Approximately 
90% of the patients with rectal cancer are diagnoses with a cT1-3 stage.50 These stages 
can be treated by a standard TME procedure. The treatment of the most advanced stage 
(cT4) is more difficult. Ingrowths into the surrounding structures are common in cT4 
rectal cancer, such as prostate in men and vagina or uterus in women. In these cases 
exenterative ‘beyond TME’ surgery is often necessary to achieve complete resections.51 
These procedures are technically demanding and time consuming. Additionally, these 
procedures are accompanied by a high morbidity and a high post-operative complications 
rate.52 Moreover, accurate high quality imaging is essential to determine the extent of 
the ‘beyond TME-surgery’. These advanced stages may profit from a multidisciplinary 
team with experience in performing these radical surgical procedures. Our study 
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suggests a survival benefit for patients treated in high volume cT4 rectal cancer hospitals 
compared to low volume cT4 hospitals. This finding is in line with the results of studies 
of hospital volumes in other complex malignancies, such as pancreatic cancer and 
esophageal cancer.53-55 However, in rectal cancer a survival difference according to the 
hospital volume has never been demonstrated. Although a recent study found a higher 
percentage of involved CRM’s in low volume hospitals compared to high volume hospitals, 
a recent population based study for the Southern part of The Netherlands found no 
benefit of treatment of colorectal cancer in high volume hospitals.50,56 The fact that we 
found a survival difference in contrast to other studies can be explained by that our study 
analyzed cT1-3 and cT4 separately. It is not naturally evident that experience in standard 
rectal cancer treatment also leads to sufficient experience for the treatment of the 
most advanced stages of rectal cancer. Our data suggests that cT4 rectal cancer should 
be considered as a separate entity within rectal cancer. Therefore, it would be more 
appropriate to apply a minimal number of cT4 rectal cancer patients treated per hospital 
annually than applying a minimal total number of rectal cancer patients per hospital.
The most appropriate approach for patients with stage IV colorectal with unresectable 
distant metastases is still under debate. It is clear that there is an indication for surgery 
in symptomatic patients. However, the indication is less clear in asymptomatic or mildly 
symptomatic patients. It could be hypothesized that surgery of the primary tumor will 
prevent future emergency surgery in case of obstruction or perforation during systemic 
therapy. Furthermore, some retrospective studies suggested a survival benefit when 
the primary tumor was resected.57-59 However, these retrospective studies are limited 
due to selection bias. Patients in poor clinical condition were excluded for surgery, while 
relatively fit patients were selected for surgery. We assessed the current evidence for 
surgery of the primary tumor in patients with stage IV colorectal cancer. The lack of 
Randomized Controlled Trials, makes it difficult to conclude whether primary tumor 
resection leads to a survival benefit. Surgeons should take notice that systemic therapy 
will probably contribute the most to a prolonged survival in metastasized colorectal 
patients. Complications of primary tumor surgery will postpone the administering of 
systemic therapy.60 For example, anastomotic leakage or surgical site infections will lead 
to a delay in the administering of systemic therapy. In addition, some patients will never 
be able to receive systemic therapy due to ongoing infectious complications. One of the 
most important goals of the treatment for incurable patients is to offer these patients 
the best possible quality of life. Surgery has a negative impact on quality of life up to 6 
months after surgery.61 The median survival of stage IV colorectal cancer patients in The 
Netherlands is only 12 months.62 This median survival can be prolonged up to 22 months 
in patients who are in a good clinical condition due to the current systemic therapy.63-65 
Nevertheless, this means that these patients suffer a loss of quality of life caused by 
the surgical treatment during a substantial period of their life expectancy. Additionally, 
181
Chapter 12
12
complications after surgery have a long-term negative impact on the patients’ quality of 
life.66 Obstructive complications or tumor perforation during palliative systemic therapy 
are arguments to perform surgery. However, the chance of emergency surgery with 
the current systemic therapy is limited.60,67,68 Nevertheless, high level of evidence is 
warranted to offer these patients the best treatment. Several Randomized Controlled 
Trials are recruiting patients, such as the SYNCHRONOUS trial69, the CAIRO4 trial70 and a 
Korean multicenter trial.71 We are awaiting the results of these trials and hopefully, these 
studies will provide us the answer if we should perform primary tumor resection in case 
of unresectable distant metastases.
The introduction of TME and neo-adjuvant (chemo-)radiotherapy reduced the number 
of patients with a local recurrence after rectal cancer surgery. However, the introduction 
of these advancements also introduced the problem of treating LRRC after TME-surgery 
and radiotherapy. LRRC has a poor overall survival, a great impact on quality of life 
and often leads to severe pain with fistulating and bleeding tumors.72,73 Surgical 
resection provides the greatest probability on durable overall survival and local control.74 
Unfortunately, TME surgery and neo-adjuvant radiotherapy makes surgical resection of 
the local recurrence more demanding. The dose of radiotherapy for the local recurrence 
is limited due to the previous pelvic radiotherapy and the use of TME surgery is causing 
that the local recurrences are no longer confined to an anatomic compartment. In 
agreement with most other studies, our results show that these local recurrences can 
be treated with acceptable overall survival and local re-recurrence rates. However, the 
complete resection rate seems to be lower in previously irradiated patients. Although this 
did not result in a higher re-recurrence rate in our series, others have reported higher 
re-recurrence rates in previously irradiated patients.75,76 A recent study showed also a 
poorer overall survival and a higher complication rate in previously irradiated patients.77 
However, that study particularly did not administer re-irradiation to previously irradiated 
patients. This may explain the fact that our study did not find a survival difference while 
they did. The results of our study were in line with a previous study from our institute.78 
Although the local control rate in the previous study was poorer, the 3-year overall 
survival rate of the current and previous study were similar. Presumably, the results of 
the previous study led to a more thorough patient selection for LRRC surgery. Thorough 
patient selection is an important aspect of LRRC treatment, as morbidity and mortality 
rates of LRRC surgery are high.77,79-81 However, if the selection of patients is too strict, 
an opportunity for curation for these patients may be suppressed. The selection of 
patients is one of the most important explanation of the overall survival differences of 
LRRC surgery reported in the literature. Re-irradiation might contribute to an improved 
outcome after LRRC surgery in a previously irradiated area.75 The main goal is to induce 
tumor downstaging and to improve local control. However, it also provides an opportunity 
to restage these patients after the end of re-irradiation. Major abdominal surgery can be 
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spared in patients with a progressive local recurrence during re-irradiation or in patients 
who have developed distant metastases during re-irradiation. This could result in an 
improved patient selection for LRRC surgery. Future research in LRRC treatment should 
focus on achieving higher numbers of complete resections. For example, patients can be 
offered induction chemotherapy prior to neo-adjuvant therapy to maximize the chance of 
a complete resection. Others have demonstrated promising results of LRRC surgery after 
induction chemotherapy.82
In LRRC surgery, a complete resection is the most important prognostic factor. 
Generally, resections in LRRC surgery are classified as R0-resections (complete 
resections), R1-resection (microscopically involved margins) or R2-resections 
(macroscopically involved margins). In this thesis, we have demonstrated that the 
minimal tumor-free resection margin is of prognostic value. In line with primary rectal 
cancer, we found a superior oncological outcome after surgery with wide tumor-free 
resection margins of more than 2mm.23,83,84 Sampling error may be a possible explanation 
for this phenomenon. For example, patients with close resection margins may actually 
have microscopically involved margins at another location. Another explanation may 
be that close margins are accompanied by a higher chance of tumor deposits outside 
the resected area. Nevertheless, the resection margin classification in our study could 
be used as an alternative for the currently used standard R0/R1/R2 classification of 
LRRC’s. In the current study, more radical procedures were not associated with a survival 
benefit. Ideally, the surgical procedure should be as minimal as possible. To determine 
the optimal approach and extensiveness of the surgical procedure accurate staging 
is essential. Unfortunately, the accuraracy of staging of the local recurrence is limited 
due to the difficulty of differentiating between tumor and fibrosis. This is similar to the 
difficulties seen in the restaging of LARC after (chemo-)radiotherapy. In the future, 
fluorescence guided surgery may be helpful to achieve a higher number of complete 
resections in LRRC surgery. It may help to distinguish between viable tumor and scarring 
or fibrosis. In several other malignancies, fluorescence guided surgery has already been 
evaluated and has shown to a potential benefit in some cases.85,86 Further investigation 
concerning the use of fluorescence guided surgery is needed in LARC and LRRC patients.
Unfortunately, approximately 60 to 70% of the diagnosed patients are not suitable 
candidates for surgical treatment due to distant metastasis or local recurrence that is too 
extended.87,88 These patients should be offered palliative care. Pelvic radiotherapy can 
relief pain in a high number of symptomatic patients.89 In case of metastasized disease, 
patients can be offered systemic therapy. However, the effect of palliative chemotherapy 
on local symptoms and overall survival is not well established. Furthermore, the 
widespread use of pelvic radiotherapy may have a negative impact on the effectiveness 
of systemic therapy on the local recurrence. Our results showed that the response of 
the local recurrence in previously irradiated area was less than the distant metastases 
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outside the irradiated area. This suggests that the effect of chemotherapy with palliative 
intent for symptomatic LRRC may be limited. However, the effect of chemotherapy on 
overall survival in LRRC remains unclear. The overall survival of the patients in this cohort 
treated with systemic therapy was 33 months, while the median survival of metastasized 
colorectal cancer is 22 months in trials with highly selected patients. 64 This suggests that 
systemic therapy in metastasized LRRC patients may be effective. However, the patients 
in our study were highly selected. It should also be realized that this study focused on 
LRRC in previously irradiated area, while the effectiveness of chemotherapy on the local 
recurrence in patients without previous radiotherapy is not fully established. Future 
research should focus on the potential benefit of systemic therapy on overall survival in 
LRRC patients and to evaluate the response of systemic therapy on the local recurrence 
without previous pelvic radiotherapy.
LRRC is a relatively uncommon and unknown disease for physicians worldwide and in 
the Netherlands.2,90 As this thesis pointed out, there is a chance for cure in dedicated 
hospitals. Therefore, it is necessary to refer all LRRC patients to one of the dedicated 
referral centers in the Netherlands. By referring a higher number of LRRC patients to 
these centers, the experience of the surgeons will be extended, leading to improved 
results and this will provide the opportunity to perform high quality research for these 
patients suffering from this relative rare disease. Simultaneously, performing high quality 
research will provide us more necessary data on the quality of life of patients treated 
curatively by surgery and palliatively by radiotherapy or systemic therapy.
In summary, this thesis aimed to further improve the multimodality treatment of LARC 
and LRRC by focusing on several aspects of the treatment. Restaging by a thoraco-
abdominal CT-scan after (chemo-)radiotherapy, applying IORT in R1-resections and 
performing cT4 rectal cancer surgery in high cT4 volume hospital seems to improve LARC 
treatment. In LRRC, applying a minimal tumor-free resection margin and considering 
patients with LRRC after previous radiotherapy and TME surgery candidates for LRRC 
surgery seem to improve LRRC treatment. The accurate selection of the most suitable 
treatment is the most important challenge in LARC and LRRC treatment. This means that 
imaging plays a key role in the multimodality treatment. Improving imaging quality will 
result in a more accurate selection of patients to administer neo-adjuvant treatment, 
applying IORT and more radical surgery.
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Summary
The treatment of rectal cancer has drastically improved the last decades. The three main 
advancements made, are the improvement of the quality of imaging, the use of neo-
adjuvant therapy and a surgical technique, called total mesorectal excision (TME). Locally 
advanced rectal cancer (LARC) comprises a difficult to manage subgroup due to a high 
chance of an incomplete resection and subsequently high recurrence rates and a poor 
overall survival. In line with LARC, locally recurrent rectal cancer (LCCR) is a challenging 
group to treat. It is a heterogenetic disease with a poor prognosis and often disabling 
symptoms. Surgery is the only chance on durable local control and overall survival. 
Unfortunately, surgery is accompanied by significant morbidity and high recurrence 
rates. A multimodality treatment has increased the chance for cure for LARC and LRRC. 
Historically, the outcome of the surgical treatment was poor. However, optimal staging, 
neo-adjuvant (chemo-)radiotherapy and personalized surgical procedures have resulted 
in improved outcomes. This thesis aimed to further improve staging, multimodality 
treatment and surgical treatment of LARC and LRRC.
In chapter 1, the current management of rectal cancer and the advancements made in 
the last decades are outlined. Additionally, the aims of the studies included in this thesis 
are outlined.
In chapter 2, we aimed to improve the accuracy of local staging by adding dynamic 
contrast enhanced (DCE) sequences to standard MR imaging after neo-adjuvant 
chemoradiotherapy. DCE may improve the ability to distinguish between viable tumor and 
non-malignant fibrosis. Unfortunately, adding DCE did not result in more accurate tumor 
staging, determining CRM involvement or detecting a complete pathological response. On 
the other hand, the accuracy of nodal staging was high, making it potentially useful in 
the current era of rectal sparing treatment and ‘watch and wait’ approach.
In chapter 3, we evaluated the additional value of restaging after a long course 
(chemo-)radiotherapy by thoraco-abdominal CT-scan in patients with LARC. LARC 
represent a subgroup of patients with a high chance of developing distant metastasis. 
The identification of distant metastases is important, as it may alter the treatment 
strategy. A change in treatment strategy due to new findings on the CT scan after 
radiotherapy was observed in 18 (12%) of 153 patients. Twelve patients (8%) were 
spared rectal surgery due to progressive metastatic disease. The makes restaging by 
thoraca-abdominal CT-scan a worthwhile step in LARC management.
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In chapter 4, we briefly summarized the benefits and limitations of local restaging 
after neo-adjuvant therapy. Unfortunately, the accuracy of restaging is poor. Currently, 
these accuracies of restaging are too poor to alter your surgical plans. The main concer 
is the chance of understaging of the local tumor, which occurs in 7-22% of the patients. 
This may lead to incomplete resections and poor oncological outcomes Radiological 
detected response to (chemo-)radiotherapy on MR imaging appears to be a valuable 
early prognostic factor and the accuracy of predicting mesorectal fascia involvement is 
reasonable. Future research should focus on intensifying neoadjuvant treatment in poor 
responders and increasing the staging accuracy by combining different techniques.
In chapter 5, we evaluated the potential benefit of intra-operative radiotherapy (IORT) 
after neo-adjuvant (chemo-)radiotherapy in patients with LARC. A single intra-operative 
radiation dose may be able to eradicate microscopic remnants. This retrospective analysis 
compared the outcome of patient treated with or without IORT. In patients with clear 
but narrow margins, IORT did not lead to an improved local recurrence-free survival. 
However, in patients with a microscopically incomplete resection, adding IORT did 
result in an improved local recurrence-free survival (84% vs. 41%). This suggests that 
IORT improves local recurrence-free survival in patient with microscopically involved 
circumferential resection margins.
In chapter 6, we hypothesized that hospital volume was associated with outcome after 
rectal cancer surgery. The management and treatment of cT4 rectal cancer is considered 
more difficult than the earlier stages of rectal cancer (cT1-3). LARC requires optimal 
staging, multimodality treatment and often personalized ‘tailor made’ surgery. Therefore, 
a survival difference may be more apparent in cT4 rectal cancer. In this population based 
study, we divided rectal cancer into a cT1-3 or a cT4 group and evaluated the long-term 
outcome according to the cT1-3 hospital volume or the cT4 hospital volume. In cT1-3 
rectal cancer, hospital volume was not associated with overall survival. In cT4 rectal 
cancer, treatment in a high cT4 hospital volume (more than 20 cT4 procedures per year) 
was associated with a superior overall survival rates compared to the treatment in a low 
volume cT4 hospital after adjusting for patient and tumor variables. Furthermore, we 
analyzed the referrals patterns of cT4 rectal cancer within The Netherlands. Unfortantely, 
cT4 rectal cancer patients are often referred incorrectly, regardless of the advice in the 
national guideline to refer these patients to dedicated tertiary centers.
In chapter 7, we evaluated the effect of surgery for the primary tumor in stage IV 
colorectal cancer patients with unresectable metastases. Several studies suggested a 
beneficial effect of primary tumor resection on overall survival. This review summarized 
the available literature of the effect of surgery on the outcome in stage IV patients. 
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However, the role of resection of the primary tumor remains unclear. Randomized 
Controlled trials are lacking and this makes it difficult to draw conclusions. With the 
current new chemotherapy regiments, including VEGF and EGF inhibitors, a relatively low 
number of patients with metastasized colorectal cancer require surgery for their primary 
tumor. The studies who are suggesting a survival benefit are likely to be influenced by 
selection bias and therefore prospective randomized controlled trials are urgently needed 
to answer this question.
In chapter 8, we focused on the treatment of locally recurrent rectal cancer (LRRC) after 
previous pelvic radiotherapy and TME surgery. TME surgery leads to local recurrences 
that are not confined to an anatomical compartment and neo-adjuvant radiotherapy for 
the primary tumor limits the dose available for the treatment of the local recurrence. This 
study evaluated the peri-operative outcomes and long-term outcome of patients treated 
after previous TME surgery with or without radiotherapy for the primary tumor. The 
long-term outcome, complication rate and mortality rate were similar in both groups. This 
demonstrates that surgery in highly selected patients is feasible and that these patients 
should be considered candidates for curative multimodality treatment and surgery.
In chapter 9, we evaluated the prognostic factors affecting the long-term outcome after 
LRRC surgery. It is well known that the resection margin status is the most important 
prognostic factor after LRRC surgery. In primary rectal cancer, patients with close 
margins have a higher risk of developing local recurrences. We hypothesized that close 
margins in LRRC surgery may result in poorer oncological outcomes as well. In this study, 
we have evaluated the long-term outcome according to the minimal resection margin. 
We found that close margins of less than 2mm were associated with a poorer outcome 
than patients with wide resection margins of more than 2mm. This finding makes that all 
efforts should be made to achieve wide resection margins by neo-adjuvant downstaging 
and the use of radical surgery when necessary.
In chapter 10, we focused on the systemic therapy in the treatment of patients with 
LRRC. Some patients with LRRC with distant metastases are treated with systemic 
therapy to increase their life expectancy. This made it possible to evaluate the effect 
of systemic therapy on the local recurrences in previously irradiated area compared to 
the response of distant metastases outside the irradiated area. Previous radiotherapy 
may result in poorer response rates due to fibrosis and impaired vascularization. This 
study found a lower response rate of the local recurrence in previously irradiated area 
according to the radiological RESIST criteria. The poor response in previously irradiated 
makes it questionable whether systemic therapy is suitable for local palliation and 
whether neo-adjuvant induction therapy for LRRC may be useful.
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In chapter 11, we summarized the latest literature of the treatment of LRRC for the 
Dutch physicians. Currently, multimodality treatment and surgery gives a chance for 
cure to patients who were considered incurable 2 to 3 decades ago. Even patients who 
underwent TME surgery and previous radiotherapy should be considered candidates for 
curative treatment. However, LRRC surgery is accompanied by significant morbidity and 
relative high mortality rates. Unfortunately, the majority of the patients are diagnoses 
with metastatic disease or a too extensive local recurrence. These patients should be 
offered optimal palliative treatment. Untreated LRRC leads often to disabling symptoms 
and severe pain. Pelvic radiotherapy can bring local symptom relief in approximately 75% 
of the patients. Unfortunately, the duration of the effect of radiotherapy is limited.
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Nederlandse samenvatting
De behandeling van het rectumcarcinoom is de afgelopen decennia sterk verbeterd. 
Hoofzakelijk zijn er drie factoren verantwoordelijk voor deze verbetering, namelijk een 
verbeterde kwaliteit van de beeldvorming, pre-operatieve behandeling met (chemo-)
radiotherapie en een optimale gepersonaliseerde chirurgie. Het lokaal voortgeschreden 
rectumcarcinoom omvat een subgroep binnen het rectumcarcinoom, waarbij de 
behandeling lastiger en uitdagender is vanwege de kans op een irradicale resectie en de 
hierbij behorende hogere kans op een lokaal recidief. Evenals het lokaal voortgeschreden 
rectumcarcinoom is de behandeling van het lokaal recidiverend rectum carcinoom zeer 
uitdagend. Een multimodaliteitsbehandeling voor het voortgeschreden rectum carcinoom 
en het lokaal recidiverend rectumcarcinoom heeft de kans op curatie vergroot. Van 
oudsher was de kans op curatie bij beide aandoeningen slecht. Optimale beeldvorming en 
stagering, neoadjuvante behandeling leidend tot tumorverkleining en gepersonaliseerde 
chirurgie, inclusief uitgebreide chirurgische procedures, heeft geresulteerd in een sterk 
verbeterde oncologische uitkomst. Dit proefschrift heeft als doel om verschillende 
aspecten van de multimodaliteitsbehandeling te analyseren en te verbeteren.
In hoofdstuk 1 zetten we de verschillende onderzoeksvragen en onderbouwing uiteen 
waar de verschillende hoofdstukken van dit proefschrift een antwoord op probeert te 
geven.
In hoofdstuk 2 hebben we geëvalueerd of het toevoegen van dynamische contrast 
series bij een standaard MRI onderzoek na het toedienen van neo-adjuvante (chemo-)
radiotherapie, de accuratesse van tumor, lymfeklier stagering en het voorspellen van 
complete respons kan verbeteren. Uit dit onderzoek bleek dat het toevoegen van 
deze series niet leidt tot verbeterde lokale tumor stagering of het voorspellen van een 
complete pathologische respons. Aan de andere kant lijkt het toevoegen van dynamische 
contrast series wel tot een meer accurate beoordeling van de lymfklier status. Dit kan 
mogelijkheden bieden in de huidige periode, alwaar we de mogelijkheden van ‘watch 
and wait’ procedure of rectumsparende chirurgie na neo-adjuvante therapie aan het 
onderzoeken zijn.
In hoofdstuk 3 hebben we de toegevoegde waarde bekeken van herstagering na een 
lang schema (chemo-)radiotherapy door middel van een thoraco-abdominale CT-scan. 
Patiënten met een lokaal voortgeschreden rectumcarcinoom hebben de hoogste kans 
op het ontwikkelen van afstandmetastasen. Gedurende de neo-adjvante periode 
die ongeveer 4-5 maanden kan duren, kan het van toegevoegde waarde zijn om te 
beoordelen of deze patiënten afstandsmetastasen hebben ontwikkeld. Uit deze studie 
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bleek inderdaad dat 12% van de patiënten (progressieve) afstandmetastasen ontwikkelde 
en dat leidde zelfs in 8% van de patiënten in de beslissing om geen rectumchirurgie 
meer uit te voeren. Dit maakt het herstageren door middel van een thoraco-abdominale 
CT-scan een zeer waardevolle stap in de behandeling van het lokaal voortgeschreden 
rectumcarcarinoom.
In hoofdstuk 4 hebben we uiteengezet wat de beperkingen en uitdagingen zijn van het 
lokaal herstageren van het rectumcarcinoom na neo-adjuvante (chemo-)radiotherapie. 
Helaas is de accuratesse van de stagering van de tumor na (chemo-)radiotherapie slecht. 
Deze accuratesse is nu nog te laag om hier je behandelplan op aan te passen. Het gevaar 
van onderstageren is te groot en dit heeft mogelijk grote consequenties, omdat dit kan 
leiden tot irradicale resecties. Herstageren met MRI is wel een belangrijk onderdeel van 
het beoordelen van een complete klinische respons, maar slechts als onderdeel van 
meerdere onderzoeken. Aan de andere kant is de respons van het rectumcarcinoom op 
chemoradiotherapie gemeten op MRI wel een zeer vroege en accurate prognostische 
factor. Dit kan in de toekomst mogelijk gebruikt worden om de behandeling te 
intensiveren bij patiënten met een slechte respons op (chemo-)radiotherapie. Daarnaast 
is de accuratesse om betrokkenheid van de mesorectale fascie te beoordelen redelijk.
In hoofdstuk 5 hebben we naar het mogelijke effect gekeken van het toepassen van 
intra-operatieve radiotherapie (IORT) bij patiënten met krap radicale of microscopisch 
irradicale resecties. Het toedienen van zo’n intra-operatieve radiotherapie dosis kan 
mogelijk microscopische overblijfselen  neutraliseren. Deze retrospectieve studie toont 
aan dat IORT bij patiënten met een krap radicale resectie de lokale controle niet lijkt te 
verbeteren. Echter bij patiënten met een microscopische irradicale resectie is de lokale 
controle significant beter bij de patiënten die behandeld zijn met IORT in vergelijking bij 
patiënten bij wie per ongeluk geen IORT is toegepast. Dit suggereert dat IORT de kans 
op een lokaal recidief bij microscopische irradicale resecties kan verminderen.
Hoofdstuk 6 is gebaseerd op de hypothese dat het ziekenhuis volume bij de 
behandeling van het rectumcarinoom van invloed is op de oncologische uitkomsten. 
De behandeling van het lokaal voortgeschreden rectumcarcinoom (cT4) is complexer 
en chirurgisch lastiger dan de behandeling van de meer vroegere stadia (cT1-3) 
van het rectumcarcinoom. Het voortgeschreden rectumcarcinoom behoeft een 
multimodaliteitsbehandeling met optimale stagering en beeldvorming om zodoende 
tot het beste oncologisch resultaat te komen. Wij hebben de cT4 rectumcarcinomen en 
de cT1-3 rectumcarcinomen afzonderlijk van elkaar geanalyseerd in een Nederlandse 
populatie database. In cT1-3 rectumcarcinomen was het cT1-3 ziekenhuisvolume 
niet geassocieerd met de overleving. In cT4 rectumcarcinomen was een hoog 
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cT4 ziekenhuisvolume wel geassocieerd met een betere overleving in vergelijking 
met ziekenhuis met een laag volume met cT4 rectumcarcinomen. Dit was dan 
wel gecorrigeerd voor patiënt en tumorkarakteristieken. Daarnaast hebben we de 
verwijzingen binnen Nederland van cT4 rectumcarcinomen geanalyseerd en hieruit bleek 
dat patienten regelmatig niet juist worden doorverwezen, ondanks de adviezen in de 
Nederlandse richtlijnen.
In hoofdstuk 7, hebben we een literatuurstudie gedaan naar het effect van chirurgie 
van het primaire colorectaal carcinoom op de overleving bij patiënten met een stadium 
IV ziekte en irresectabele afstandsmetastasen. Verscheidene studies hebben een positief 
effect op overleving aangetoond. Dit review toont aan dat de rol van resectie nog steeds 
onduidelijk is, omdat er geen gerandomiseerd onderzoek beschikbaar is. Daarnaast komt 
er met de huidige nieuwe systemische therapie maar een heel klein gedeelte van de 
patiënten in aanmerking voor (spoed) chirurgie van de primaire tumor wegens klachten. 
Desondanks suggereren de meeste studies een overlevingswinst bij resectie van de 
primaire tumor.
In hoofdstuk 8 hebben we ons toegespitst op het lokaal recidiverend rectumcarcinoom. 
We hebben specifiek gekeken naar de uitkomst van een lastig te behandelen subgroep 
van het lokaal recidiverend rectumcarcinoom na totale mesorectale excisie en 
radiotherapie. TME leidt tot lokaal recidieven die niet gelimiteerd zijn tot een specifiek 
anatomisch compartiment omringd door een fascie. Neo-adjuvante radiotherapie voor 
de primaire tumor leidt tot een beperktere beschikbare radiotherapie dosis voor de 
behandeling van het lokale recidief. Deze studie heeft de peri-operatieve resultaten en 
lange termijn resultaten van het lokaal recidiverend rectumcarcinoom na TME chirurgie 
met of zonder eerdere radiotherapie voor de primaire tumor met elkaar vergeleken. De 
resultaten toonden aan dat de lange termijn oncologische uitkomst hetzelfde was en 
dat er ook dat er geen significant verschil was in het aantal complicaties percentage. Dit 
houdt in dat ook deze specifieke groep ook in opzet curatief behandeld moet worden met 
een multimodaliteitsbehandeling en chirurgie.
In hoofdstuk 9 hebben we de prognostische factoren na de chirurgische behandeling 
van het lokaal recidiverend rectumcarcinoom geëvalueerd. Het is bekend dat de 
resectiemarge de belangrijkste prognostische factor na chirurgie van het LRRC is. In het 
primaire rectumcarcinoom leiden echter niet alleen daadwerkelijke irradicale resecties 
tot een slechtere prognose, maar ook een krap radicale hebben een slectere uitkomst. 
Deze studie heeft geanalyseerd of een krap radicale resectie (≤2mm) leidt tot een 
oncologische slechtere uitkomst dan een ruim radicale resectie van meer dan 2 mm. 
Uit deze studie blijkt dat in overeenstemming met met het primaire rectumcarcinoom 
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dat krap radicale resecties leiden tot een oncologisch slechtere uitkomst. Dit toont het 
belang aan van een ruim radicale resectie. Dit kan bereikt worden door middel van neo-
adjuvante inductie behandeling en indien noodzakelijk uitgebreide radicale multiviscerale 
chirurgie
In hoofdstuk 10 is het effect van systemische therapie op de behandeling van het 
lokaal recidiverend rectumcarcinoom geanalyseerd. In enkele gevallen zijn patiënten 
met een lokaal recidiverend rectumcarcinoom met afstandsmetastasen behandeld met 
systemische therapie. Dit maakte het mogelijk om het effect van systemische therapie 
op het lokale recidief in al eerder bestraald gebied te beoordelen en dit te vergelijken 
met afstandmetastasen buiten dit bestraalde gebied. De eerdere radiotherapie maakt 
het effect van chemotherapie mogelijk minder effectief door de aanwezigheid van fibrose 
en een mogelijk verminderde vascularisatie van dit gebied. Deze studie toont inderdaad 
een lagere respons van het lokale recidief aan in vergelijking met de afstandmetastasen 
buiten het bestraalde gebied. Deze slechte respons maakt het discutabel of systemische 
therapie zinvol is als palliatie. Daarnaast maakt dit  het twijfelachtig of systemische 
therapie als inductietherapie zinvol is.
In hoofdstuk 11 hebben we de meest recente literatuur van de behandeling van het 
lokaal recidiverend rectumcarcinoom beoordeeld en samengevat voor de Nederlandse 
beroepsbeoefenaar. Een multimodaliteitsbehandeling kan tegenwoordig leiden tot 
genezing. Dit is in tegenstelling tot een jaar of 25 geleden toen al deze patiënten 
ongeneesbaar werden geacht. Zelfs patiënten die eerder TME chirurgie en radiotherapie 
hebben ontvangen zijn mogelijke kandidaten voor een curatieve chirurgische 
behandeling. Helaas is de meerderheid van de patiënten niet geschikt voor chirurgische 
behandeling. Dit komt vanwege de aanwezigheid van afstandsmetastasen of een te 
uitgebreid lokaal recidief. Deze patiënten dienen optimaal palliatief behandeld te worden, 
vanwege de zeer invaliderende en hevige pijn die vaak geassocieerd is met een lokaal 
recidief. Radiotherapie is hier het meest geschikt voor. In ongeveer 75% van de patiënten 
geeft radiotherapie vermindering van de klachten. Helaas is de duur van deze palliatie 
beperkt.
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PhD Portfolio
1. PhD training TOTAL:  31.9 ECTS
General courses Year Workload
- Biomedical Enlish Writing and communication 2013 3 ECTS
- Good Clinical Practice (GCP) 2013 1 ECTS
- Basic introduction Course SPSS 2013 1 ECTS
- Biostastics for clinicans 2013 1 ECTS
Specific Courses
- ANIOS surgery ikazia ziekenhuis 2013-2014
Seminars and workshops
- Fundamental Critical Care Support (FCCS) 2015 1 ECTS
Presentations
National conferences
- NVvH chirurgendagen 2012 1 ECTS
- NVvH chirugendagen 2013 1,5 ECTS
- NVvH Chirugendagen 2014 1,5 ECTS
- NVvH najaarsdagen 2013 2 ECTS
- Wetenschapsdag Erasmus MC 2014 1 ECTS
- Daniel den Hoed Wetenschapsdag 2014 1 ECTS
International conferences 
- ESMO World Congress on Gastrointestinal Cancer 2013 2 ECTS
- ECCO European Cancer Congress 2014 2 ECTS
Attendence (inter)national conferations 
- NVvH chirurgendagen 2012-2017 3.6 ECTS
- NVvH najaarsvergadering 2012-2017 1.8 ECTS
- ESMO World Congress on Gastrointestinal Cancer 2013 1.2 ECTS
- ECCO European Cancer Congress 2014 1.3 ECTS
2. Teaching
Supervising practicals and excoursons, tutoring
- Basic life support examintor 2014 1 ECTS
- Supervising Master’s theses 2014 2 ECTS
- Clinical teaching medical students (klinisch redeneren) 2013-2014 2 ECTS
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Dankwoord
De laatste loodjes wegen het zwaarst. Dit bleek wel in de afrondende fase van dit 
proefschrift. Veel dank ben ik verschuldigd aan meerdere personen die mij gedurende dit 
project hebben begeleid.
Professor Verhoef, beste Kees; Dankzij jou heb ik de Daniel nog in z’n gloriejaren mogen 
meemaken. Dank dat jij het zag zitten om iemand te begeleiden die nachtdiensten met 
het opstarten van een promotietraject wilde combineren. Alhoewel dit in het begin even 
aanpoten was, maakte de sfeer in de Daniel alles goed. Met laagdrempelige begeleiding, 
enthousiasme en humor was jij daar voor een groot deel verantwoordelijk voor. Dierbare 
herinneringen zullen me bijblijven; Paella eten in Barcelona, peper op de steengrill op 
de mooiste bowlingbaan van ’t land en businessclass naar Washington. Met name ook 
bedankt voor het geduld dat je hebt gehad.
Dr. Burger, beste Pim; Als ik iemand veel verschuldigd ben, dan ben jij het wel. Jij zag het 
in mij zitten om mij op dit project te zetten. Het begon allemaal op de assistenten kamer 
op 10-midden, waar we in korte tijd ons eerste artikel schreven. Hoewel het daarna wat 
langzamer ging, heb ik ongelooflijk veel van je geleerd. Jouw capaciteit om dingen op te 
schrijven, heb ik altijd bewonderd. Ook de vrijdagochtenden aan de Heemraadsingel waar 
je je dochters in een wipstoel zette om tijd te maken voor mij waardeerde ik altijd zeer.
Commissieleden; Professor Marijnen, Professor Lange, Professor Rutten. Het is voor mij 
een eer dat u plaats wilde nemen in de leescommissie. Hartelijk dank daarvoor.
Co-auteurs; met name Prof. de Wilt, dr. Van Meerten, Dr. Nuyttens, bedankt voor alle 
input en adviezen die jullie me hebben gegeven bij het schrijven van de artikelen van dit 
proefschrift.
Secretariaat chirurgische oncologie DDHK; dank voor al jullie hulp met dingen die jullie 
eigenlijk helemaal niet hoefden te doen.
Chirurgen in de DDHK; Dirk Grunhagen, Joost Rothbarth en Linetta Koppert, dank voor 
ongelooflijk goede sfeer die jullie creëerden in de Daniel en alle hulp die jullie mij hebben 
geboden.
Onderzoekers in DDHK; Elvira, Sepideh en Eric, bedankt voor de gezelligheid en hulp 
waar nodig. Met name Ninos, bedankt voor de eerste maanden dat je mij introduceerde 
in het onderzoeksleven en je bijdrage aan dit proefschrift.
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Chirurgen Ikazia Ziekenhuis; mede dankzij jullie is het mogelijk geweest om dit 
proefschrift te schrijven. Met name dr. Den Hoed en dr. Vles, samen bedachten we de 
‘nachtdienst constructie’ die de basis van dit proefschrift vormde.
Assistenten in het Ikazia ziekenhuis; Inmiddels veel verschillende samenstellingen 
meegemaakt, maar het is altijd een feest geweest om met jullie te werken.
Paranifmen; Victorien, 2 jaar lang hebben wij onderzoeks lief en leed gedeeld. Jouw 
bereidheid altijd maar te blijven lachen om m’n slechte grappen waardeerde ik zeer. 
Gelukkig waren bijna al mijn grappen goed. Ik ben blij dat ik iemand ken die Barrones 
is, een Oost-Duits communistische opvoeding heeft genoten, in het weekend op 
een ‘landgoedje’ Oehoe’s gaat schieten en nu aan mijn zijde wil staan tijdens mijn 
verdediging.
Benny; Vrienden die je maakt tijdens je studententijd heb je voor het leven. Bij jou gaat 
dit inderdaad op. Vanaf het moment dat ik je vanaf de stad op mijn rug naar Kralingen 
moest tillen na een verloren ‘scissor-pepper’ was onze vriendschap geboren. Ik ben blij 
dat je mij wil bijstaan bij mijn verdediging.
Broer en zus; Harmen en Sabine, Hoewel we door enig leeftijdsverschil in onze jeugd 
vaak in andere fases zaten, zitten we nu allemaal in hetzelfde schuitje. Huisje, boompje, 
beestje, waarbij ik geniet van de momenten dat we met zo’n grote familie bij elkaar zijn.
Papa en mama, je beseft je pas echt wat jullie allemaal voor me gedaan hebben als je 
zelf iemand mag opvoeden. Jullie hebben ervoor gezorgd dat ik totaal onbezorgd leven 
heb gehad en hebben mij alle kansen geboden die je maar kan wensen. Daarmee hebben 
jullie misschien wel de grootste bijdrage aan dit boek geleverd. Pap, nu ben je niet meer 
de enige Zeer Wel Edelgeleerde Heer.
Lieve Nathalie; met jou ‘never a dull moment’. Ik ken niemand met zoveel 
doorzettingsvermogen als jij. Niet alles zit mee, maar daar zal jij je nooit bij neerleggen. 
Hoewel promoveren nooit een geliefd gespreksonderwerp was, heb je me altijd gesteund 
en geholpen. Jij gaf ons ons grootste geluk, Max. Ik kan me geen lievere en betere 
moeder voor Max bedenken. Het geluk op Max z’n gezicht als hij lekker met je aan het 
‘spele’ is of als jij hem moet ‘pakke’, is voor mij onbetaalbaar. Hierom en om veel meer 
redenen, hou ik zoveel van je.
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Curriculum Vitae
Wijnand Jochem Alberda werd op 6 november 1983 geboren in Rotterdam. Hij groeide 
op in Krimpen aan den IJssel, alwaar hij onder de rook van Rotterdam in Capelle aan den 
IJssel in 2002 zijn atheneum diploma behaalde. Direct hierna werd hij helaas uitgeloot 
voor de studie geneeskunde waardoor hij 1 jaar economie en business administration 
heeft gestudeerd aan de Erasmus Universiteit in Rotterdam.
In 2003 werd hij alsnog ingeloot voor Geneeskunde waar hij uiteindelijk in 2010 zijn 
arts-examen heeft behaald. Gedurende de studie werkte hij als Forgeron op de Spoed 
Eisende Hulp in het Ikazia Ziekenhuis, waar zijn interesse voor het vak Heelkunde werd 
geboren. Zijn interesse werd verder aangewakkerd doordat hij na het behalen van zijn 
arts-examen in 2010 als ANIOS startte in het Ikazia Ziekenhuis op de afdeling heelkunde 
(opleider P.T. den Hoed)
Gedurende zijn ANIOS-schap kwam hij in contact met Prof. Verhoef en dr. Burger. Deze 
boden hem de kans om een promotietraject in de Daniel den Hoed kliniek in Rotterdam 
te starten. Eind 2012 startte hij aan zijn promotie onderzoek wat hij het eerste jaar 
combineerde met diensten als ANIOS in het Ikazia Ziekenhuis. In zijn compensatietijd 
had hij zo de kans de basis voor dit proefschrift te leggen. Na 1,5 jaar full time onderzoek 
te hebben gedaan mocht hij in juni 2014 starten aan zijn opleiding tot chirurg. Hij begon 
zijn eerste jaar in het Erasmus MC (opleider B. Wijnhoven), waarna hij in 2015 terug 
mocht komen op het oude nest in het ikazia ziekenhuis waar hij tot op heden zeer blij is 
met de keuzes die hij heeft gemaakt.
Hij woont met veel plezier in Rotterdam met zijn vriendin Nathalie Roost en zijn zoon 
Max (24-8-2016).
